US20230159581A1 - Novel anti-infective and anti-inflammatory compounds - Google Patents
Novel anti-infective and anti-inflammatory compounds Download PDFInfo
- Publication number
- US20230159581A1 US20230159581A1 US17/873,451 US202217873451A US2023159581A1 US 20230159581 A1 US20230159581 A1 US 20230159581A1 US 202217873451 A US202217873451 A US 202217873451A US 2023159581 A1 US2023159581 A1 US 2023159581A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- alkenyl
- compound
- alkynyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims description 190
- 230000002924 anti-infective effect Effects 0.000 title claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 3
- -1 nitroxy group Chemical group 0.000 claims abstract description 125
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 150000002148 esters Chemical class 0.000 claims abstract description 13
- 230000004060 metabolic process Effects 0.000 claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 6
- 230000003211 malignant effect Effects 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 239
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical class C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 160
- 229960004099 azithromycin Drugs 0.000 claims description 115
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 109
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 72
- 125000003342 alkenyl group Chemical group 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 125000000304 alkynyl group Chemical group 0.000 claims description 52
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 25
- 229920000768 polyamine Polymers 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 15
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 15
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
- 210000002865 immune cell Anatomy 0.000 claims description 15
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 14
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 14
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 14
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 229910052740 iodine Inorganic materials 0.000 claims description 13
- 229910004679 ONO2 Inorganic materials 0.000 claims description 12
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 12
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 11
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 239000002207 metabolite Substances 0.000 claims description 11
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 229920002401 polyacrylamide Polymers 0.000 claims description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 9
- 235000013824 polyphenols Nutrition 0.000 claims description 9
- 230000004888 barrier function Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- VWAMTBXLZPEDQO-UZSBJOJWSA-N (2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-7-propyl-1-oxa-7-azacyclopentadeca Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)CN([C@@H](C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CCC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 VWAMTBXLZPEDQO-UZSBJOJWSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960002314 gamithromycin Drugs 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 5
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 5
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 claims description 5
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 5
- 150000002823 nitrates Chemical class 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- ZOYWWAGVGBSJDL-UHFFFAOYSA-N D-desosamine Natural products CC1CC(N(C)C)C(O)C(O)O1 ZOYWWAGVGBSJDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- 239000012848 Dextrorphan Substances 0.000 claims description 3
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001444 amodiaquine Drugs 0.000 claims description 3
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004754 astemizole Drugs 0.000 claims description 3
- 229960001985 dextromethorphan Drugs 0.000 claims description 3
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims description 3
- 229950006878 dextrorphan Drugs 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 229960002464 fluoxetine Drugs 0.000 claims description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical class C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 229960002296 paroxetine Drugs 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical class ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 150000007970 thio esters Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 33
- 150000003573 thiols Chemical class 0.000 abstract description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 303
- 239000000243 solution Substances 0.000 description 109
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 107
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- 239000000047 product Substances 0.000 description 88
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 84
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 82
- 229960003712 propranolol Drugs 0.000 description 82
- 230000015572 biosynthetic process Effects 0.000 description 73
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 68
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 62
- 238000003786 synthesis reaction Methods 0.000 description 60
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 47
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 47
- 238000003756 stirring Methods 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 37
- 241000894006 Bacteria Species 0.000 description 36
- 235000015165 citric acid Nutrition 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
- 239000006260 foam Substances 0.000 description 34
- 238000010626 work up procedure Methods 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 33
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 235000002639 sodium chloride Nutrition 0.000 description 29
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 27
- 239000002253 acid Substances 0.000 description 27
- 229960004171 hydroxychloroquine Drugs 0.000 description 26
- 239000007858 starting material Substances 0.000 description 26
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 239000012074 organic phase Substances 0.000 description 23
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 23
- 150000002118 epoxides Chemical class 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 125000003977 lipoyl group Chemical group S1SC(C([H])([H])C(C(C(C(=O)[*])([H])[H])([H])[H])([H])[H])([H])C([H])([H])C1([H])[H] 0.000 description 21
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 21
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 20
- MSQDVGOEBXMPRF-UHFFFAOYSA-N cyclohexane;propan-2-one Chemical compound CC(C)=O.C1CCCCC1 MSQDVGOEBXMPRF-UHFFFAOYSA-N 0.000 description 20
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical group C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 20
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 19
- 238000004809 thin layer chromatography Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 229910000029 sodium carbonate Inorganic materials 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 125000002252 acyl group Chemical group 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000003039 volatile agent Substances 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 12
- 239000012047 saturated solution Substances 0.000 description 12
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 235000011054 acetic acid Nutrition 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 229960000633 dextran sulfate Drugs 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 235000021391 short chain fatty acids Nutrition 0.000 description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
- 108010036949 Cyclosporine Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229960001265 ciclosporin Drugs 0.000 description 9
- 238000010549 co-Evaporation Methods 0.000 description 9
- 206010009887 colitis Diseases 0.000 description 9
- 229930182912 cyclosporin Natural products 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- 229930105110 Cyclosporin A Natural products 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 238000006396 nitration reaction Methods 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000019260 propionic acid Nutrition 0.000 description 8
- 241000894007 species Species 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 7
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910017604 nitric acid Inorganic materials 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 6
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FREZLSIGWNCSOQ-UHFFFAOYSA-N 3-methylbutanoyl 3-methylbutanoate Chemical compound CC(C)CC(=O)OC(=O)CC(C)C FREZLSIGWNCSOQ-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 5
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 229960004132 diethyl ether Drugs 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 210000000680 phagosome Anatomy 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 150000004763 sulfides Chemical class 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 4
- LPTKLVOENDVAOD-UHFFFAOYSA-N 3-bromopropyl nitrate Chemical compound [O-][N+](=O)OCCCBr LPTKLVOENDVAOD-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 239000003929 acidic solution Substances 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000000935 solvent evaporation Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- FZYUKBLYECHAGN-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-(methylamino)oxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](NC)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 FZYUKBLYECHAGN-HOQMJRDDSA-N 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- HNDXPZPJZGTJLJ-UEJFNEDBSA-N (4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4s,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2-piperidin-1-ylethyl)-15-(piperidin-1-ylmethyl)-1-oxacyclohexadeca-11,13-diene-2,10-dione Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1CCCCC1)CN1CCCCC1)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O HNDXPZPJZGTJLJ-UEJFNEDBSA-N 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 3
- LFKLPJRVSHJZPL-UHFFFAOYSA-N 1,2:7,8-diepoxyoctane Chemical compound C1OC1CCCCC1CO1 LFKLPJRVSHJZPL-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WTLNOANVTIKPEE-UHFFFAOYSA-N 2-acetyloxypropanoic acid Chemical compound OC(=O)C(C)OC(C)=O WTLNOANVTIKPEE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000004135 Bone phosphate Substances 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000000364 acidic sodium aluminium phosphate Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000019347 bone phosphate Nutrition 0.000 description 3
- GENAAZKZRURPIA-UHFFFAOYSA-N butanoic acid;2-hydroxypropanoic acid Chemical compound CCCC(O)=O.CC(O)C(O)=O GENAAZKZRURPIA-UHFFFAOYSA-N 0.000 description 3
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 3
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 3
- 239000004281 calcium formate Substances 0.000 description 3
- 235000019255 calcium formate Nutrition 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 3
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 3
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 229940041033 macrolides Drugs 0.000 description 3
- 235000012243 magnesium silicates Nutrition 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- JAYXSROKFZAHRQ-UHFFFAOYSA-N n,n-bis(oxiran-2-ylmethyl)aniline Chemical compound C1OC1CN(C=1C=CC=CC=1)CC1CO1 JAYXSROKFZAHRQ-UHFFFAOYSA-N 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920000647 polyepoxide Polymers 0.000 description 3
- 229920001021 polysulfide Polymers 0.000 description 3
- 239000005077 polysulfide Substances 0.000 description 3
- 150000008117 polysulfides Polymers 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000019254 respiratory burst Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000012237 sodium aluminium phosphate Nutrition 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 3
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 229960002659 tildipirosin Drugs 0.000 description 3
- 229940005605 valeric acid Drugs 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- WHQDTWBSYHNXPV-UHFFFAOYSA-N (5-amino-1-pyridin-4-ylpyrazol-4-yl)-(3-hydroxyphenyl)methanone Chemical compound N1=CC=C(C=C1)N1N=CC(=C1N)C(=O)C1=CC(=CC=C1)O WHQDTWBSYHNXPV-UHFFFAOYSA-N 0.000 description 2
- MXLMEJMTTINUAK-UHFFFAOYSA-N (5-amino-1-pyridin-4-ylpyrazol-4-yl)-(3-methoxyphenyl)methanone Chemical compound N1=CC=C(C=C1)N1N=CC(=C1N)C(=O)C1=CC(=CC=C1)OC MXLMEJMTTINUAK-UHFFFAOYSA-N 0.000 description 2
- YYCFMPXUBDHCRM-UHFFFAOYSA-N (5-amino-1-pyridin-4-ylpyrazol-4-yl)-[3-(2,3-dihydroxypropoxy)phenyl]methanone Chemical compound N1=CC=C(C=C1)N1N=CC(=C1N)C(=O)C1=CC(=CC=C1)OCC(CO)O YYCFMPXUBDHCRM-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HMEICDIGPORGFI-UHFFFAOYSA-N 2-(oxiran-2-ylmethyl)-3-[3-(oxiran-2-yl)propyl]oxirane Chemical compound O1C(CC2OC2)C1CCCC1CO1 HMEICDIGPORGFI-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- DVOPCQDTEPKYKW-UHFFFAOYSA-N 2-nitrooxypropanoic acid Chemical compound OC(=O)C(C)O[N+]([O-])=O DVOPCQDTEPKYKW-UHFFFAOYSA-N 0.000 description 2
- YKAVHPRGGAUFDN-JTQLBUQXSA-N 24464-30-0 Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]2(C)O[C@]3([C@@H]([C@H]2O)C)[C@H](C)C[C@](O3)(C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YKAVHPRGGAUFDN-JTQLBUQXSA-N 0.000 description 2
- AHIPJALLQVEEQF-UHFFFAOYSA-N 4-(oxiran-2-ylmethoxy)-n,n-bis(oxiran-2-ylmethyl)aniline Chemical compound C1OC1COC(C=C1)=CC=C1N(CC1OC1)CC1CO1 AHIPJALLQVEEQF-UHFFFAOYSA-N 0.000 description 2
- LBCCPKFTHIBIKU-UHFFFAOYSA-N Aethyl-propyl-glyoxal Natural products CCCC(=O)C(=O)CC LBCCPKFTHIBIKU-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004114 Ammonium polyphosphate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004132 Calcium polyphosphate Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000001879 Curdlan Substances 0.000 description 2
- 239000004134 Dicalcium diphosphate Substances 0.000 description 2
- ZFIVKAOQEXOYFY-UHFFFAOYSA-N Diepoxybutane Chemical compound C1OC1C1OC1 ZFIVKAOQEXOYFY-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- 239000004130 Ferrous hexacyanomanganate Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000004235 Orange GGN Substances 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000004111 Potassium silicate Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 239000004113 Sepiolite Substances 0.000 description 2
- 239000004115 Sodium Silicate Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000191965 Staphylococcus carnosus Species 0.000 description 2
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000004102 Synthetic calcium aluminate Substances 0.000 description 2
- 239000004110 Zinc silicate Substances 0.000 description 2
- OJPCORFCPQCXES-UHFFFAOYSA-N [3-[3-(5-amino-1-pyridin-4-ylpyrazole-4-carbonyl)phenoxy]-2-butanoyloxypropyl] butanoate Chemical compound N1=CC=C(C=C1)N1N=CC(=C1N)C(=O)C1=CC(=CC=C1)OCC(COC(CCC)=O)OC(CCC)=O OJPCORFCPQCXES-UHFFFAOYSA-N 0.000 description 2
- QWHHHKWSCJLZPP-UHFFFAOYSA-N [3-[3-[5-amino-1-(4-fluorophenyl)pyrazole-4-carbonyl]phenoxy]-2-butanoyloxypropyl] butanoate Chemical compound FC1=CC=C(C=C1)N1N=CC(=C1N)C(=O)C1=CC(=CC=C1)OCC(COC(CCC)=O)OC(CCC)=O QWHHHKWSCJLZPP-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000001809 ammonium phosphatide Substances 0.000 description 2
- 235000010986 ammonium phosphatide Nutrition 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 239000001202 beta-cyclodextrine Substances 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- XUCHXOAWJMEFLF-UHFFFAOYSA-N bisphenol F diglycidyl ether Chemical compound C1OC1COC(C=C1)=CC=C1CC(C=C1)=CC=C1OCC1CO1 XUCHXOAWJMEFLF-UHFFFAOYSA-N 0.000 description 2
- 239000004161 brilliant blue FCF Substances 0.000 description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000279 calcium ferrocyanide Substances 0.000 description 2
- 235000012251 calcium ferrocyanide Nutrition 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- 235000012255 calcium oxide Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KTRFZWJCHOQHMN-UHFFFAOYSA-N chloromethanethioic s-acid Chemical compound SC(Cl)=O KTRFZWJCHOQHMN-UHFFFAOYSA-N 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- ZWAJLVLEBYIOTI-UHFFFAOYSA-N cyclohexene oxide Chemical compound C1CCCC2OC21 ZWAJLVLEBYIOTI-UHFFFAOYSA-N 0.000 description 2
- MOUVOWJUMAKBBM-UHFFFAOYSA-N cyclopenta-1,3-diene;2-cyclopenta-1,3-dien-1-ylacetic acid;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.OC(=O)CC1=CC=C[CH-]1 MOUVOWJUMAKBBM-UHFFFAOYSA-N 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- LSGWSXRILNPXKJ-UHFFFAOYSA-N ethyl oxirane-2-carboxylate Chemical compound CCOC(=O)C1CO1 LSGWSXRILNPXKJ-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019344 ferrous hexacyanomanganate Nutrition 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001806 glycerol esters of wood rosin Substances 0.000 description 2
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- HQZMRJBVCVYVQA-UHFFFAOYSA-N hydron;methyl 2-(methylamino)acetate;chloride Chemical compound Cl.CNCC(=O)OC HQZMRJBVCVYVQA-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 150000007931 macrolactones Chemical class 0.000 description 2
- 239000001755 magnesium gluconate Substances 0.000 description 2
- 235000015778 magnesium gluconate Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000000802 nitrating effect Effects 0.000 description 2
- KOSYAAIZOGNATQ-UHFFFAOYSA-N o-phenyl chloromethanethioate Chemical compound ClC(=S)OC1=CC=CC=C1 KOSYAAIZOGNATQ-UHFFFAOYSA-N 0.000 description 2
- 239000001912 oat gum Substances 0.000 description 2
- 235000019313 oat gum Nutrition 0.000 description 2
- 235000019236 orange GGN Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000010451 perlite Substances 0.000 description 2
- 235000019362 perlite Nutrition 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 2
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000004224 potassium gluconate Substances 0.000 description 2
- 235000013926 potassium gluconate Nutrition 0.000 description 2
- 239000004293 potassium hydrogen sulphite Substances 0.000 description 2
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 2
- 239000004304 potassium nitrite Substances 0.000 description 2
- 235000010289 potassium nitrite Nutrition 0.000 description 2
- 235000019353 potassium silicate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000010515 propionylation reaction Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 235000019355 sepiolite Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000019361 synthetic calcium aluminate Nutrition 0.000 description 2
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 2
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008791 toxic response Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000010455 vermiculite Substances 0.000 description 2
- 235000019354 vermiculite Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000019352 zinc silicate Nutrition 0.000 description 2
- ALHZEIINTQJLOT-UHFFFAOYSA-N (1-chloro-1-oxopropan-2-yl) acetate Chemical compound ClC(=O)C(C)OC(C)=O ALHZEIINTQJLOT-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- KYTWXIARANQMCA-PGYIPVOXSA-N (3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradec Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N\O)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-PGYIPVOXSA-N 0.000 description 1
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 1
- PCGDBWLKAYKBTN-UHFFFAOYSA-N 1,2-dithiole Chemical compound C1SSC=C1 PCGDBWLKAYKBTN-UHFFFAOYSA-N 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- 239000001733 1,4-Heptonolactone Substances 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- PXDYILJJHOVNLO-UHFFFAOYSA-N 11-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound CC1(O)CC(C)CN(C)C(C)C(O)C(O)(C)C(CC)OC(=O)C(C)C(O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 PXDYILJJHOVNLO-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- IVIDDMGBRCPGLJ-UHFFFAOYSA-N 2,3-bis(oxiran-2-ylmethoxy)propan-1-ol Chemical compound C1OC1COC(CO)COCC1CO1 IVIDDMGBRCPGLJ-UHFFFAOYSA-N 0.000 description 1
- OKPBGFSFTUQDJP-UHFFFAOYSA-N 2,4,6-triaminocyclohexane-1,3,5-triol Chemical compound NC1C(O)C(N)C(O)C(N)C1O OKPBGFSFTUQDJP-UHFFFAOYSA-N 0.000 description 1
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- OLQJQHSAWMFDJE-UHFFFAOYSA-N 2-(hydroxymethyl)-2-nitropropane-1,3-diol Chemical compound OCC(CO)(CO)[N+]([O-])=O OLQJQHSAWMFDJE-UHFFFAOYSA-N 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- ZLCKDYMZBZNBMJ-UHFFFAOYSA-N 2-bromoethyl carbonochloridate Chemical compound ClC(=O)OCCBr ZLCKDYMZBZNBMJ-UHFFFAOYSA-N 0.000 description 1
- UUODQIKUTGWMPT-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC=C(C(F)(F)F)C=N1 UUODQIKUTGWMPT-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 description 1
- YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 description 1
- CWEPACWBWIOYID-UHFFFAOYSA-N 4'-hydroxypropanolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=C(O)C2=C1 CWEPACWBWIOYID-UHFFFAOYSA-N 0.000 description 1
- GYSKHQYTYQKKQW-UHFFFAOYSA-N 4-(4-anilino-3-methoxyphenyl)-4-oxobut-2-enenitrile Chemical compound C1(=CC=CC=C1)NC1=C(C=C(C=C1)C(=O)C=CC#N)OC GYSKHQYTYQKKQW-UHFFFAOYSA-N 0.000 description 1
- 239000004101 4-Hexylresorcinol Substances 0.000 description 1
- 235000019360 4-hexylresorcinol Nutrition 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000001741 Ammonium adipate Substances 0.000 description 1
- 239000001729 Ammonium fumarate Substances 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 239000001715 Ammonium malate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004257 Anoxomer Substances 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 239000001878 Bakers yeast glycan Substances 0.000 description 1
- 235000019311 Bakers yeast glycan Nutrition 0.000 description 1
- 208000034920 Body Weight Maintenance Diseases 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 239000001842 Brominated vegetable oil Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 239000001749 Calcium fumarate Substances 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 239000002970 Calcium lactobionate Substances 0.000 description 1
- 239000004136 Calcium sodium polyphosphate Substances 0.000 description 1
- 239000004140 Calcium stearoyl fumarate Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000001884 Cassia gum Substances 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 239000004128 Copper(II) sulphate Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WPYCRFCQABTEKC-UHFFFAOYSA-N Diglycidyl resorcinol ether Chemical compound C1OC1COC(C=1)=CC=CC=1OCC1CO1 WPYCRFCQABTEKC-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004249 Erythorbin acid Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000006824 Eschweiler-Clarke methylation reaction Methods 0.000 description 1
- 239000004144 Ethoxylated Mono- and Di-Glyceride Substances 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 239000004398 Ethyl lauroyl arginate Substances 0.000 description 1
- 239000002714 Extracts of rosemary Substances 0.000 description 1
- 101150050349 FFAR2 gene Proteins 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- 239000004230 Fast Yellow AB Substances 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004263 Guaiac resin Substances 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004284 Heptyl p-hydroxybenzoate Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004233 Indanthrene blue RS Substances 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000002310 Isopropyl citrate Substances 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000001834 Lactylated fatty acid esters of glycerol and propane-1 Substances 0.000 description 1
- 239000001698 Lecitin citrate Substances 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004145 Methyl glucoside-coconut oil ester Substances 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004118 Natrolite-phonolite Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000004396 Octenyl succinic acid modified gum arabic Substances 0.000 description 1
- 239000004218 Orcein Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000003216 Oxystearin Substances 0.000 description 1
- 239000004143 Partial polyglycerol esters of polycondensed fatty acids of castor oil Substances 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 description 1
- 239000004142 Polyoxypropylene-polyoxyethylene polymer Substances 0.000 description 1
- 239000004237 Ponceau 6R Substances 0.000 description 1
- 239000004236 Ponceau SX Substances 0.000 description 1
- 239000001747 Potassium fumarate Substances 0.000 description 1
- 239000004285 Potassium sulphite Substances 0.000 description 1
- 102000000804 Pregnane X Receptor Human genes 0.000 description 1
- 108010001511 Pregnane X Receptor Proteins 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 239000004116 Sepiolitic clay Substances 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 239000004268 Sodium erythorbin Substances 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 239000004139 Sodium stearoyl fumarate Substances 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 239000001882 Soybean hemicellulose Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004138 Stearyl citrate Substances 0.000 description 1
- 239000004393 Stigmasterol-rich plant sterol Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000001852 Succistearin Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GUARTUJKFNAVIK-QPTWMBCESA-N Tulathromycin A Chemical compound C1[C@](OC)(C)[C@@](CNCCC)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)NC[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C GUARTUJKFNAVIK-QPTWMBCESA-N 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000004234 Yellow 2G Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000004191 allura red AC Substances 0.000 description 1
- 235000012741 allura red AC Nutrition 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 239000001063 aluminium ammonium sulphate Substances 0.000 description 1
- 235000011124 aluminium ammonium sulphate Nutrition 0.000 description 1
- 239000001132 aluminium potassium sulphate Substances 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 239000001144 aluminium sodium sulphate Substances 0.000 description 1
- 239000001164 aluminium sulphate Substances 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000011162 ammonium carbonates Nutrition 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 235000019284 anoxomer Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 235000012213 anti-caking agent fatty acid Nutrition 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- XMPZLAQHPIBDSO-UHFFFAOYSA-N argon dimer Chemical compound [Ar].[Ar] XMPZLAQHPIBDSO-UHFFFAOYSA-N 0.000 description 1
- 238000006172 aromatic nitration reaction Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000004176 azorubin Substances 0.000 description 1
- 235000012733 azorubine Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 210000002457 barrier cell Anatomy 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000004126 brilliant black BN Substances 0.000 description 1
- 235000012709 brilliant black BN Nutrition 0.000 description 1
- 235000019323 brominated vegetable oil Nutrition 0.000 description 1
- XFEIRVZQVUQECX-UHFFFAOYSA-N bromo ethyl carbonate Chemical compound CCOC(=O)OBr XFEIRVZQVUQECX-UHFFFAOYSA-N 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 239000004109 brown FK Substances 0.000 description 1
- 235000012713 brown FK Nutrition 0.000 description 1
- 239000001678 brown HT Substances 0.000 description 1
- 235000012670 brown HT Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 230000006242 butyrylation Effects 0.000 description 1
- 238000010514 butyrylation reaction Methods 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000404 calcium aluminium silicate Substances 0.000 description 1
- 235000012215 calcium aluminium silicate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000011001 calcium citrates Nutrition 0.000 description 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
- 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000004294 calcium hydrogen sulphite Substances 0.000 description 1
- 235000010260 calcium hydrogen sulphite Nutrition 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 235000019307 calcium lactobionate Nutrition 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 235000019348 calcium sodium polyphosphate Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000019332 calcium stearoyl fumarate Nutrition 0.000 description 1
- 239000003916 calcium stearoyl-2-lactylate Substances 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 239000004295 calcium sulphite Substances 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- 239000001427 calcium tartrate Substances 0.000 description 1
- 235000011035 calcium tartrate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000019241 carbon black Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 235000019318 cassia gum Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 235000012698 chlorophylls and chlorophyllins Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 239000001679 citrus red 2 Substances 0.000 description 1
- 235000013986 citrus red 2 Nutrition 0.000 description 1
- AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004121 copper complexes of chlorophylls and chlorophyllins Substances 0.000 description 1
- 235000012700 copper complexes of chlorophylls and chlorophyllins Nutrition 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- JRTOHKKTANFFHM-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound C1(CCC1)C(=O)O.C1(CCC1)C(=O)O JRTOHKKTANFFHM-UHFFFAOYSA-N 0.000 description 1
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 1
- BFUZANWGLHWYKK-UHFFFAOYSA-N cyclopenta-1,3-diene iron(2+) 5-methylcyclopenta-1,3-dien-1-ol Chemical compound [Fe++].c1cc[cH-]c1.C[c-]1cccc1O BFUZANWGLHWYKK-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 239000004316 dimethyl dicarbonate Substances 0.000 description 1
- 235000010300 dimethyl dicarbonate Nutrition 0.000 description 1
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical group [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 1
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003669 enzymatically hydrolysed carboxymethyl cellulose Substances 0.000 description 1
- 235000010951 enzymatically hydrolysed carboxymethyl cellulose Nutrition 0.000 description 1
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 235000019280 erythorbin acid Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 235000019334 ethoxylated mono- and di- glycerides Nutrition 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- WCMOMHYTQOTCKC-UHFFFAOYSA-N ethyl 2-(1,4-diazepan-1-yl)acetate;dihydrochloride Chemical compound Cl.Cl.CCOC(=O)CN1CCCNCC1 WCMOMHYTQOTCKC-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 235000019455 ethyl lauroyl arginate Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019306 extracts of rosemary Nutrition 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 235000019233 fast yellow AB Nutrition 0.000 description 1
- 239000000542 fatty acid esters of ascorbic acid Substances 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 239000000182 glucono-delta-lactone Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000010193 gold Nutrition 0.000 description 1
- 239000004333 gold (food color) Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000004120 green S Substances 0.000 description 1
- 235000012701 green S Nutrition 0.000 description 1
- 235000019278 guaiac resin Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019251 heptyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000019239 indanthrene blue RS Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000003290 indole 3-propionic acid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- 235000010213 iron oxides and hydroxides Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019328 lactylated fatty acid esters of glycerol and propane-1 Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 239000004335 litholrubine BK Substances 0.000 description 1
- 235000010187 litholrubine BK Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical group 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000011160 magnesium carbonates Nutrition 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000001369 metatartaric acid Substances 0.000 description 1
- 235000011042 metatartaric acid Nutrition 0.000 description 1
- BLWYXBNNBYXPPL-RXMQYKEDSA-N methyl (2r)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@H]1CCCN1 BLWYXBNNBYXPPL-RXMQYKEDSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000019335 methyl glucoside-coconut oil ester Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000010935 mono and diglycerides of fatty acids Nutrition 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 235000019358 natrolite-phonolite Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- JCZMXVGQBBATMY-UHFFFAOYSA-N nitro acetate Chemical compound CC(=O)O[N+]([O-])=O JCZMXVGQBBATMY-UHFFFAOYSA-N 0.000 description 1
- JBCXQJHXIYZCNI-UHFFFAOYSA-N nitro benzoate Chemical compound [O-][N+](=O)OC(=O)C1=CC=CC=C1 JBCXQJHXIYZCNI-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000019450 octenyl succinic acid modified gum arabic Nutrition 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 235000019248 orcein Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000004306 orthophenyl phenol Substances 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019339 partial polyglycerol esters of polycondensed fatty acids of castor oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000004177 patent blue V Substances 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001955 polyclycerol esters of fatty acids Substances 0.000 description 1
- 235000010963 polyclycerol esters of fatty acids Nutrition 0.000 description 1
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000019320 polyoxyethene (8) stearate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 235000019338 polyoxypropylene-polyoxyethylene polymer Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000004175 ponceau 4R Substances 0.000 description 1
- 235000012731 ponceau 4R Nutrition 0.000 description 1
- 235000019238 ponceau 6R Nutrition 0.000 description 1
- 235000019237 ponceau SX Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001608 potassium adipate Substances 0.000 description 1
- 235000011051 potassium adipate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000441 potassium aluminium silicate Substances 0.000 description 1
- 235000012219 potassium aluminium silicate Nutrition 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 235000012249 potassium ferrocyanide Nutrition 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 239000001415 potassium malate Substances 0.000 description 1
- 235000011033 potassium malate Nutrition 0.000 description 1
- 239000004297 potassium metabisulphite Substances 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004331 potassium propionate Substances 0.000 description 1
- 235000010332 potassium propionate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 1
- 239000004018 propan-1,2-diol esters of fatty acids Substances 0.000 description 1
- 235000010959 propan-1,2-diol esters of fatty acids Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 230000006289 propionylation Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- MMLHRYAPGSEXCA-UHFFFAOYSA-N pyridin-4-ylhydrazine;hydrochloride Chemical compound Cl.NNC1=CC=NC=C1 MMLHRYAPGSEXCA-UHFFFAOYSA-N 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004180 red 2G Substances 0.000 description 1
- 235000012739 red 2G Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019234 riboflavin-5-sodium phosphate Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108700027361 sarcosine methyl ester Proteins 0.000 description 1
- VXGABWCSZZWXPC-UHFFFAOYSA-N sarcosine methyl ester hydrochloride Natural products CNCC(=O)OC VXGABWCSZZWXPC-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000019356 sepiolitic clay Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000010191 silver Nutrition 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000001601 sodium adipate Substances 0.000 description 1
- 235000011049 sodium adipate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000429 sodium aluminium silicate Substances 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 235000019279 sodium erythorbin Nutrition 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000264 sodium ferrocyanide Substances 0.000 description 1
- 235000012247 sodium ferrocyanide Nutrition 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 235000011032 sodium malates Nutrition 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004307 sodium orthophenyl phenol Substances 0.000 description 1
- 235000010294 sodium orthophenyl phenol Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000019331 sodium stearoyl fumarate Nutrition 0.000 description 1
- 239000003724 sodium stearoyl-2-lactylate Substances 0.000 description 1
- 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000001590 sorbitan monolaureate Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 235000019317 soybean hemicellulose Nutrition 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000019330 stearyl citrate Nutrition 0.000 description 1
- 239000001574 stearyl tartrate Substances 0.000 description 1
- 235000011075 stearyl tartrate Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003429 steroid acids Chemical class 0.000 description 1
- 235000019452 stigmasterol-rich plant sterol Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 235000019324 succistearin Nutrition 0.000 description 1
- 239000001957 sucroglyceride Substances 0.000 description 1
- 235000010964 sucroglyceride Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 235000012751 sunset yellow FCF Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000000541 tocopherol-rich extract Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960002859 tulathromycin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000004108 vegetable carbon Substances 0.000 description 1
- 235000012712 vegetable carbon Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 235000019235 yellow 2G Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/40—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the same carbon atom of the carbon skeleton, e.g. amino-ketals, ortho esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the human body senses bacteria, fungi or other parasites by both recognition of their surface patterns and via reception of the metabolic products of those organisms.
- the immune system is sensitive to the presence of anaerobic organisms which, by their nature are able to infect poorly perfused tissue, or emanate from the anaerobic lumen of the gut.
- Anaerobes seem to be a particular source of danger signals for the immune system because they often produce toxins and are able to proliferate in the absence of oxygen, where immune cells are less active and less able to use oxidative burst to kill the bacteria they ingest.
- SCFAs short chain fatty acids
- IPA 3-Indolepropionic acid
- deoxybileacids and polyphenol metabolites like phenylpropionic acid.
- these metabolites are variously sensed by a range of receptors that include SCFA receptors (e.g. FFA2), the pregnane X receptor or the arylhydrocarbon receptor.
- PAM Products of Anaerobic Metabolism
- PAMS Products of Anaerobic Metabolism
- Another type of signal is that of bacterial cell wall materials or bacterial nucleic acids. These materials are often ligands for the Toll-like-receptor (TLR) family. These are referred to as Pathogen-associated molecular patterns or PAMPs.
- TLR Toll-like-receptor
- PAMPs Pathogen-associated molecular patterns
- signaling of this type is commonly associated with the gut epithelium, it is also a potential signal in the interaction between the immune system surveilling the gut or the periphery.
- the lysosomes of the gut or the immune system cells are exposed to bacterial metabolites because these materials are released as bacteria are lysed following phagocytosis.
- Nitric oxide functions as a neurotransmitter, autacoid constitutive mediator, inducible mediator, cytoprotective molecule, and cyctotoxic molecule. Since NO plays multiple physiological roles in the regulation of numerous and diverse organ functions, defects in the NO pathway lead to a variety of pathophysiological states. Possible disorders are: arterioscleroses, hypertension, coronary artery disease, cardiac failure, pulmonary hypertension, stroke, impotence, gastrointestinal ulcers, asthma, and other CNS and systemic disorders [1] .
- NOC NOC
- NOR NONOate compounds
- a class of activators of soluble guanylyl cyclase (e. g. YC-1) is known as NO-sensitizer, which may potentiate the effect of minimal NO concentrations [4] .
- NO donors One major drawback of all those NO donors consists in the fact that they exert their action largely in the extracellular environment. For example, nitro-glycerine leads to the release of NO in the plasma which stimulates vasodilation by its action on smooth muscle surrounding vessels.
- nitro and nitrooxy compounds belongs to the most widespread examples for electrophilic substitution reactions. In general all methods for nitration lead to the formation of nitronium cations as electrophiles, in most cases generated in situ [5] . Few examples are published employing NO species as a salt, e.g. nitronium tetrafluoroborate that can be employed for highly regioselective aromatic nitration [6] . Obstacles common to all methods are, besides desired selectivity, relatively harsh reaction conditions: acidity, oxidizing reactants, and temperature. Thus, classical procedures are limited to stable systems that withstand these reaction conditions.
- NO has many biological functions and as such can serve as a molecular warhead if appropriately delivered by a carrier molecule. In this regard it shares properties in common with compounds like CO and H 2 S.
- Another class of small effect molecule of natural origin are the short chain fatty acids (SCFAs) alluded to above. These compounds are products of fermentation and in the gut serve as signals of microbial metabolism which are received by the gut epithelium and in turn used to coordinate anti-microbial homeostasis and epithelial microbial modulation.
- SCFAs short chain fatty acids
- Acid trapped compounds are often amine containing compounds that are amphiphilic. They partition into the cell and concentrate in acidic compartments due to their conversion to an ionized form at pH 5-6 which is common in such organelles.
- Such acid-trapped molecules can be prepared with suitable linking groups such as hydroxyl groups. Multiple hydroxyl groups may be used to anchor one or more active molecules.
- acid-trapped compounds including common drugs such as propranolol, amodiaquine, dextromethorphan, Dextrorphan, paroxetine, fluoxetine, astemizole or imipramine.
- Azithromycin has two amine groups and is particularly strongly trapped.
- These acid trapped molecules can be derivatized, that is, decorated with signaling molecules related to anaerobic metabolism such as SCFAs, NO, or HS-donors to form compounds of the invention.
- SCFAs anaerobic metabolism
- HS-donors to form compounds of the invention.
- Using multiple signaling molecules, or combinations thereof in multiple positions allows for a flexible means to tune the properties of the molecules. For example, we described different effects for a compound carrying 3 SCFA esters versus one carrying a NO ester and a SCFA or a third donor and an SCFA. In particular, there is a hierarchy of effect with longer fatty acids promoting differing immune responses. For example propionate differs from acetate in the degree of effect in this setting.
- the invention relates to compounds useful in modulating immune cell activity or the barrier function of epithelial cells.
- the invention comprises compounds (e.g., derivative compounds of Amphiphilic Lysosomally trapped Compounds (ALC), such ALC compounds including those of the formulae in any tables herein), which are subject to lysosomal trapping and which bear moieties that are able to release TLR ligands, products of anaerobic metabolism, specifically SCFAs, sulfides, lactates, or NO, bile acids, polyamines, decarboxylated amino acids and polyphenol metabolites like phenylpropionic acid.
- ALC Amphiphilic Lysosomally trapped Compounds
- the invention also provides a method of identifying a compound useful for modulating immune cell activity against bacteria: incubating such a compound with blood cells, preferably leukocytes, providing those cells with bacteria, incubating the cells with bacteria, washing the cells and treating them with a non-permeable antibiotic to reduce extracellular bacteria, then counting intracellular bacteria to observe which compounds reduce the number of intracellular bacteria surviving.
- the ratio of the concentration of the compound in the immune cells to non-immune cells such as erythrocytic cells as a measure of its lysosomal partition.
- non-immune cells such as erythrocytic cells
- erythrocytic cells it is advantageous to determine the ratio of the concentration of the compound in the immune cells to non-immune cells such as erythrocytic cells as a measure of its lysosomal partition.
- the carrier compounds are macrolides with at least one ONO 2 -, SNO 2 - or NNO 2 -moiety. In other embodiments the carrier compounds are macrolides with at least one SCFA-moiety. In other embodiments, the carrier molecule is amphiphilic with at least one protonatable amine.
- the term “macrolide” refers to any macrocyclic lactone with 10 or more atoms connected within the ring system. Reference to an atom includes all isotopes of that atom. For example, structures drawn with carbon or hydrogen include isotopes such as 13 C or 2 H.
- An anti-microbial compound is a compound that inhibits the growth or division or replication of an organism such as a virus, bacteria, fungus, parasite, mycoplasma or other pathogen.
- One embodiment is a compound comprising an Amphiphilic Lysosomally trapped Compound (ALC) conjugated via an ester, thioester or nitroester to a product of Anaerobic Metabolism (PAM) or one or more PAMs of the same or different types.
- the compound is one in which the PAM is selected from one or more of Short Chain Fatty Acid (SCFA), NO, H 2 S, mercaptans, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid.
- SCFA Short Chain Fatty Acid
- NO NO
- H 2 S mercaptans
- polyamines decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid.
- the compound is one in which the ALC is selected from a macrolide, polyamine, propranolol analog, chloroquine analog, amodiaquine, dextromethorphan, dextrorphan, paroxetine, fluoxetine, astemizole or imipramine analog.
- Another embodiment is a macrolide comprising at least one ONO 2 -, SNO 2 - or NNO 2 moiety.
- the compound has the following formula (including any possible salts thereof, except for nitrates, and any structures with exchanged isotopes, as possible by state of the art):
- X is a SCFA esterified to ALC and 0-5 indicates the number of moieties conjugated
- Y is an NO donating group or an H 2 S donating group esterified to ALC and 0-5 indicates the number of moieties conjugated;
- Z is a group donating sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid.
- R 1 can be, but is not limited to
- R 2 can be, but is not limited to:
- R 3 can be, but is not limited to:
- R 4 can be, but is not limited to:
- R 5 can be, but is not limited to:
- R 6 can be, but is not limited to:
- R 7 can be independently chosen from:
- R 8 can be, but is not limited to:
- R 9 can be, but is not limited to
- R 12 can be, but is not limited to:
- R 14 , R 15 can independently be, but are not limited to:
- the compound has the following formula (including any possible salts thereof, except for nitrates, and any structures with exchanged isotopes, as possible by state of the art):
- X is a SCFA esterified to ALC and 0-5 indicates the number of moieties conjugated
- Y is an NO donating group or an H 2 S donating group esterified to ALC and 0-5 indicates the number of moieties conjugated;
- Z is a group donating sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid.
- R 1 can be, but is not limited to
- R 2 can be, but is not limited to:
- R 3 can be, but is not limited to:
- R 4 can be, but is not limited to:
- R 5 can be, but is not limited to:
- R 6 can be, but is not limited to:
- R 7 can be independently chosen from:
- R 8 can be, but is not limited to:
- R 9 can be, but is not limited to
- R 12 can be, but is not limited to:
- R 14 , R 15 can independently be, but are not limited to:
- the compound has the following formula (including any any possible salts thereof, except for nitrates, and any structures with exchanged isotopes, as possible by state of the art):
- R 1 , R 2 , R 4 , R 5 , R 6 , X, and Z are defined as in formula 2;
- R 3a , R 3b both —H
- R 7 , R 14 , and R 15 are defined as in formula 2.
- X can be O or S
- R 1 may be but not limited to —(C ⁇ O)CH 3 , —(C ⁇ O)CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 COOH, —(C ⁇ O)(C ⁇ O)CH 3 , - 13 (C ⁇ O)CHCHCOOH, —(C ⁇ O)CH(OH)CH 3 , —(C ⁇ O)C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 2 Y, or —(C ⁇ O)CH(ONO 2 )CH 3 ;
- Y can be a 5-membered saturated ring containing a disulfide bond
- R 1 may be but not limited to —(C ⁇ O)CH 3 , —(C ⁇ O)CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 COOH, —(C ⁇ O)(C ⁇ O)CH 3 , —(C ⁇ O)CHCHCOOH, —(C ⁇ O)CH(OH)CH 3 , —(C ⁇ O)C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 2 Y, or —(C ⁇ O)CH(ONO 2 )CH 3 ;
- Y can be a 5-membered saturated ring containing a disulfide bond
- R 1 may be but not limited to —(C ⁇ O)CH 3 , —(C ⁇ O)CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 COOH, —(C ⁇ O)(C ⁇ O)CH 3 , —(C ⁇ O)CHCHCOOH, —(C ⁇ O)CH(OH)CH 3 , —(C ⁇ O)C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 2 Y, or —(C ⁇ O)CH(ONO 2 )CH 3 ;
- Y can be a 5-membered saturated ring containing a disulfide bond
- R 1 is NO 2
- R 2 H or CH 3
- R 3 OR 5
- R 5 may be but not limited to —(C ⁇ O)CH 3 , —(C ⁇ O)CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 CH 2 COOH, —(C ⁇ O)(C ⁇ O)CH 3 , —(C ⁇ O)CHCHCOOH, —(C ⁇ O)CH(OH)CH 3 , —(C ⁇ O)C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 3 , —(C ⁇ O)CH 2 C(CH 3 ) 2 , —(C ⁇ O)CH 2 CH 2 CH 2 CH 2 Y, or —(C ⁇ O)CH(ONO 2 )CH 3 ;
- Y can be a 5-membered saturated ring containing a disulfide bond
- Substituents on ALC Formulae e.g., Macrofides, Hydroxychloroquine, Propranolol, etc.
- Mac a macrolide ring or macrolide ring system, for example, but not limited to azithromycin or gamithromycin, each without the desosamin residue.
- Mac a macrolide ring or macrolide ring system, for example, but not limited to azithromycin or gamithromycin, each without the desosamin residue;
- R 1 , R 2 independently of each other H, OH, OR 4 , -C 1 -C 10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl;
- alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: fluorine, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 9 )heterocycloalkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 4 )alkoxy, hydroxyl (—OH), nitro (—NO 2 ), cyano (—CN), azido (—N 3 ), mercapto (—SH), (C 1 -C 4 )alkthio, —NR 4 R 5 , R 4 C( ⁇ O)—, R 4 C( ⁇ O)O—, R
- N(R 1 R 2 ) is an aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane, 1-substituted piperazine, or morpholine moiety;
- R 3 -C 1 -C 10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkenyl, (C 1 -C 4 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 1 -C 9 )heterocycloalkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 4 )alkoxy, hydroxyl (—OH), nitro (—NO 2 ), cyano (—to CN), azido (—N 3 ), mer
- R 4 , R 5 , R 6 and R 7 can independently be, but are not limited to:
- macrolactone refers to the family of well-known macrolactone antibiotics and also the various macrolactone ALCs described herein.
- the invention provides a composition
- a composition comprising a compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier.
- the composition can further comprise an additional therapeutic agent.
- the invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or symptom thereof.
- the method includes administering to a subject in need thereof a therapeutically effective amount of a compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof.
- the disease, disorder, or symptom thereof can be, for example, an infectious disease, an inflammatory disease, a malignant disease, a bacterial infection, an inflammatory reaction to a bacterial translocation event, an inflammation of the GI tract including intestines, colon, liver and pancreas, an inflammation of the airways, a systemic inflammatory disease or a malignant or neoplastic disease.
- the invention provides a method of stimulating immune or epithelial cells to form an anti-infective barrier or anti-infective response comprising contacting the cells with a compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., any of the formulae, any formula in the tables herein
- salt, solvate, hydrate or prodrug thereof e.g., any of the formulae, any formula in the tables herein
- a further aspect of the method is wherein the contacting results in the intracellular release of a PAM comprising one or more of a molecule type selected from SCFA, NO, H 2 S, sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid from the compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof.
- a PAM comprising one or more of a molecule type selected from SCFA, NO, H 2 S, sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid from the compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof.
- a further aspect of the method is that comprising the intracellular release of one or more types of a short chain fatty acid moiety from the compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof.
- a further aspect of the method is that comprising the intracellular release of a short chain fatty acid moiety containing 2 or more carbons from an appropriate carrier molecule.
- the compound of the invention is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound of the invention to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
- a pharmaceutically-acceptable formulation e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound of the invention to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
- these pharmaceutical compositions are suitable bar topical or oral administration to a subject.
- the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- phrases “pharmaceutically acceptable” refers to those compound of the inventions of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- salts or “pharmaceutically acceptable. carrier” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention.
- substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example.
- sugars such as lactose, glucose and sucrose
- wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, anti-oxidants and preservatives, can also be present.
- Solubilizing agents including for example, cremaphore and beta-cyclodextrins can also be used in the pharmaceutical compositions herein.
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- Initial dosages also can be estimated from in vivo data, such as animal models. Animal models useful for testing the efficacy of compounds to treat or prevent the various diseases described above are well-known in the art.
- Dosage amounts will typically be in the range of from about 0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, (e.g., 0.01 to 1 mg/kg effective dose) but can be higher or lower, depending upon, among other factors, the activity of the compound, its bioavailability, the mode of administration, and various factors discussed above. Dosage amount and interval can be adjusted individually to provide plasma levels of the compound(s) which are sufficient to maintain therapeutic or prophylactic effect. In cases of local administration or selective uptake, such as local topical administration, the effective local concentration of active compound(s) cannot be related to plasma concentration. Skilled artisans will be able to optimize effective local dosages without undue experimentation
- the compound(s) can be administered once per day, a few or several times per day, or even multiple times per day, depending upon, among other things, the indication being treated and the judgment of the prescribing physician.
- the compound(s) will provide therapeutic or prophylactic benefit without causing substantial toxicity.
- Toxicity of the compound(s) can be determined using standard pharmaceutical procedures.
- the dose ratio between toxic and therapeutic (or prophylactic) effect is the therapeutic index.
- Compounds(s) that exhibit high therapeutic indices are preferred.
- Another object of the present invention is the use of a compound as described herein (e.g., of any formulae herein) in the manufacture of a medicament for use in the treatment of a disorder or disease herein.
- Another object of the present invention is the use of a compound as described herein (e.g., of any formulae herein) for use in the treatment of a disorder or disease herein.
- Many compounds of this invention have one or more double bonds, or one or more asymmetric centers. Such compounds can occur as racemates, racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans- or E- or Z-double isomeric forms.
- N-oxides refers to one or more nitrogen atoms, when present in a compound, are in N-oxide form, i.e., N ⁇ O.
- stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., treating a disease).
- the present invention relates to a mild and highly selective process for the in situ introduction of the O—, S— and N-nitrate group into compounds of any othe formulae herein.
- NO donors are well known in medicine as a means to modulate blood pressure and inflammation [13] .
- Such NO donors exert their action, as aforementioned, largely in the extracellular environment.
- release of NO in the blood results in effects on the endothelium which are desirable.
- modulators of inflammation general release of NO may result in side effects such as loss of blood pressure which are undesirable.
- SCFAs are volatile. malodourous and unstable.
- PAMs such as polyamines are similarly unattractive for direct use. While these products such as SCFAs or NO (inhaled gas) have been applied to the body, they are used in amounts that are undesirable. The technical problem to solve, was, therefore, to focus the release of these products (NO, SCFA, PAMs) to cells associated with inflammation, cancer or infection such that lower amounts could be used.
- Macrolide anti-bacterial compounds are well known for their ability to be concentrated in acidic compartments, notably the phagosomes of immune cells such as neutrophils and macrophage [14] .
- Phagosomes are the organs where bacteria and other debris are digested by the phagocytes using oxidative processes and digestive enzymes. Certain bacteria resist this process by reducing the capacity of the cell to produce antibacterial factors (lower pH, proteases, active oxygen species, antibacterial enzymes, NO).
- a compound was also trapped in the phagosome that was capable of donating a stimulatory factor such as SCFA, PAM or NO, then there is the potential to overcome the inhibition due to the bacterium. More importantly, if the Phagocyte absorbs a compound able to donate SCFA, PAM or NO prior to that phagocyte encountering bacteria, it is potentially stimulated to better kill bacteria immediately on contact with them. This is potentially of significance in treating infections by bacteria such as Legionella, Pasteurella, Listeria and Mycobacterium species that are intracellular parasites. It is also potentially significant in the stimulation of barrier cells to resist the effect of bacteria, or to maintain physical barriers toward bacteria.
- SCFA In addition to their roles in immunology, SCFA, NO and PAM have a role in homeostasis, acute inflammation and wound healing [15] .
- Phagocytes like macrophages are involved in many aspects of metabolism and are sensitive to SCFA, NO and PAM.
- the delivery of these substances preferentially to cells of this type is a means to allow them to respond to the stimulus of SCFA, PAM or NO without using high systemic levels. This is achieved by delivering the substances as conjugates to lysosomally tropic compounds (ALCs).
- ALCs lysosomally tropic compounds
- Anti-infective barrier means the ability of epithelium to prevent the penetration of bacteria or other pathogens.
- Stimulating the formation of an anti-infective barrier means increasing the ability of epithelium to prevent the penetration of bacteria or other pathogens through the up-regulation of tight junction formation or other barrier functions.
- Anti-infective response means the ability of immune cells or similar to prevent the growth of bacteria or other pathogens via phagocytosis, oxidative burst or other toxic responses inactivating the pathogen.
- Stimulating the formation of an anti-infective response means increasing the ability of immune cells or similar cells to prevent the growth of bacteria or other pathogens via phagocytosis, oxidative burst or other toxic responses inactivating the pathogen.
- ALC means an Amphiphilic Lysosomally trapped Compound.
- PAM Product of Anaerobic Metabolism.
- PAMs include but are not limited to SCFA, NO, H 2 S, mercaptans that eventually generate H 2 S/HS ⁇ polyamines (e.g., compounds of Table 7), amino acid residues lacking the C-terminus (decarboxlated), bile acids (e.g., steroid acids found in the bile of mammals and other vertebrates, such as chenodeoxycholic acid, cholic acid, deoxycholic acid, lithocholic acid, and the like), or degradation products from polyphenol metabolism such as 3-(3-Hydroxyphenyl)propanoic (hMPP) acid, SCFA means Short Chain Fatty Acid, which is a fatty acid molecule haying an aliphatic tail of eight or less carbon atoms.
- Nitric Oxide Nitric Oxide
- the compounds reported here are useful in many respects. They are anti-microbial, anti-inflammatory, able to accumulate in tumors and donate NO and able to protect against inflammation of the intestine. Selected embodiments are able to modulate inflammation of the liver and protect against accumulation of fat or the resulting fibrosis.
- the compounds are readily soluble as salts, may be provided by the oral route, or via other means. They are adequately stable for pharmacological use when stored at the appropriate pH conditions.
- FIG. 1 TNFa-Production by LPS treated mice with either Vehicle (1% citric acid in water, 5 mL/kg) or 10 ⁇ mol/kg Compound E2 or Compound E3.
- FIG. 2 Change in body weight in mice in which arthritis has been induced using bovine collagen. Animals were treated with either Vehicle (1% citric acid in water, 5 mL/kg) or the indicated doses of compound E2 ⁇ mol/kg. Data are from 10 animals per group, and data points significant different from Vehicle are marked with *.
- FIG. 3 Number of mice maintaining body weight in which intestinal inflammation has been induced using Dextran Sulfate. Mice were treated with Vehicle (1% citric acid in water, 5 mL/kg) or the indicated doses of compound E2 in ⁇ mol/kg.
- FIG. 4 Killing of phagocytosed Salmonella typhimurium by murine macrophages treated with either the commercial antibiotic azithromycin or Compound E2.
- Compound E2 stimulates the killing of bacterial cells by macrophages.
- FIG. 5 Effect of substance E5 on the response of mice to an infection by Staphylococcus. Treatment with the substance E5 results in a faster recovery of weight due to faster clearance of bacteria
- FIG. 6 Effect of substances E2, E5 and Azithromycin on the ability of mice to clear an infection by Staphylococcus aureus Newman. Bacteria are quantified as CFU recovered from a standard sample of kidney. Treatment with substances decreases recovered bacteria in a dose responsive manner.
- FIG. 7 Effect of substances on the ability of mice to tolerate dextran sulfate colitis. Cyclosporine is provided at a dose of 25 mg/kg, all other substances including azithromycin are provided at a dose of 0.1 ⁇ mol/kg.
- FITC fluorocein labelled dextran
- FIG. 20 The compounds containing R 1 nitrate ester have preferential distribution to the lung. Data show the concentration of the substance in the lung and liver at 6 h after administration of a 10 mg/kg dose p.o. in 2% citric acid.
- FIG. 21 The effect of various compounds on the rate of killing of Salmonella typhimurium following incubation and phagocytosis by J774 murine cells.
- the number of surviving bacteria is an indicator of the degree of intracellular killing of the bacteria, All substances are supplied at an initial concentration of 1 ⁇ M.
- the compound to be nitrated (1 equiv.) (—SH, —OH, —NH) is dissolved or suspended in acetic acid (approximately 6.0 ml per 1 mmol compound to be nitrated) and a solution of nitric acid (10% in acetic anhydride, about 3.25 ml per 1 mmol compound to be nitrated) is slowly added to the system while cooling in an ice bath.
- acetic acid approximately 6.0 ml per 1 mmol compound to be nitrated
- nitric acid 10% in acetic anhydride, about 3.25 ml per 1 mmol compound to be nitrated
- Method 1 Acetic acid (40 mL) and Azithromycin (5 g, 6.73 mmol) were charged in a round bottom flask. Initially, the reaction solidified which eventually during stifling, produced a homogenous solution. The resulting solution was cooled in an ice-bath. Acetic anhydride (19.8 mL, 209.5 mmol) was taken up in another reaction flask and cooled in an in ice bath. To this was added dropwise, nitric acid (2.2 mL, 46.43 mmol). After complete addition, the mixture was transferred to a dropping funnel and attached to the first reaction vessel containing the macrolide. The HNO 3 -Ac 2 O mixture was slowly added to the reaction (ca. 1 drop per second).
- Method 2 Hydroxyalkyl species (1 mmol) was suspended in acetonitrile in a round bottom flask while stirring (magnetic stir bar, 300 rpm). Silver nitrate (2 eq. per hydroxyl group) was added and the mixture was cooled in an ice bath. Phosgene (solution in toluene, 1 eq. per hydroxyl group) was carefully added dropwise. Immediate precipitation of silver chloride and formation of carbon dioxide indicated formation of nitro donor (caution: too quick CO 2 formation may result in strong foaming. Do not seal the flask!). After a couple of minutes a yellow color was obtained and stirring was continued for 15 minutes.
- E-3 was synthesized using standard nitration procedure described above starting from E-20.
- Method 1 A solution of propionic acid (1.2 mmol) in 1.2-dichloroethane was treated with 1-Ethyl-3-(3-dimethyl-aminopropyl)carbodiimid (1.2 mmol) in the presence of a catalytical amount of DMAP for 30 min. at ambient temperature. Temperature was raised to 55°C., E-1 (1 mmol) was added and stirring was continued until TLC (acetone-cyclohexane 1:3) indicated complete consumption of the starting materials. The system was extracted with water (3 ⁇ 10 ml). After drying over Na 2 SO 4 all volatile components were evaporated in vacuo, traces of pyridine species were removed by co-evaporation with toluene (2 ⁇ ). The crude products were purified by column chromatography (acetone-cyclohexane 1:3), yielding the product E-5 as white amorphous foam (39%).
- Method 3 A-1 (300 mg, 0.40 mmol), was dissolved in DCM (10 mL); to this solution was added TEA (279 ⁇ L, 5 eq) and propionylchloride (175 ⁇ L, 5 eq) subsequently and the mixture was stirred overnight at room temperature. Additional TEA (112 ⁇ L, 2 eq) and propionyl chloride (70 ⁇ L, 2 eq) were added and again mixture was stirred overnight at room temperature. Once more additional TEA (112 ⁇ L, 2 eq) and propionyl chloride (70 ⁇ L, 2 eq) were added and stirring at room temperature was continued overnight.
- Erythromycin oxime was nitrated as described in the general procedure, followed by subsequent acetylation of crude nitration product with acetic anhydride in DCM with pyridine as catalyst.
- Column chromatography acetone-cyclohexane 1:3 furnished the product E-8 as white amorphous foam (39%, two steps).
- Azithromycin was nitrated as described above. After desired mono-nitration MeOH was added to the reaction mixture and stirring was continued for one further hour. Thus in situ generated methyl nitrate acted as methylating agent transferring one methyl group to 11-O-position of the macrolide at ambient temperature. Standard aqueous workup with subsequent purification by column chromatography (acetone-cyclohexane 1:3) delivered methylated macrolide nitrate E-11 as white amorphous solid (63%, two steps).
- Azithromycin (20.0 g; 26.7 mmol) was dissolved in 120 ml of MeOH. NaHCO 3 (6.0 g; 71.5 mmol) was added, followed by a solution of K 2 CO 3 (12.0 g; in water (80 ml; cooled down to RT), and finally iodine (6.3 g; 24.8 mmol). The mixture was stirred vigorously at ambient temperature until the dark color had disappeared. A second batch of iodine (6.3 g; 24.8 mmol) and K 2 CO 3 carbonate (4.2 g; 30 mmol) were added.
- Azido- ⁇ -D-Glucopyranoside is synthesized from corresponding sugar acetate as is known to literature [16] . After removal of any protective groups sugar azide is nitrated following above procedure. Due to its high explosive risk the substance is always kept as DCM solution and is stashed in the refrigerator.
- 250 mg of 2′-(2-Mercaptoethoxy)carbonyl-3-decladinosylazithromycin and 250 mg of ammonium polysulfide are mixed with 10 ml of degassed and argonized glacial acetic acid and stirred with exclusion of oxygen for 12 h. All volatiles are removed in vacuo, and the residue is extracted with oxygen free saturated aqueous sodium hydrogen carbonate solution 3 times. The residue is washed with water (oxygen free), dried in vacuo and used as such.
- 250 mg of 2′-(2-Mercaptoethoxy)carbonyl-3-decladinosylazithromycin are dissolved in a mixture of 5 ml of tert. butanol and 5 ml of dichloromethane.
- 250 ⁇ l of tert. butylnitrite are added, and the mixture is stirred for 48 h with exclusion of light. All volatiles are removed i.v. keeping the temperature below 20° C. and light excluded. The red residue is used as such
- Propranolol HCl 200 mg, 0.68 mmol was taken up in dichloromethane (4 mL). To this was added dropwise butyryl chloride (69 ⁇ L, 0.71 mmol) and the reaction was stirred at room temperature for 1 hour. To the reaction was added triethylamine (194 ⁇ L, 1.4 mmol). After 30 min, additional butyryl chloride (30 ⁇ L, 0.3 mmol) was added. Reaction was monitored by the disappearance of starting material. The reaction was stopped after 20 min by the addition of 10 mL 10% aqueous Na 2 CO 3 solution. The two phases were stirred for 5 min separated.
- Hydroxychloroquine sulfate (1099 mg, 2.53 mmol) was charged into a round bottom flask. H 2 O (10 mL) and dichloromethane (10 mL) were added. Pyridine (412 ⁇ L, 5.1 mmol) was added and the reaction stirred vigorously for 5 min. Butyric anhydride (420 ⁇ L, 2.65 mmol) was added and the reaction stirred at room temperature for 3 h. The phases were separated and the dichloromethane layer was washed successively with a saturated aqueous NH 4 Cl solution (2 ⁇ 15 mL), H 2 O (2 ⁇ 10 mL), dried over Na 2 SO 4 and evaporated in vacuo. Co-evaporation with toluene is necessary to remove residual pyridine from the system. This was followed by re-dissolving the residue in DCM and solvent evaporation twice to produce a yellow oil (93 mg, 9% yield).
- Typical methylation reaction of Hydroxychloroquine or Propranolol was achieved using Eschweiler-Clarke-methylation reaction. Acylation reactions were carried out using typical procedures described above.
- carrier molecules are prepared by reacting symmetric or unsymmetric di- or poly-epoxides with secondary amines, thus containing the common structural element of 2 or more alcohols, vicinally neighbored by a tertiary amine.
- carrier molecules can be prepared by reacting epoxides with diethanolamine.
- the reaction products are containing 2-hydroxy tertiary amines.
- the 2-aminoalcohols of these carriers can be esterified to short chain carboxylic acids or nitric acid.
- One molecule can contain esters of different of these acids. Examples for short chain carboxylic acids are:
- these carrier molecules are prepared by reacting symmetric or unsymmetric di- or polyamines with epoxides, thus containing the common structural element of 2 or more alcohols, vicinally neighboured by a tertiary amine.
- the 2-aminoalcohols of these carriers can be esterified to short chain carboxylic acids or nitric acid.
- One molecule can contain esters of different of these acids. Examples for short chain carboxylic acids are:
- Diethyl azodicarboxylate (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (25 mL) at 0° C. and treatment is continued for 30 min.
- Propranolol (5 mmol) and thioacetic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 h at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Lactic acid (10 mmol) is suspended in acetonitrile (20 mL) in a 3-necked round bottom flask and is cooled to 0° C. in an ice bath while stirring (300 rpm).
- Diphosgene is added (5 mmol) followed by careful dropwise addition of silver nitrate solution (20 mmol, dissolved in acetonitrile).
- the mixture is stirred for 30 min at 0° C., subsequently is allowed to warm up to ambient temperature and stirring is continued for further 30 min. Afterwards any precipitates are filtered off and the mixture is carefully concentrated in vacuo, As crude products are likely to be explosive compounds the system was not fully dried but taken up in THF (10 mL) to be immediately used in the following step.
- Diethyl azodicarboxylat (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (25 mL) at 0° C. and treatment is continued for 30 min.
- 2-O-nitrolactic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 hours at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Mixed disulfides may also be accessible in this way but require slight alterations.
- Bacteria including the species Escherichia coli, Bacillus pumilus, Salmonella sp., Micrococcus luteus and Staphylococcus carnosus are cultured in appropriate media (Luria broth for all except S. canosus ). Overnight cultures are mixed with fresh medium to reach an optical density at 600 nM of ca. 0.1 AU. These cultures are mixed with solutions of substances to be tested at concentrations ranging from 100 ⁇ M to 0.05 ⁇ M in a microtitre plate. The growth of the culture is monitored by measuring the optical density at various times after the addition of the inhibitor. Reduction in the rate of increase in optical density corresponds to an inhibition of bacterial growth.
- the activity of various of the test substances may be observed by reductions in optical density relative to untreated control cultures. The data are summarized in Table 3 and Table 4.
- Substances may act directly on bacteria, or they may act to promote the killing of the bacteria by phagocytes.
- cultures murine macrophages are incubated with a test bacteria and the number of bacteria surviving are counted in terms of the viable colony forming units (CFU).
- CFU viable colony forming units
- lyse cells with water add 200 ⁇ l H2O incubate 10′, push a few times through 27 gauge needle using a 1 ml syringe
- the potential efficacy of a Compound for Inflammatory bowel disease may be modeled as follows. C57 BLK6 or BALBc mice are provided with drinking water containing 2.5% or 2.8% dextran sulfate. Animals are weighed and observed for signs of intestinal disturbance daily. Signs include diarrhea or occult blood. Compound is formulated by mixing with a solution of 0.1 up to 1% citric acid depending on concentration. Compound is provided by oral gavage daily. Example data for the efficacy of compounds cited here is provided in FIG. 3 , 7 , 8 or 10 - 19 .
- the potential efficacy of a Compound for rheumatoid arthritis may be modeled as follows. DBA1 mice are induced by a subcutaneous injection of bovine collagen in 0.05M acetic acid, emulsified in Freund's adjuvant. 21 days later, a second injection of this material is made without inclusion of mycobacterial material in the adjuvant. Animals are weighed and observed for signs of inflammation daily. Signs include weight loss, swelling of paws, redness and reduced mobility. Compound is formulated by mixing with a solution of 1% citric acid. Compound is provided by oral gavage daily. Data for the efficacy of compounds cited here is provided in FIG. 2 .
- the potential efficacy of a Compound in modulating immune reactions may be determined as follows. Swiss or C57 Blk6 mice are induced to produce cytokines by a subcutaneous injection of lipopolysaccharide, Typically, compound is provided at time 0. Compound is formulated by mixing with a solution of 1% citric acid for oral treatment or, dissolved in PEG 300 and diluted in water for intra-peritoneal treatment. Compound is provided by oral gavage. 30 minutes after providing compound, animals are treated with an intra-peritoneal injection of a solution of lipopolysaccharide in the concentration range that will provide 0.01 mg/kg lipopolysaccharide. Data for the efficacy of compounds cited here is provided in FIG. 1 .
- the potential efficacy of a Compound in treating a malignant disease may be determined as follows. Tumours are known to be deficient in nitric oxide and this is considered to be a cause of local tolerance. Providing a nitric oxide donor that is accumulated in macrophages in the tumour environment provides a means to artificially modify the local NO status. C57 Blk6 mice are injected subcutaneously with an murine ovarian cancer cell line expressing ovalbumin. Mice bearing tumours are selected after 14 days. Typically, compound is provided at this time. Compound is formulated by mixing with a solution of 1% citric acid for oral treatment. Compound is provided by oral gavage. Animals are monitored daily for tumour size, body weight and activity score. The activity of the compound may be determined in combination with other therapies including anti-bodies or vaccines based on a tumour antigen. In this case ovalbumin, can serve as a model antigen.
- 11-O-Nitro-azithromycin (0.25 mmol) was dissolved in dry dichloromethane (5 mL). To this was added EDCI (2 eq., 0.5 mmol) and 2-ferrocenyl acetic acid (1.1 eq., 0.28 mmol). The reaction was stirred overnight at room temperature. The solvent was removed in vacuo and the resulting white amorphous foam. The resulting crude product was purified by column chromatography with a gradient starting at 10% of acetone in cyclohexane (0.2% Et 3 N).
- Diethyl azodicarboxylat (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (2.5 mL) at 0° C. and treatment is continued for 30 min.
- Propranolol (5 mmol) and propionic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 hours at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Diethyl azodicarboxylate (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (25 mL) at 0° C. and treatment is continued for 30 min.
- Propranolol (5 mmol) and 2-acetoxypropionic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 hours at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Method 1 ALC (1.0 mmol) was taken up in 15 mL dichloromethane. Pyridine (1.2 eq.) was added and the resulting solution was cooled in an ice bath for approximately 10 minutes. At this point, a solution of acetic anhydride (1.2 eq) was added dropwise. The reaction was stirred continually at this temperature and then progressively warmed to room temperature where it was stirred overnight. Reaction progress was monitored either by TLC and/or MS. The reaction was washed with a saturated solution of ammonium chloride (3 ⁇ ), water (3 ⁇ ) and dried over anhydrous Na 2 SO 4 . The solvent was evaporated in vacuo. Co-evaporation with toluene is necessary to remove residual pyridine from the system. This was followed by re-dissolving the residue in DCM and solvent evaporation twice to produce a white foam, which was dried under high-vacuum to produce acetylated product.
- the filtrate was collected and then washed with a saturated solution of sodium hydrogencarbonate (3 ⁇ ), water (1 ⁇ ) and dried over anhydrous Na 2 SO 4 .
- the solvent was evaporated in vacuo. This was followed by re-dissolving the residue in a small volume of methanol.
- the solution was transported dropwise into ice-cold water (2 ⁇ volume of methanol) and stored in the freezer overnight.
- the precipitated product was filtered off and dried under high-vacuum to produce a product.
- Method 1 Compound A-1 was taken up in dichloromethane and stirred for 10 min. At this point, a solution of carboxylic anhydride and triethylamine in dichloromethane was added dropwise. The reaction was stirred continually at room temperature. The reaction solution was washed with 5% citric acid three times to extract the product. Acidic solution was then washed with ethyl acetate (2 ⁇ ) and afterwards neutralized with Na 2 CO 3 . Product was extracted with ethyl acetate (3 ⁇ ). The solution was washed with a saturated solution of sodium chloride (2 ⁇ ), water (2 ⁇ ) and dried over anhydrous Na 2 SO 4 . The to solvent was evaporated in vacuo to produce a white foam containing product.
- Method 2 Compound A-1 was taken up in dichloromethane and was cooled in an ice bath for approximately 10 minutes. At this point, a solution of carboxylic chloride in dichloromethane was added dropwise. The reaction was stirred continually at this temperature for 15 min and then progressively warmed to room temperature where it was stirred for 2.5 h.
- reaction was washed with a 10% solution of Na 2 CO 3 (3 ⁇ ), water (3 ⁇ ) and dried over anhydrous Na 2 SO 4 .
- the solvent was evaporated in vacuo. Co-evaporation with toluene is necessary three times. This was followed by re-dissolving the residue in dichloromethane to produce a white foam, which was dried under high-vacuum to produce product.
- Method 3 Starting material was taken up in dichloromethane and stirred for 10 min. At this point, a solution of carboxylic chloride and triethylamine in dichloromethane was added dropwise. The reaction was stirred continually at room temperature for two days. The reaction solution was washed with 5% citric acid three times to extract the product. Acidic solution was then washed with ethyl acetate (2 ⁇ ) and afterwards neutralized with Na 2 CO 3 . Product was extracted with ethyl acetate (3 ⁇ ). The solution was washed with a saturated solution of sodium chloride (2 ⁇ ), water (2 ⁇ ) and dried over anhydrous Na 2 SO 4 . The solvent was evaporated in vacuo to produce a white foam containing product.
- Method 4 Compound E-48 or E-39 was solved in methanol to hydrolyze butyric esters. The reaction was stirred continually at room temperature for two days. The reaction solution was washed with ethyl acetate three times to extract the product. The ethyl acetate phase was washed with 5% citric acid (3 ⁇ ). Acidic solution was then washed with ethyl acetate (2 ⁇ ) and afterwards neutralized with Na 2 CO 3 . Product was extracted with ethyl acetate (3 ⁇ ). The solution was washed with a saturated solution of sodium chloride (2 ⁇ ), water (2 ⁇ ) and dried over anhydrous Na 2 SO 4 . The solvent was evaporated in vacuo to produce a white foam containing product.
- the product was dried at the oil pump. Products were obtained as colorless solids or foams.
- Method 1 Isovaleric acid (4.4 equiv./equiv. ALC) and HOBt 85% (4.4 equiv./equiv. ALC) were dissolved in DMF (12.5 mml/mmol ALC). The solution was cooled down to 0-5° C. in an ice-bath. At this temperature a solution of Dicyclohexylcarbodiimide (4.5 equiv./equiv. ALC) in DCM (5 ml/mmol ALC) was added dropwise within 30 min. the solution was kept at this temperature for another 10 min. Then Azithromycin (1 equiv.) was added in one portion. While stirring, the solution was allowed to come to room temperature within 2 h.
- Method 2 B Analogue to 2 A but after stirring at room temperature for 2 h additional pyridine (2 equiv.) and isovaleric acid anhydride (2 equiv.) were added and stirring was continued overnight.
- Macrolide (1 mmol) is dissolved in DMF (500 ⁇ l). Epichlorohydrin (1 mL) is added and the mixture is heated to 80° C. for 12 h. When MS analysis indicates complete conversion, all volatiles are removed in vacuo and the residue is dissolved in ethanol (1 ml). The solution is poured into 25 ml of water. The precipitate is isolated and can be used directly for the next step or is chromatographed to obtain the pure epoxide.
- Epoxide (1 mmol) is dissolved in 2-propanol (500 ⁇ l), and an excess of 5 equivalent of an amine is added. The mixture is heated from 12 h to 100 h at 80° C. When MS indicates complete conversion, all volatiles are evaporated and the residue subjected to chromatography to separate the 2 regioisomeric amines.
- Method 1 Compound A-1 (2000 mg, 2.67 mmol) was taken up in 10 mL dichloromethane and stirred. Separately 4.4 eq of a carboxylic acid and 4.4 eq of 1,1′-Carbonyldiimidazole were solved in dichloromethane (10 mL) and stirred over 20 min. Both solutions were unified and stirred continually at room temperature. The dichloromethane phase was washed with saturated NaHCO 3 solution (2 ⁇ ) and dried with Na 2 SO 4 (anhydrous). The solvent was evaporated in vacuo to produce a white foam containing products of reaction.
- ALCs can be prepared by reacting symmetrical or unsymmetrical di- or poly-epoxides with secondary amines. This will provide ALCs that contains common structural element of 2 or more alcohols, vicinally neighbored by a tertiary amine. Some polyamines are also commercially available.
- ALCs can be prepared by reacting epoxides with diethanolamine.
- the reaction products are containing 2-hydroxy tertiary amines.
- Polyamine (1 mmol) containing at least 2 NH-functions and the epoxide are mixed and heated without solvent to 80° C. Excess epoxide can be removed by column chromatography selectively. Products are sufficient, when at least 2 tertiary ß-hydroxyamines are present.
- Corresponding polyepoxide (1 mmol) is mixed with 1.05 mmol secondary amine per epoxide function and heated to 80° C. without solvent for 12 h.
- N-Hydroxyalkyl compound (5 mmol) was suspended in excess carboxyl acid anhydride (>100 mmol, >20 eq.) in a round bottom flask while stirring (magnetic stir bar, 500 rpm). The mixture was cooled in an ice bath and sulfuric acid (>96%, 3 drops) was carefully added as catalyst. Stirring was continued until a clear solution was obtained. When ESI-MS indicated full conversion of starting materials the reaction mixture was poured on ice. The system was stirred for 2 or more hours in order to hydrolyze any anhydride. The mixture was neutralized by addition of sodium bicarbonate and extracted with dichloromethane (3 ⁇ ). Separation of organic phase, drying over sodium sulfate and evaporation of any volatiles in vacuo yielded the product as colorless oil.
- 1,1′-Carbonyldiimidazole was dissolved in dichloromethane (dry, 25 mL) and to this was added the carboxylic acid slowly at room temperature. The solution was stirred at room temperature before a suspension of N;N,N′,N′-tetrakis (2-hydroxyethyl)-ethylendiamine (A-19.2) in dichloromethane (dry, 5 mL) was added in one portion at room temperature and the mixture was stirred at RT. The reaction mixture was filled into a separation funnel and washed. The organic phase was dried (Na 2 SO 4 ) and concentrated to dryness in vacuo. The crude product was purified by column chromatography.
- H-L-orn(Boc)2CT Resin (0.68 mmol/g, 100-200 mesh, 2.99 g, 2.07 mmol) was filled into a 20 mL syringe with frit.
- Dichloromethane dry, 10 mL
- MeOH MeOH
- diisopropylethylamine 2 mL
- the mixture was shaken at room temperature for 30 min, then the liquid was sucked off and the resin was washed (3 ⁇ dimethylformamide 15 mL, 1 ⁇ diethylether 15 mL).
- the resin was filled into a 100 mL round bottom flask. DMF (25 mL) was added and the resin was swollen for 5 min. Then diisopropylethylamine (3.8 mL, 22.3 mmol) and 2-bromoethanol (1.434 mL, 20.3 mmol) were added subsequently at room temperature. The reaction mixture was stirred at 60° C. (bath temperature) for 24 h.
- the resin was filled into a 20 mL syringe with frit and was washed:
- a test cleavage showed the product by mass spectrometry
- ALC A-1 (0.25 mmol) was dissolved in dry dichloromethane (5 mL). To this was added EDCI (2 eq., 0.5 mmol) and 2-ferrocenyl acetic acid (1.1 eq., 0.28 mmol). The reaction was stirred overnight at room temperature. The solvent was removed in vacuo and the resulting white amorphous foam. The resulting crude product was purified by column chromatography with a gradient starting at 10% of acetone in cyclohexane (0.2% Et 3 N).
- the reaction conditions also produced the des-cladinosyl product E-600.
- the distribution of compounds to target organs is of specific importance to the efficacy of anti-infective compounds.
- the compounds are formulated and administered to a suitable animal model. Compounds were administered p.o. 10 mg/kg in 2% citric acid in BALBc and organs were recovered at 6 h. Organs were extracted in Acetonitrile (6 ⁇ volume of the sample), centrifuged at 14000 g for 5 minutes. Samples were analysed by LCMSMS (SCIEX 4500). Data are the mean of 3 animals.
- the distribution of compounds to target cells is of specific importance to the efficacy of anti-infective compounds.
- the compounds are dissolved in DMSO or citric acid and mixed with whole blood, plasma or cell medium.
- cultured macrophages To these solutions are added cultured macrophages, cultured immune cells, bone marrow derived macrophages, peritoneal macrophages or buffy coat cells.
- the mixture is incubated at 37° C. for 1, 2, or 3 hours.
- the immune cells are separated from the medium and the concentration of the compounds is determined by extraction in Acetonitrile (6 ⁇ volume of the sample), followed by centrifugation at 14000 g for 5 minutes.
- the resulting extracts are analyzed by LCMSMS (SCIEX 4500 in positive mode). Data are the mean of 3 animals.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.
Description
- This application claims priority to U.S. Provisional Application No. 62/466,827, filed Mar. 3, 2017, which is incorporated herein by reference in its entirety.
- The human body senses bacteria, fungi or other parasites by both recognition of their surface patterns and via reception of the metabolic products of those organisms. In particular, the immune system is sensitive to the presence of anaerobic organisms which, by their nature are able to infect poorly perfused tissue, or emanate from the anaerobic lumen of the gut. Anaerobes seem to be a particular source of danger signals for the immune system because they often produce toxins and are able to proliferate in the absence of oxygen, where immune cells are less active and less able to use oxidative burst to kill the bacteria they ingest.
- Amongst the signals that human cells respond to are the products of fermentation such as the short chain fatty acids (SCFAs) acetate, propionate and butyrate. Less characterised mediators with similar function include: lactic acid, H2S, HS—, nitrite, polyamines and similar decarboxylated amino acids such as 3-Indolepropionic acid (IPA), deoxybileacids and polyphenol metabolites like phenylpropionic acid. In a most general sense, these metabolites are variously sensed by a range of receptors that include SCFA receptors (e.g. FFA2), the pregnane X receptor or the arylhydrocarbon receptor. For convenience, we will describe here these materials as Products of Anaerobic Metabolism (PAM or PAMS for the plural). Another type of signal is that of bacterial cell wall materials or bacterial nucleic acids. These materials are often ligands for the Toll-like-receptor (TLR) family. These are referred to as Pathogen-associated molecular patterns or PAMPs. For simplicity here, we will refer to all signal types as PAM or PAMs in the plural.
- Although signaling of this type is commonly associated with the gut epithelium, it is also a potential signal in the interaction between the immune system surveilling the gut or the periphery. In particular, the lysosomes of the gut or the immune system cells are exposed to bacterial metabolites because these materials are released as bacteria are lysed following phagocytosis.
- We have observed that delivering donors of SCFAs, TLR ligands, and other bacterial metabolites to the phagosome of immune cells results in immune stimulation such that phagocytosed bacteria are more rapidly killed. This effect can be augmented by the presentation of additional signals in parallel, for example nitric oxide (NO), delivered from a nitro ester.
- Nitric oxide functions as a neurotransmitter, autacoid constitutive mediator, inducible mediator, cytoprotective molecule, and cyctotoxic molecule. Since NO plays multiple physiological roles in the regulation of numerous and diverse organ functions, defects in the NO pathway lead to a variety of pathophysiological states. Possible disorders are: arterioscleroses, hypertension, coronary artery disease, cardiac failure, pulmonary hypertension, stroke, impotence, gastrointestinal ulcers, asthma, and other CNS and systemic disorders[1].
- Synthetic chemical reagents that release NO continuously over a period of time, under physiological conditions, have been in use for a long time in treatment of cardiovascular diseases[2]. Most widely used are organic nitrates (e. g. glyceryl trinitrate): These NO donors need thiols as a cofactor for generating NO. They can use endogenous sources of thiols.
- Other important series of NO donors are the so called NOC, NOR, and NONOate compounds which were reviewed by Wang et al[3].
- Furthermore a class of activators of soluble guanylyl cyclase (e. g. YC-1) is known as NO-sensitizer, which may potentiate the effect of minimal NO concentrations[4].
- One major drawback of all those NO donors consists in the fact that they exert their action largely in the extracellular environment. For example, nitro-glycerine leads to the release of NO in the plasma which stimulates vasodilation by its action on smooth muscle surrounding vessels.
- A similar drawback for the use of short chain fatty acids or hydrogen sulfides as pharmaceutical agents is that they are potent odorants and required in relatively large amounts (the SCFA receptors have affinities in the milli-molar range). Thus they require specific delivery if they are to be effective.
- Another difficulty in the use of NO donors is the synthetic methods. The preparation of nitro and nitrooxy compounds belongs to the most widespread examples for electrophilic substitution reactions. In general all methods for nitration lead to the formation of nitronium cations as electrophiles, in most cases generated in situ[5]. Few examples are published employing NO species as a salt, e.g. nitronium tetrafluoroborate that can be employed for highly regioselective aromatic nitration[6]. Obstacles common to all methods are, besides desired selectivity, relatively harsh reaction conditions: acidity, oxidizing reactants, and temperature. Thus, classical procedures are limited to stable systems that withstand these reaction conditions. Unfortunately this excludes many substance classes like drugs, organic molecules, reducing sugars or other natural products. Transformation of these compounds to corresponding nitrates would result in valuable compounds. Especially in the case of O-nitration synthesis faces several problems: Starting materials or intermediates in many cases do not withstand conventional reaction conditions like HNO3-H2SO4-mixtures. Thus the strategy of synthesis has to be changed, utilizing mild nitrating agents like acetyl nitrate[7,8,9] or benzoyl nitrate[9,10,11,12], herein referred to as acyl nitrates. Chemically theses nitrating agents are mixed anhydrides from nitric acid and corresponding carboxylic acids, mainly generated in situ by reaction of a carboxylic anhydride with nitric acid.
- NO has many biological functions and as such can serve as a molecular warhead if appropriately delivered by a carrier molecule. In this regard it shares properties in common with compounds like CO and H2S. Another class of small effect molecule of natural origin are the short chain fatty acids (SCFAs) alluded to above. These compounds are products of fermentation and in the gut serve as signals of microbial metabolism which are received by the gut epithelium and in turn used to coordinate anti-microbial homeostasis and epithelial microbial modulation. Similarly, TLR ligands are regulators of the immune response.
- While all of these small natural modulators are known as extracellular signals, there use as intracellular modulators is not described. Here we report compounds that are designed to release these molecules in the cytoplasm and more importantly, acidic organelles such as the phagosome or lysosome. Release of these molecules in the lysosome serves to inform the cell that it has digested a bacterium and thereby induces an anti-bacterial program that in turn enables a more robust response to intracellular organisms that may otherwise suppress bacteriolysis.
- In particular we describe molecules which are acid trapped and able to donate a compound that is the product of anaerobic metabolism, Acid trapped compounds are often amine containing compounds that are amphiphilic. They partition into the cell and concentrate in acidic compartments due to their conversion to an ionized form at pH 5-6 which is common in such organelles. Such acid-trapped molecules can be prepared with suitable linking groups such as hydroxyl groups. Multiple hydroxyl groups may be used to anchor one or more active molecules. There are many such acid-trapped compounds including common drugs such as propranolol, amodiaquine, dextromethorphan, Dextrorphan, paroxetine, fluoxetine, astemizole or imipramine. Another example is the macrolide class including compounds such as azithromycin, erythromycin or clarithromycin which are “acid trapped” in lysosomes by virtue of their 2′ amine groups and amphilic properties. Azithromycin has two amine groups and is particularly strongly trapped. These acid trapped molecules can be derivatized, that is, decorated with signaling molecules related to anaerobic metabolism such as SCFAs, NO, or HS-donors to form compounds of the invention. Using multiple signaling molecules, or combinations thereof in multiple positions allows for a flexible means to tune the properties of the molecules. For example, we described different effects for a compound carrying 3 SCFA esters versus one carrying a NO ester and a SCFA or a third donor and an SCFA. In particular, there is a hierarchy of effect with longer fatty acids promoting differing immune responses. For example propionate differs from acetate in the degree of effect in this setting.
- The invention relates to compounds useful in modulating immune cell activity or the barrier function of epithelial cells. The invention comprises compounds (e.g., derivative compounds of Amphiphilic Lysosomally trapped Compounds (ALC), such ALC compounds including those of the formulae in any tables herein), which are subject to lysosomal trapping and which bear moieties that are able to release TLR ligands, products of anaerobic metabolism, specifically SCFAs, sulfides, lactates, or NO, bile acids, polyamines, decarboxylated amino acids and polyphenol metabolites like phenylpropionic acid.
- The invention also provides a method of identifying a compound useful for modulating immune cell activity against bacteria: incubating such a compound with blood cells, preferably leukocytes, providing those cells with bacteria, incubating the cells with bacteria, washing the cells and treating them with a non-permeable antibiotic to reduce extracellular bacteria, then counting intracellular bacteria to observe which compounds reduce the number of intracellular bacteria surviving.
- Optionally, it is advantageous to determine the ratio of the concentration of the compound in the immune cells to non-immune cells such as erythrocytic cells as a measure of its lysosomal partition. Preferred are compounds that are preferentially taken up by immune cells.
- In some embodiments the carrier compounds are macrolides with at least one ONO2-, SNO2- or NNO2-moiety. In other embodiments the carrier compounds are macrolides with at least one SCFA-moiety. In other embodiments, the carrier molecule is amphiphilic with at least one protonatable amine. The term “macrolide” refers to any macrocyclic lactone with 10 or more atoms connected within the ring system. Reference to an atom includes all isotopes of that atom. For example, structures drawn with carbon or hydrogen include isotopes such as 13C or 2H.
- An anti-microbial compound is a compound that inhibits the growth or division or replication of an organism such as a virus, bacteria, fungus, parasite, mycoplasma or other pathogen.
- One embodiment is a compound comprising an Amphiphilic Lysosomally trapped Compound (ALC) conjugated via an ester, thioester or nitroester to a product of Anaerobic Metabolism (PAM) or one or more PAMs of the same or different types. In a further embodiment, the compound is one in which the PAM is selected from one or more of Short Chain Fatty Acid (SCFA), NO, H2S, mercaptans, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid. In a further embodiment, the compound is one in which the ALC is selected from a macrolide, polyamine, propranolol analog, chloroquine analog, amodiaquine, dextromethorphan, dextrorphan, paroxetine, fluoxetine, astemizole or imipramine analog.
- Another embodiment is a macrolide comprising at least one ONO2-, SNO2- or NNO2 moiety.
- In some embodiments, the compound has the following formula (including any possible salts thereof, except for nitrates, and any structures with exchanged isotopes, as possible by state of the art):
- ALC conjugated or esterified with 1 or more of any of: X(1-5), Y(0-5), Z(0-3);
- Where ALC=Amphiphilic Lysosomally trapped Compound;
- X is a SCFA esterified to ALC and 0-5 indicates the number of moieties conjugated;
- Y is an NO donating group or an H2S donating group esterified to ALC and 0-5 indicates the number of moieties conjugated;
- Z is a group donating sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid.
- Wherein,
- X=—N(CH3)—CH2—;
-
- —CH2—N(CH3)—;
- —C(═O)—;
- —C(═NOR8)—;
- —C(═NR12)—;
- R1 can be, but is not limited to
-
- -(C1-C10)alkyl;
- -(C1-C10)alkyliden-OH;
- -(C1-C10)alkyliden-ONO2;
- R2 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7,—C(═S)(NH)R7;
- R3 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
- If Z=O, R4 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
- R5 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
- or Z=O or NR9 and the R4 and R5 bearing atoms are connected via
-
- —C(═O)— (If Z=O: carbonate linkage, if Z=NR9: carbamate linkage)
- or the R4 and R5 bearing atoms are connected via W;
- W may be but is not limited to
- —(—)CH-(C1-C12)alkyl;
- —(—)CH-(C3-C12)alkenyl;
- —(—)CH-(C3-C12)alkynyl;
- —(—)CH-(C1-C8)[(C1-C4)alkoxy]alkyl;
- —(—)CH-(C1-C8)[(C1-C4)alkoxy]alkenyl;
- wherein alkyl, alkenyl, alkynyl are optionally substituted by one to five substituents selected independently from halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxy, nitro, cyano, azido, mercapto, —NR14R15, R14C(═O)—, R14C(═O)O—, R14OC(═O)O—, R14NHC(═O)—, R14C(═O)NH—, R14R15NC(═O)—, R14OC(═O)—, and —xNO2 with x=O;S;N;
- R6 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
- R7 can be independently chosen from:
-
- —H;
- -ferrocene;
- -C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: ferrocene, halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3); mercapto (—SH), —NR14R15, R14C(═O)—, R14C(═O)O—, R14OC(═O)O—, R14NHC(═O)—, R14C(═O)NH—, R14R15NC(═O)—, R14OC(═O)—, and —XNO(y) with X=O; S; N and y=1 or 2;
- R8 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)—R7;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- R9 can be, but is not limited to
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)—R7;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- R12 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)—R7;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- R14, R15 can independently be, but are not limited to:
-
- —H;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are optionally substituted by one to five substituents selected independently from halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), and —XNOy with X=O; S; N and y=1 or 2;
- or N(R14R15) is an aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane, 1-substituted piperazine, or morpholine moiety.
- In some embodiments, the compound has the following formula (including any possible salts thereof, except for nitrates, and any structures with exchanged isotopes, as possible by state of the art):
- ALC conjugated or esterified with 1 or more of any of: X(1-5), Y(0-5), Z(0-3);
- Where ALC=Amphiphilic Lysosomally trapped Compound;
- X is a SCFA esterified to ALC and 0-5 indicates the number of moieties conjugated;
- Y is an NO donating group or an H2S donating group esterified to ALC and 0-5 indicates the number of moieties conjugated;
- Z is a group donating sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid.
- Wherein,
- X=—N(CH3)—CH2—;
-
- —CH2—N[(CH2)nCH3]—; wherein n is 0-4;
- —C(═O)—;
- —C(═NOR8)—;
- —C(═NR12)—;
- R1 can be, but is not limited to
-
- -(C1-C10)alkyl;
- -(C1-C10)alkyliden-OH;
- -(C1-C10)alkyliden-ONO2;
- R2 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7,—C(═S)(NH)R7;
- R3 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
- If Z=O, R4 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7,—C(═S)(NH)R7;
- R5 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7,—C(═S)(NH)R7;
- or Z=O or NR9 and the R4 and R5 bearing atoms are connected via
-
- —C(═O)— (If Z=O: carbonate linkage, if Z=NR9: carbamate linkage)
- or the R4 and R5 bearing atoms are connected via W;
- W may be but is not limited to
- —(—)CH-(C1-C12)alkyl;
- —(—)CH-(C3-C12)alkenyl;
- —(—)CH-(C3-C12)alkynyl;
- —(—)CH-(C1-C8)[(C1-C4)alkoxy]alkyl;
- —(—)CH-(C1-C8)[(C1-C4)alkoxy]alkenyl;
- wherein alkyl, alkenyl, alkynyl are optionally substituted by one to five substituents selected independently from halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxy, nitro, cyano, azido, mercapto, —NR14R15, R14C(═O)—, R14C(═O)O—, R14OC(═O)O—, R14NHC(═O)—, R14C(═O)NH—, R14R15NC(═O)—, R14OC(═O)—, and —xNO2 with x=O;S;N;
- R6 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
- R7 can be independently chosen from:
-
- —H;
- -ferrocene;
- -C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: ferrocene, halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3); mercapto (—SH), —NR14R15, R14C(═O)—, R14C(═O)O—, R14OC(═O)O—, R14NHC(═O)—, R14C(═O)NH—, R14R15NC(═O)—, R14OC(═O)—, and —XNO(y) with X=O; S; N and y=1 or 2;
- R8 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)—R7;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- R9 can be, but is not limited to
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)—R7;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- R12 can be, but is not limited to:
-
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)—R7;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- R14, R15 can independently be, but are not limited to:
-
- —H;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)alkynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are optionally substituted by one to five substituents selected independently from halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), and —XNOy with X=O; S; N and y=1 or 2;
- or N(R14R15) is an aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane, 1-substituted piperazine, or morpholine moiety.
- In some embodiments, the compound has the following formula (including any any possible salts thereof, except for nitrates, and any structures with exchanged isotopes, as possible by state of the art):
- Wherein R1, R2, R4, R5, R6, X, and Z are defined as in
formula 2; - R3a, R3b=both —H;
-
- or in the case R3a is —H, R3b can be:
- —OH;
- —OR14;
- —NR14R15;
- —C(═O)—R7;
- or R3a=R3b=(═O);
-
- =any possible cyclic or non-cyclic acetal;
- (=NR12);
- =any possible cyclic or non-cyclic aminal;
- —OC(═O)R7;
- OR14;
- and R7, R14, and R15 are defined as in
formula 2. - Where X can be O or S;
- When X=O, R1 may be but not limited to —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, -13 (C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
- R2=R3=H;
- Y=can be a 5-membered saturated ring containing a disulfide bond;
- When X=O, R1 may be but not limited to —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
- R2=CH3; R3=H; or
- When X=O, R1=NO2; R2 consists of linker —CH2CH2OR4, where R4 may be but not limited to —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, or —(C═O)CH2CH2CH2CH2Y; R3=H;
- Y=can be a 5-membered saturated ring containing a disulfide bond; or
- When X=O, R1 may be but not limited to —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
- Y=can be a 5-membered saturated ring containing a disulfide bond;
- R2 consists of linker —CH2CH2OR4, where R4=NO2; R3=H; or
- When X=O, R1 is NO2, R2=H or CH3, R3=OR5, where R5 may be but not limited to —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
- Y=can be a 5-membered saturated ring containing a disulfide bond; or
- When X=S, R1 may be but not limited to —(C═O)CH3, a metal salt, or forms a disulfide bridge with itself, R2=R3=H.
- Definition of Substituents on ALC Formulae (e.g., Macrofides, Hydroxychloroquine, Propranolol, etc.)
-
—NO2 Nitro —(C═O)—C6H4—NO2 p-nitrobenzoyl —(C═O)C6H5 benzoyl —(C═O)CH2CH2COOH succinyl —(C═O)CH2CH3 propionyl —(C═O)CH2CH2CH3 butyryl —(C═O)CH3 acetyl —(C═O)(C═O)CH3 Pyruvyl —(C═O)CHCHCOOH Maleyl —(C═O)CH(OH)CH3 Lactyl —(C═O)CH(ONO2)CH3 2-O-Nitrolactyl —(C═O)C(CH3)2 Isobutyryl —(C═O)CH2CH2CH2CH3 Valeryl —(C═O)CH2C(CH3)2 Isovalericyl —(C═O)CH(CH3)O(C═O)CH3 Acetoxypropionyl —(C═O)CH2CH2(C═O)—Z Succinyl-dithiole-3-thione —(C═O)OCH2CH2S(S)nH Polysulfide ethyl carbonate —(C═O)OCH2CH2SNO NO-thioethylcarbonate —(C═S)OC6H5 O-Phenylchlorothiono carbonate —(C═O)CH2CH2CH2CH2CH3 hexanoyl —CH2CH2Br bromoethyl —(C═O)OCH2CHCH2 Vinyl carbonate —(C═O)CH2CH2CH2CH2Y Lipoyl - Wherein
- Mac=a macrolide ring or macrolide ring system, for example, but not limited to azithromycin or gamithromycin, each without the desosamin residue.
- Compounds with the Structure
- Wherein
- Mac=a macrolide ring or macrolide ring system, for example, but not limited to azithromycin or gamithromycin, each without the desosamin residue;
- R″=independently of each other
- —H;
- —NO(y) with y=1 or 2;
- —C(═O)OR3, —C(═S)OR3, —C(═O)R3, —C(═S)R3, —C(═O)(NH)R3, —C(=S)(NH)R3;
- R1, R2=independently of each other H, OH, OR4, -C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl;
- wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: fluorine, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C9)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), (C1-C4)alkthio, —NR4R5, R4C(═O)—, R4C(═O)O—, R4OC(═O)O—, R4NHC(═O)—, R4C(═O)NH—, R4R5NC(═O)—, R4OC(═O)— and —XNO(y) with X=O; S; N and y=1 or 2;
- or N(R1R2) is an aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane, 1-substituted piperazine, or morpholine moiety;
- R3=-C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: halogen, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C9)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—to CN), azido (—N3), mercapto (—SH), (C1-C4)alkthio, —NR6R7, R6C(═O)—, R6C(═O)O—, R6OC(═O)O—, R6NHC(═O)—, R6C(═O)NH—, R6R7NC(═O)—, R6OC(═O)—, and —XNO(y) with X=O; S; N and y=1 or 2;
- R4, R5, R6 and R7 can independently be, but are not limited to:
-
- —H;
- -(C1-C12)alkyl;
- -(C1-C12)alkenyl;
- -(C1-C12)akynyl;
- -(C1-C8)[(C1-C4)alkoxy]alkyl;
- -(C1-C8)[(C1-C4)alkoxy]alkenyl;
- -(C6-C10)aryl-(C1-C5)alkyl;
- -(C2-C9)heteroaryl-(C1-C5)alkyl;
- wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are optionally substituted by one to five substituents selected independently from ferrocene, halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C9)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), (C1-C6)acyloxy, nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), and —XNOy with X=O; S; N and y=1 or 2.
- Unless, otherwise stated, the word “macrolide”herein refers to the family of well-known macrolactone antibiotics and also the various macrolactone ALCs described herein.
- In one aspect, the invention provides a composition comprising a compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier. In a further aspect, the composition can further comprise an additional therapeutic agent.
- In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or symptom thereof. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof. The disease, disorder, or symptom thereof can be, for example, an infectious disease, an inflammatory disease, a malignant disease, a bacterial infection, an inflammatory reaction to a bacterial translocation event, an inflammation of the GI tract including intestines, colon, liver and pancreas, an inflammation of the airways, a systemic inflammatory disease or a malignant or neoplastic disease.
- In one aspect, the invention provides a method of stimulating immune or epithelial cells to form an anti-infective barrier or anti-infective response comprising contacting the cells with a compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof. A further aspect of the method is wherein the contacting results in the intracellular release of a PAM comprising one or more of a molecule type selected from SCFA, NO, H2S, sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid from the compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof. A further aspect of the method is that comprising the intracellular release of one or more types of a short chain fatty acid moiety from the compound of any of the formulae herein (e.g., any of the formulae, any formula in the tables herein), or salt, solvate, hydrate or prodrug thereof. A further aspect of the method is that comprising the intracellular release of a short chain fatty acid moiety containing 2 or more carbons from an appropriate carrier molecule.
- In an embodiment, the compound of the invention is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound of the invention to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
- In certain embodiments, these pharmaceutical compositions are suitable bar topical or oral administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- The phrase “pharmaceutically acceptable” refers to those compound of the inventions of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- The term “pharmaceutically acceptable salts” or “pharmaceutically acceptable. carrier” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention.
- Some examples of substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, anti-oxidants and preservatives, can also be present. Solubilizing agents, including for example, cremaphore and beta-cyclodextrins can also be used in the pharmaceutical compositions herein.
- The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- Initial dosages also can be estimated from in vivo data, such as animal models. Animal models useful for testing the efficacy of compounds to treat or prevent the various diseases described above are well-known in the art.
- Dosage amounts will typically be in the range of from about 0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, (e.g., 0.01 to 1 mg/kg effective dose) but can be higher or lower, depending upon, among other factors, the activity of the compound, its bioavailability, the mode of administration, and various factors discussed above. Dosage amount and interval can be adjusted individually to provide plasma levels of the compound(s) which are sufficient to maintain therapeutic or prophylactic effect. In cases of local administration or selective uptake, such as local topical administration, the effective local concentration of active compound(s) cannot be related to plasma concentration. Skilled artisans will be able to optimize effective local dosages without undue experimentation
- The compound(s) can be administered once per day, a few or several times per day, or even multiple times per day, depending upon, among other things, the indication being treated and the judgment of the prescribing physician.
- Preferably, the compound(s) will provide therapeutic or prophylactic benefit without causing substantial toxicity. Toxicity of the compound(s) can be determined using standard pharmaceutical procedures. The dose ratio between toxic and therapeutic (or prophylactic) effect is the therapeutic index. Compounds(s) that exhibit high therapeutic indices are preferred.
- The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
- Another object of the present invention is the use of a compound as described herein (e.g., of any formulae herein) in the manufacture of a medicament for use in the treatment of a disorder or disease herein. Another object of the present invention is the use of a compound as described herein (e.g., of any formulae herein) for use in the treatment of a disorder or disease herein.
- Many compounds of this invention have one or more double bonds, or one or more asymmetric centers. Such compounds can occur as racemates, racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans- or E- or Z-double isomeric forms.
- Further, the aforementioned compounds also include their N-oxides. The term “N-oxides” refers to one or more nitrogen atoms, when present in a compound, are in N-oxide form, i.e., N→O.
- Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., treating a disease).
- In another aspect the present invention relates to a mild and highly selective process for the in situ introduction of the O—, S— and N-nitrate group into compounds of any othe formulae herein.
- NO, SCFA or PAM are difficult to use directly in Pharmaceutical compositions.
- The use of NO donors is well known in medicine as a means to modulate blood pressure and inflammation[13]. Such NO donors exert their action, as aforementioned, largely in the extracellular environment. In the case of blood pressure regulators, release of NO in the blood results in effects on the endothelium which are desirable. In the case of modulators of inflammation, general release of NO may result in side effects such as loss of blood pressure which are undesirable.
- Similarly, the SCFAs are volatile. malodourous and unstable. PAMs such as polyamines are similarly unattractive for direct use. While these products such as SCFAs or NO (inhaled gas) have been applied to the body, they are used in amounts that are undesirable. The technical problem to solve, was, therefore, to focus the release of these products (NO, SCFA, PAMs) to cells associated with inflammation, cancer or infection such that lower amounts could be used.
- The compounds reported here are mostly located in intracellular compartments and thus may donate NO or SCFA or PAM to an intracellular receptor, preferably an intra-phagosomal or lysosomal receptor. Macrolide anti-bacterial compounds are well known for their ability to be concentrated in acidic compartments, notably the phagosomes of immune cells such as neutrophils and macrophage[14]. Phagosomes are the organs where bacteria and other debris are digested by the phagocytes using oxidative processes and digestive enzymes. Certain bacteria resist this process by reducing the capacity of the cell to produce antibacterial factors (lower pH, proteases, active oxygen species, antibacterial enzymes, NO).
- If, however, a compound was also trapped in the phagosome that was capable of donating a stimulatory factor such as SCFA, PAM or NO, then there is the potential to overcome the inhibition due to the bacterium. More importantly, if the Phagocyte absorbs a compound able to donate SCFA, PAM or NO prior to that phagocyte encountering bacteria, it is potentially stimulated to better kill bacteria immediately on contact with them. This is potentially of significance in treating infections by bacteria such as Legionella, Pasteurella, Listeria and Mycobacterium species that are intracellular parasites. It is also potentially significant in the stimulation of barrier cells to resist the effect of bacteria, or to maintain physical barriers toward bacteria.
- In addition to their roles in immunology, SCFA, NO and PAM have a role in homeostasis, acute inflammation and wound healing[15]. Phagocytes like macrophages are involved in many aspects of metabolism and are sensitive to SCFA, NO and PAM. The delivery of these substances preferentially to cells of this type is a means to allow them to respond to the stimulus of SCFA, PAM or NO without using high systemic levels. This is achieved by delivering the substances as conjugates to lysosomally tropic compounds (ALCs).
- Thus the efficacy of molecules described herein in various models of inflammation and resolution of inflammation were examined. In these models, example compounds reported here were able to reduce the effects of inflammation, support body weight maintenance, and reduce disease signs without causing appreciable toxicity.
- Definitions
- “Anti-infective barrier” means the ability of epithelium to prevent the penetration of bacteria or other pathogens.
- Stimulating the formation of an anti-infective barrier means increasing the ability of epithelium to prevent the penetration of bacteria or other pathogens through the up-regulation of tight junction formation or other barrier functions.
- “Anti-infective response” means the ability of immune cells or similar to prevent the growth of bacteria or other pathogens via phagocytosis, oxidative burst or other toxic responses inactivating the pathogen.
- Stimulating the formation of an anti-infective response means increasing the ability of immune cells or similar cells to prevent the growth of bacteria or other pathogens via phagocytosis, oxidative burst or other toxic responses inactivating the pathogen.
- “ALC” means an Amphiphilic Lysosomally trapped Compound.
- “PAM” means Product of Anaerobic Metabolism. PAMs include but are not limited to SCFA, NO, H2S, mercaptans that eventually generate H2S/HS− polyamines (e.g., compounds of Table 7), amino acid residues lacking the C-terminus (decarboxlated), bile acids (e.g., steroid acids found in the bile of mammals and other vertebrates, such as chenodeoxycholic acid, cholic acid, deoxycholic acid, lithocholic acid, and the like), or degradation products from polyphenol metabolism such as 3-(3-Hydroxyphenyl)propanoic (hMPP) acid, SCFA means Short Chain Fatty Acid, which is a fatty acid molecule haying an aliphatic tail of eight or less carbon atoms.
- “NO” means Nitric Oxide.
- The compounds reported here are useful in many respects. They are anti-microbial, anti-inflammatory, able to accumulate in tumors and donate NO and able to protect against inflammation of the intestine. Selected embodiments are able to modulate inflammation of the liver and protect against accumulation of fat or the resulting fibrosis.
- The compounds are readily soluble as salts, may be provided by the oral route, or via other means. They are adequately stable for pharmacological use when stored at the appropriate pH conditions.
-
FIG. 1 : TNFa-Production by LPS treated mice with either Vehicle (1% citric acid in water, 5 mL/kg) or 10 μmol/kg Compound E2 or Compound E3. -
FIG. 2 : Change in body weight in mice in which arthritis has been induced using bovine collagen. Animals were treated with either Vehicle (1% citric acid in water, 5 mL/kg) or the indicated doses of compound E2 μmol/kg. Data are from 10 animals per group, and data points significant different from Vehicle are marked with *. -
FIG. 3 : Number of mice maintaining body weight in which intestinal inflammation has been induced using Dextran Sulfate. Mice were treated with Vehicle (1% citric acid in water, 5 mL/kg) or the indicated doses of compound E2 in μmol/kg. -
FIG. 4 : Killing of phagocytosed Salmonella typhimurium by murine macrophages treated with either the commercial antibiotic azithromycin or Compound E2. Compound E2 stimulates the killing of bacterial cells by macrophages. -
FIG. 5 : Effect of substance E5 on the response of mice to an infection by Staphylococcus. Treatment with the substance E5 results in a faster recovery of weight due to faster clearance of bacteria -
FIG. 6 : Effect of substances E2, E5 and Azithromycin on the ability of mice to clear an infection by Staphylococcus aureus Newman. Bacteria are quantified as CFU recovered from a standard sample of kidney. Treatment with substances decreases recovered bacteria in a dose responsive manner. -
FIG. 7 : Effect of substances on the ability of mice to tolerate dextran sulfate colitis. Cyclosporine is provided at a dose of 25 mg/kg, all other substances including azithromycin are provided at a dose of 0.1 μmol/kg. -
FIG. 8 : Effect of substances E5 and Cyclosporin on the liver weight of mice treated with dextran sulfate colitis. Data are the mean of N=8 and are plotted with the 95% confidence interval. -
FIG. 9 : Effect of substances E-5 and E-241 versus Vehicle on the development of EAE in the C57B6 mouse. Plotted is the clinical score based with antigen injected onday 0 and substance started onday 7. Data are the mean of N=8. -
FIG. 10 : Effect of substances compared with the positive control Cyclosporin on the body weight of mice treated with dextran sulfate colitis. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 11 : Effect of substances compared with the positive control Cyclosporin on the colon length of mice treated with dextran sulfate colitis. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 12 : Effect of substances compared with the positive control Cyclosporin on the amount of fluorocein labelled dextran (FITC) taken up into the serums of mice treated with dextran sulfate colitis. 4 h prior to sampling, mice are treated with an oral suspension of FITC dextran which would normally not enter the blood stream. The effect of DSS is to disrupt the gut epithelium allowing larger molecules to enter the blood stream. Reductions in FITC dextran suggest improved barrier function. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 13 : Effect of substances compared with the positive control Cyclosporin on the serum Calcium of mice treated with dextran sulfate to induce colitis atday 8 after starting DSS. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 14 : Effect of substances compared with the positive control Cyclosporin on the clinical score of mice treated with dextran sulfate to induce colitis atday 8 after starting DSS. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 15 : Effect of substances compared with the positive control Cyclosporin on the serum Potassium of mice treated with dextran sulfate to induce colitis atday 8 after starting DSS. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 16 : Effect of substances compared with the positive control Cyclosporin on the serum Total Bilirubin of mice treated with dextran sulfate to induce colitis atday 8 after starting DSS. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 17 : Body weight of BALBc mice atday 7 after commencing 2.5% DSS in water. DSS causes lesions in the colon that lead to weight loss. Substance E-2, amongst others, protects against weight loss. Data are the mean of N=8 and are plotted with the 95% confidence interval. -
FIG. 18 : Body weight and clinical score of BALBc mice atday 9 after commencing 2.5% DSS in water. DSS causes lesions in the colon that lead to weight loss. Substances E-3, E-238 and E-553, amongst others, stimulate inflammation. All doses 1.34 μmol/kg. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 19 : Body weight and clinical score of BALBc mice atday 7 after commencing 2.5% DSS in water. DSS causes lesions in the colon that lead to weight loss. Substance like E-51 with weight greater than Vehicle protect against inflammation. Doses are as indicated. Data are the mean of N=8 and are plotted with the 95% confidence interval. Above the bars are the p values vs. Vehicle for a T-test. -
FIG. 20 : The compounds containing R1 nitrate ester have preferential distribution to the lung. Data show the concentration of the substance in the lung and liver at 6 h after administration of a 10 mg/kg dose p.o. in 2% citric acid. -
FIG. 21 : The effect of various compounds on the rate of killing of Salmonella typhimurium following incubation and phagocytosis by J774 murine cells. The number of surviving bacteria is an indicator of the degree of intracellular killing of the bacteria, All substances are supplied at an initial concentration of 1 μM. - General Procedure for the Introduction of the Nitrooxide Group
- The compound to be nitrated (1 equiv.) (—SH, —OH, —NH) is dissolved or suspended in acetic acid (approximately 6.0 ml per 1 mmol compound to be nitrated) and a solution of nitric acid (10% in acetic anhydride, about 3.25 ml per 1 mmol compound to be nitrated) is slowly added to the system while cooling in an ice bath. When TLC indicated complete consumption of starting materials the mixture is poured onto ice hydrolyzing any remains of acetic anhydride, followed by cautious neutralization of acid species with sodium bicarbonate. Extraction of the aqueous system with dichloromethane (3×), drying of combined organic phases over sodium sulfate and subsequent purification of crude products by column chromatography (acetone-cyclohexane 1:3→1:1) yields products as amorphous white foams.
- The invention will be further described in the following intermediates and examples. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any, manner.
- Unless otherwise specified, all commercially available reagents and solvents were used without prior purification. All chemical structures and names are generated from ChemDraw Ultra (Cambridge).
-
TABLE 1 Examples of ALC Core Entry ALC Core Structure A-1 Azithromycin (R1 to R5 = H, R6 = CH3) A-2 Erythromycin (X = OH) (R1 to R5 = H, R6 = CH3) or Erythromycin N-Oxime (X = N—OH) A-3 Hydroxychloroquine (R1 = H, R2 = CH3) A-4 N-ethanol HCQ (R1 = H, R2 = H) A-5 Propranolol (R1 = H, R2 = CH3) A-6 N-ethanol-propranolol (R1 = H, R2 = H) A-7 4-hydroxypropranolol (R1 = H, R2 = H, R3 = H) A-8 2-(4-fluorophenyl)-3-amino-4-(3-[2,3- di{butyroyloxy}propyloxy]phenyl)- carbonylpyrazole (R1 = H, R2 = H) A-9 2-(4-pyridyl)-3-amino-4-(3-[2,3- di{butyroyloxy}propyloxy]- phenyl)carbonylpyrazole (R1 = H, R2 = H) A-10 C5Y0073 (R1 to R5 = H, R6 = CH3) or 14-(4-Dimethylamino-3-hydroxy-6- methyl-tetrahydro-pyran-2-yloxy)-5-ethyl- 1,6,7-trihydroxy-2,6,8,9,11,13,15- heptamethyl-4,16-dioxa-9-aza- bicyclo[11.2.1]hexadecan-3-one A-11/ E-16 CSY0041 (R1 to R6 = H) or 2-Ethyl-3,4,10-trihydroxy-13-(5-hydroxy- 4-methoxy-4,6-dimethyl-tetrahydro- pyran-2-yloxy)-11-(3-hydroxy-6-methyl-4- methylamino-tetrahydro-pyran-2-yloxy)- 3,5,6,8,10,12,14-heptamethyl-1-oxa-6- aza-cyclopentadecan-15-one A-12 C5Y1239 (R1 to R5 = H) or 11-(4-Dimethylamino-3-hydroxy-6- methyl-tetrahydro-pyran-2-yloxy)-2-ethyl- 3,4,10,13-tetrahydroxy-3,5, 6,8,10,12,14-heptamethyl-1-oxa-6-aza- cyclopentadecan-15-one A-13.1 CSY1130 (R1 to R6 = H) (preparation see Example or 11-{4-[Bis-(2-hydroxy-ethyl)-amino]-3- hydroxy-6-methyl-tetrahydro-pyran-2- yloxy}-2-ethyl-3,4,10-trihydroxy-13-(5- hydroxy-4-methoxy-4,6-dimethyl- tetrahydro-pyran-2-yloxy)- 3,5,6,8,10,12,14-heptamethyl-1- oxa-6-aza-cyclopentadecan-15-one A-13.2 CSY5632 (R1 to R6 = H) or (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- 11-(((2S,3S,6R)-3-(bis(2- hydroxyethyl)amino)-4-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2- ethyl-3,4,10-trihydroxy-13- (((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyltetrahydro-2H-pyran-2-yl)oxy)- 3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacydopentadecan-15-one A-14.1 CSY2219 (R1 to R5 = H) or 2-Ethyl-3,4,10-trihydroxy-13-(5-hydroxy- 4-methoxy-4,6-dimethyl-tetrahydro- pyran-2-yloxy)-11-(3-hydroxy-6-methyl-4- morpholin-4-yl-tetrahydro-pyran-2- yloxy)-3,5,6,8,10,12,14-heptamethyl-1- oxa-6-aza-cyclopentadecan-15-one A-14.2 CSY5602 (R1 to R5 = H) or (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2- ethyl-3,4,10-trihydroxy-13- (((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyltetrahydro-2H-pyran-2-yl)oxy)- 11-(((2S,3S,6R)-4-hydroxy-6-methyl-3- morpholinotetrahydro-2H-pyran-2- yl)oxy)-3,5,6,8,10,12,14-heptamethyl-1- oxa-6-azacyclopentadecan-15-one A-15 CSY1019 (R1 to R5 = H) or 11-(4-Dimethylamino-6-methyl-3- nitrooxy-tetrahydro-pyran-2-yloxy)-2- ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4- methoxy-4,6-dimethyl-tetrahydro-pyran- 2-yloxy)-3,5,6,8,10,12,14-heptamethyl-1- oxa-6-aza-cyclopentadecan-15-one A-16 Tildipirosin (R1 to R3 = H) A-17 Gamithromycin (R1 to R5 = H) A-18 Tylosin (R1 to R5 = H) A-19.1 Polyamines (R1 to R2 = H) A-19.2 Polyamines (R1 to R4 = H) A-19.3 Polyamines (R1 = R2 = H; R3 = alkyl, usually ethyl) A-20.1 Tris(hydroxymethyl)nitromethane (R1 to R3 = H) A-20.2 Sodium Tris(hydroxymethyl)aminopropylsulfonate (R1 to R3 = H) A-21 Clarithromycin (R1 to R4 = H) A-22 Tulathromycin (R1 to R5 = 0) -
TABLE 2 Examples of compounds showing the appropriate substituents. Compound formulae based on “ALC core” structures as detailed in Table 1 (above). Compound Entry ALC Core R1 R2 R3 R4 R5 R6 E-1 Azithromycin NO2 H H H H CH3 E-2 Azithromycin NO2 Ac H H H CH3 E-3 Azithromycin NO2 H H H H C-10 alkyl E-4 Azithromycin NO2 Ac H H H C-10 alkyl E-5 Azithromycin NO2 Propionyl H H H CH3 E-6 Azithromycin p-Nitro NO2 NO2 H H CH3 benzoyl E-7 Azithromycin Benzoyl NO2 H H H CH3 E-8 Erythromycin NO2 Ac H H H CH3 oxime E-9 Azithromycin Ac NO2 H H H CH3 E-10 Azithromycin H NO2 H H H CH3 E-11 Azithromycin NO2 ch3 H H H CH3 E-12 Azithromycin H Tetranitro H H H CH3 moiety1 E-13 Azithromycin NO2 Propionyl H H Propionyl CH3 E-14 Azithromycin H H H H H Propanol- NO2 E-15 Azithromycin H H H H H CH3 E-16 Azithromycin H H H H H H E-17/I-7 Azithromycin H Ac H H H CH3 E-18 Azithromycin H Propionyl H H H CH3 E-19 Azithromycin H Butyryl H H H CH3 E-20/I-2 Azithromycin H H H H H C-10 alkyl E-21 Azithromycin NO2 NO2 H H H CH3 E-22/I-4 Azithromycin Ac CH2CCH H H H CH3 E-23/I-6 Azithromycin Ac Ac H H H CH3 E-24 Azithromycin NO2 Butyryl H H H CH3 E-25//I-3 Azithromycin Ac H H H H CH3 E-26/I-8 Azithromycin Benzoyl H H H H CH3 E-27 Azithromycin Succinyl H H H H CH3 E-28 Azithromycin Ac Propionyl H H H CH3 E-29 Azithromycin Ac Butyryl H H H CH3 E-30 Azithromycin Propionyl H H H H CH3 E-31 Azithromycin Propionyl NO2 H H H CH3 E-32 Azithromycin Propionyl Ac H H H CH3 E-33 Azithromycin Propionyl Propionyl H H H CH3 E-34 Azithromycin Propionyl Butyryl H H H CH3 E-35 Azithromycin Butyryl H H H H CH3 E-36 Azithromycin Butyryl NO2 H H H CH3 E-37 Azithromycin Butyryl Ac H H H CH3 E-38 Azithromycin Butyryl Propionyl H H H CH3 E-39 Azithromycin Butyryl Butyryl H H H CH3 E-40 Azithromycin H Succinyl H H H CH3 E-41 Azithromycin H Pyruvyl H H H CH3 E-42 Azithromycin H Maleyl H H H CH3 E-43 Azithromycin H Lactyl H H H CH3 E-44 Azithromycin H Isobutyryl H H H CH3 E-45 Azithromycin H Valeryl H H H CH3 E-46 Azithromycin H Isovaleryl H H H CH3 E-47 Azithromycin Butyryl Butyryl Butyryl Butyryl H CH3 E-48 Azithromycin Butyryl Butyryl Butyryl H H CH3 E-49 Azithromycin Ac Ac Ac Ac H CH3 E-50 Azithromycin Ac Ac Ac H H CH3 E-51 Azithromycin Propionyl Propionyl Propionyl Propionyl H CH3 E-52 Azithromycin Propionyl Propionyl Propionyl H H CH3 E-53 Azithromycin Succinyl Succinyl Succinyl Succinyl H CH3 E-54 Azithromycin Pyruvyl Pyruvyl Pyruvyl Pyruvyl H CH3 E-55 Azithromycin Maleyl Maleyl Maleyl Maleyl H CH3 E-56 Azithromycin Lactyl Lactyl Lactyl Lactyl H CH3 E-57 Azithromycin Isobutyryl Isobutyryl Isobutyryl Isobutyryl H CH3 E-58 Azithromycin Valeryl Valeryl Valeryl Valeryl H CH3 E-59 Azithromycin Isovaleryl Isovaleryl Isovaleryl Isovaleryl H CH3 E-60 Azithromycin Succinyl Succinyl Succinyl H H CH3 E-61 Azithromycin Pyruvyl Pyruvyl Pyruvyl H H CH3 E-62 Azithromycin Maleyl Maleyl Maleyl H H CH3 E-63 Azithromycin Lactyl Lactyl Lactyl H H CH3 E-64 Azithromycin Isobutyryl Isobutyryl Isobutyryl H H CH3 E-65 Azithromycin Valeryl Valeryl Valeryl H H CH3 E-66 Azithromycin Isovaleryl Isovaleryl Isovaleryl H H CH3 E-67 Azithromycin Succinyl Succinyl H H H CH3 E-68 Azithromycin Pyruvyl Pyruvyl H H H CH3 E-69 Azithromycin Maleyl Maleyl H H H CH3 E-70 Azithromycin Lactyl Lactyl H H H CH3 E-71 Azithromycin Isobutyryl Isobutyryl H H H CH3 E-72 Azithromycin Valeryl Valeryl H H H CH3 E-73 Azithromycin Isovaleryl Isovaleryl H H H CH3 E-74 Azithromycin Acetoxypropionyl H H H H CH3 E-75 Azithromycin Lipoyl Lipoyl H H H CH3 E-76 Azithromycin H Lipoyl H H H CH3 E-77 Azithromycin Lipoyl H H H H CH3 E-78 Azithromycin NO2 Lipoyl H H H CH3 E-79 Azithromycin NO2 Succinyl - H H H CH3 dithiole- 3-thione E-80 Azithromycin Succinyl - H H H H CH3 dithiole- 3-thione E-81 Azithromycin Polysulfide H H H H CH3 ethyl carbonate E-82 Azithromycin NO- H H H H CH3 thioethylcarbonate E-83 Azithromycin O-Phenyl H H H H CH3 chlorothionocarbonate E-84 Azithromycin n- H H H H CH3 hexanoyl E-85 Azithromycin Bromoethylcarbonate H H H H CH3 E-86 Azithromycin Vinyll H H H H CH3 carbonate E-87 Hydroxychloroquine Ac H E-88 Hydroxychloroquine Propionyl H E-89 Hydroxychloroquine Butyryl H E-90 Hydroxychloroquine Succinyl H E-91 Hydroxychloroquine Pyruvyl H E-92 Hydroxychloroquine Maleyl H E-93 Hydroxychloroquine Lactyl H E-94 Hydroxychloroquine Isobutyryl H E-95 Hydroxychloroquine Valeryl H E-96 Hydroxychloroquine Isovaleryl H E-97 Hydroxychloroquine Lipoyl H E-98 Hydroxychloroquine Ac CH3 E-99 Hydroxychloroquine Propionyl CH3 E-100 Hydroxychloroquine Butyryl CH3 E-101 Hydroxychloroquine Succinyl CH3 E-102 Hydroxychloroquine Pyruvyl CH3 E-103 Hydroxychloroquine Maleyl CH3 E-104 Hydroxychloroquine Lactyl CH3 E-105 Hydroxychloroquine Isobutyryl CH3 E-106 Hydroxychloroquine Valeryl CH3 E-107 Hydroxychloroquine Isovaleryl CH3 E-108 Hydroxychloroquine Lipoyl CH3 E-109 N-ethanol HCQ NO2 Ac E-110 N-ethanol HCQ NO2 Propionyl E-111 N-ethanol HCQ NO2 Butyryl E-112 N-ethanol HCQ NO2 Succinyl E-113 N-ethanol HCQ NO2 Pyruvyl E-114 N-ethanol HCQ NO2 Maleyl E-115 N-ethanol HCQ NO2 Lactyl E-116 N-ethanol HCQ NO2 Isobutyryl E-117 N-ethanol HCQ NO2 Valeryl E-118 N-ethanol HCQ NO2 Isovaleryl E-119 N-ethanol HCQ NO2 Lipoyl E-120 N-ethanol HCQ Ac NO2 E-121 N-ethanol HCQ Propionyl NO2 E-122 N-ethanol HCQ Butyryl NO2 E-123 N-ethanol HCQ Succinyl NO2 E-124 N-ethanol HCQ Pyruvyl NO2 E-125 N-ethanol HCQ Maleyl NO2 E-126 N-ethanol HCQ Lactyl NO2 E-127 N-ethanol HCQ Isobutyryl NO2 E-128 N-ethanol HCQ Valeryl NO2 E-129 N-ethanol HCQ Isovaleryl NO2 E-130 N-ethanol HCQ Lipoyl NO2 E-131 Propranolol Ac H E-132 Propranolol Propionyl H E-133 Propranolol Butyryl H E-134 Propranolol Succinyl H E-135 Propranolol Pyruvyl H E-136 Propranolol Maleyl H E-137 Propranolol Lactyl H E-138 Propranolol Isobutyryl H E-139 Propranolol Valeryl H E-140 Propranolol Isovaleryl H E-141 Propranolol Lipoyl H E-142 Propranolol 2-O- H Nitrolactyl E-143 Propranolol Ac CH3 E-144 Propranolol Propionyl CH3 E-145 Propranolol Butyryl CH3 E-146 Propranolol Succinyl CH3 E-147 Propranolol Pyruvyl CH3 E-148 Propranolol Maleyl CH3 E-149 Propranolol Lactyl CH3 E-150 Propranolol Isobutyryl CH3 E-151 Propranolol Valeryl CH3 E-152 Propranolol Isovaleryl CH3 E-153 Propranolol Lipoyl CH3 E-154 N-ethanol- NO2 Ac propranolol E-155 N-ethanol- NO2 Propionyl propranolol E-156 N-ethanol- NO2 Butyryl propranolol E-157 N-ethanol- NO2 Succinyl propranolol E-158 N-ethanol- NO2 Pyruvyl propranolol E-159 N-ethanol- NO2 Maleyl propranolol E-160 N-ethanol- NO2 Lactyl propranolol E-161 N-ethanol- NO2 Isobutyryl propranolol E-162 N-ethanol- NO2 Valeryl propranolol E-163 N-ethanol- NO2 Isovaleryl propranolol E-164 N-ethanol- NO2 Lipoyl propranolol E-165 N-ethanol- Propionyl NO2 propranolol E-166 N-ethanol- Butyryl NO2 propranolol E-167 N-ethanol- Succinyl NO2 propranolol E-168 N-ethanol- Pyruvyl NO2 propranolol E-169 N-ethanol- Maleyl NO2 propranolol E-170 N-ethanol- Lactyl NO2 propranolol E-171 N-ethanol- Isobutyryl NO2 propranolol E-172 N-ethanol- Valeryl NO2 propranolol E-173 N-ethanol- Isovaleryl NO2 propranolol E-174 N-ethanol- Lipoyl NO2 propranolol E-175 4-hydroxy NO2 H Ac propranolol E-176 4-hydroxy NO2 H Propionyl propranolol E-177 4-hydroxy NO2 H Butyryl propranolol E-178 4-hydroxy NO2 H Succinyl propranolol E-179 4-hydroxy NO2 H Pyruvyl propranolol E-180 4-hydroxy NO2 H Maleyl propranolol E-181 4-hydroxy NO2 H Lactyl propranolol E-182 4-hydroxy NO2 H Isobutyryl propranolol E-183 4-hydroxy NO2 H Valeryl propranolol E-184 4-hydroxy NO2 H Isovaleryl propranolol E-185 4-hydroxy NO2 H Lipoyl propranolol E-186 4-hydroxy NO2 CH3 Ac propranolol E-187 4-hydroxy NO2 CH3 Propionyl propranolol E-188 4-hydroxy NO2 CH3 Butyryl propranolol E-189 4-hydroxy NO2 CH3 Succinyl propranolol E-190 4-hydroxy NO2 CH3 Pyruvyl propranolol E-191 4-hydroxy NO2 CH3 Maleyl propranolol E-192 4-hydroxy NO2 CH3 Lactyl propranolol E-193 4-hydroxy NO2 CH3 Isobutyryl propranolol E-194 4-hydroxy NO2 CH3 Valeryl propranolol E-195 4-hydroxy NO2 CH3 Isovaleryl propranolol E-196 4-hydroxy NO2 CH3 Lipoyl propranolol E-197 A-8 Ac Ac E-198 A-8 Propionyl Propionyl E-199 A-8 Butyryl Butyryl E-200 A-8 Succinyl Succinyl E-201 A-8 Pyruvyl Pyruvyl E-202 A-8 Maleyl Maleyl E-203 A-8 Lactyl Lactyl E-204 A-8 Isobutyryl Isobutyryl E-205 A-8 Valeryl Valeryl E-206 A-8 Isovaleryl Isovaleryl E-207 A-8 Lipoyl Lipoyl E-208 A-9 Ac Ac E-209 A-9 Propionyl Propionyl E-210 A-9 Butyryl Butyryl E-211 A-9 Succinyl Succinyl E-212 A-9 Pyruvyl Pyruvyl E-213 A-9 Maleyl Maleyl E-214 A-9 Lactyl Lactyl E-215 A-9 Isobutyryl Isobutyryl E-216 A-9 Valeryl Valeryl E-217 A-9 Isovaleryl Isovaleryl E-218 A-9 Lipoyl Lipoyl E-219 A-10 H Tetranitro H H CH3 moiety1 E-220 A-10 H H H H Propanol- NO2 E-221 A-10 H H H H CH3 E-222 A-10 H H H H H E-223 A-10 H Ac H H CH3 E-224 A-10 H Propionyl H H CH3 E-225 A-10 H Butyryl H H CH3 E-226 A-10 H H H H C-10 alkyl E-227 A-10 Ac CH2CCH H H CH3 E-228 A-10 Ac Ac H H CH3 E-229 A-10 Ac H H H CH3 E-230 A-10 Benzoyl H H H CH3 E-231 A-10 Succinyl H H H CH3 E-232 A-10 Ac Propionyl H H CH3 E-233 A-10 Ac Butyryl H H CH3 E-234 A-10 Propionyl H H H CH3 E-235 A-10 Propionyl Ac H H CH3 E-236 A-10 Propionyl Propionyl H H CH3 E-237 A-10 Propionyl Butyryl H H CH3 E-238 A-10 Butyryl H H H CH3 E-239 A-10 Butyryl Ac H H CH3 E-240 A-10 Butyryl Propionyl H H CH3 E-241 A-10 Butyryl Butyryl H H CH3 E-242 A-10 H Succinyl H H CH3 E-243 A-10 H Pyruvyl H H CH3 E-244 A-10 H Maleyl H H CH3 E-245 A-10 H Lactyl H H CH3 E-246 A-10 H Isobutyryl H H CH3 E-247 A-10 H Valeryl H H CH3 E-248 A-10 H Isovaleryl H H CH3 E-249 A-10 Butyryl Butyryl Butyryl H CH3 E-250 A-10 Butyryl Butyryl H H CH3 E-251 A-10 Ac Ac Ac H CH3 E-252 A-10 Ac Ac H H CH3 E-253 A-10 Propionyl Propionyl Propionyl H CH3 E-254 A-10 Propionyl Propionyl H H CH3 E-255 A-11/E-16 Butyric H H H H Butyric E-256 A-11/E-16 Butyric Butyric H H H Butyric E-257 A-11/E-16 Butyric Butyric Butyric H H Butyric E-258 A-11/E-16 H H H H H Mannose E-259 A-11/E-16 Propionic H H H H Propionic E-260 A-11/E-16 Propionic Propionic H H H Propionic E-261 A-11/E-16 Propionic Propionic Propionic H H Propionic E-262 A-11/E-16 Ac H H H H Ac E-263 A-11/E-16 Ac Ac H H H Ac E-264 A-11/E-16 Ac Ac Ac H H Ac E-265 A-12 NO2 H H H H E-266 A-12 Ac Ac H H H E-267 A-12 Ac Ac Ac H H E-268 A-12 Ac Ac Ac Ac H E-269 A-12 Propionic Propionic H H H E-270 A-12 Propionic Propionic Propionic H H E-271 A-12 Propionic Propionic Propionic Propionic H E-272 A-12 Butyric Butyric H H H E-273 A-12 Butyric Butyric Butyric H H E-274 A-12 Butyric Butyric Butyric Butyric H E-275 A-12 Succinic Succinic H H H E-276 A-12 Pyruvic Pyruvic H H H E-277 A-12 Maleic Maleic H H H E-278 A-12 Lactic Lactic H H H E-279 A-12 Isobutyric Isobutyric H H H E-280 A-12 Isobutyric Isobutyric Isobutyric H H E-281 A-12 Isobutyric Isobutyric Isobutyric Isobutyric H E-282 A-12 Valeric Valeric H H H E-283 A-12 Valeric Valeric Valeric H H E-284 A-12 Valeric Valeric Valeric Valeric H E-285 A-12 Isovaleric Isovaleric H H H E-286 A-12 Isovaleric Isovaleric Isovaleric H H E-287 A-12 Isovaleric Isovaleric Isovaleric Isovaleric H E-288 A-12 Lipoic Lipoic H H H E-289 A-12 Lipoic Lipoic Lipoic H H E-290 A-12 Lipoic Lipoic Lipoic Lipoic H E-291 A-13.1 H H H H H Ac E-292 A-13.1 Ac H H H H Ac E-293 A-13.1 Ac Ac H H H Ac E-294 A-13.1 Ac Ac Ac H H Ac E-295 A-13.1 H H H H H Propionic E-296 A-13.1 Propionic H H H H Propionic E-297 A-13.1 Propionic Propionic H H H Propionic E-298 A-13.1 Propionic Propionic Propionic H H Propionic E-299 A-13.1 H H H H H Butyric E-300 A-13.1 Butyric H H H H Butyric E-301 A-13.1 Butyric Butyric H H H Butyric E-302 A-13.1 Butyric Butyric Butyric H H Butyric E-303 A-13.1 H H H H H Succinic E-304 A-13.1 H H H H H Pyruvic E-305 A-13.1 H H H H H Maleic E-306 A-13.1 H H H H H Lactic E-307 A-13.1 H H H H H Isobutyric E-308 A-13.1 Isobutyric H H H H Isobutyric E-309 A-13.1 Isobutyric Isobutyric H H H Isobutyric E-310 A-13.1 Isobutyric Isobutyric Isobutyric H H Isobutyric E-311 A-13.1 H H H H H Valeric E-312 A-13.1 Valeric H H H H Valeric E-313 A-13.1 Valeric Valeric H H H Valeric E-314 A-13.1 Valeric Valeric Valeric H H Valeric E-315 A-13.1 H H H H H Isovaleric E-316 A-13.1 Isovaleric H H H H Isovaleric E-317 A-13.1 Isovaleric Isovaleric H H H Isovaleric E-318 A-13.1 Isovaleric Isovaleric Isovaleric H H Isovaleric E-319 A-13.1 H H H H H Lipoic E-320 A-13.1 Lipoic H H H H Lipoic E-321 A-13.1 Lipoic Lipoic H H H Lipoic E-322 A-13.1 Lipoic Lipoic Lipoic H H Lipoic E-323 A-13.2 H H H H H Ac E-324 A-13.2 Ac H H H H Ac E-325 A-13.2 Ac Ac H H H Ac E-326 A-13.2 Ac Ac Ac H H Ac E-327 A-13.2 H H H H H Propionic E-328 A-13.2 Propionic H H H H Propionic E-329 A-13.2 Propionic Propionic H H H Propionic E-330 A-13.2 Propionic Propionic Propionic H H Propionic E-331 A-13.2 H H H H H Butyric E-332 A-13.2 Butyric H H H H Butyric E-333 A-13.2 Butyric Butyric H H H Butyric E-334 A-13.2 Butyric Butyric Butyric H H Butyric E-335 A-13.2 H H H H H Succinic E-336 A-13.2 H H H H H Pyruvic E-337 A-13.2 H H H H H Maleic E-338 A-13.2 H H H H H Lactic E-339 A-13.2 H H H H H Isobutyric E-340 A-13.2 Isobutyric H H H H Isobutyric E-341 A-13.2 Isobutyric Isobutyric H H H Isobutyric E-342 A-13.2 Isobutyric Isobutyric Isobutyric H H Isobutyric E-343 A-13.2 H H H H H Valeric E-344 A-13.2 Valeric H H H H Valeric E-345 A-13.2 Valeric Valeric H H H Valeric E-346 A-13.2 Valeric Valeric Valeric H H Valeric E-347 A-13.2 H H H H H Isovaleric E-348 A-13.2 Isovaleric H H H H Isovaleric E-349 A-13.2 Isovaleric Isovaleric H H H Isovaleric E-350 A-13.2 Isovaleric Isovaleric Isovaleric H H Isovaleric E-351 A-13.2 H H H H H Lipoic E-352 A-13.2 Lipoic H H H H Lipoic E-353 A-13.2 Lipoic Lipoic H H H Lipoic E-354 A-13.2 Lipoic Lipoic Lipoic H H Lipoic E-355 A-14.1 Ac H H H H E-356 A-14.1 Ac Ac H H H E-357 A-14.1 Ac Ac Ac H H E-358 A-14.1 Propionic H H H H E-359 A-14.1 Propionic Propionic H H H E-360 A-14.1 Propionic Propionic Propionic H H E-361 A-14.1 Butyric H H H H E-362 A-14.1 Butyric Butyric H H H E-363 A-14.1 Butyric Butyric Butyric H H E-364 A-14.1 Succinic H H H H E-365 A-14.1 Pyruvic H H H H E-366 A-14.1 Maleic H H H H E-367 A-14.1 Lactic H H H H E-368 A-14.1 Isobutyric H H H H E-369 A-14.1 Isobutyric Isobutyric H H H E-370 A-14.1 Isobutyric Isobutyric Isobutyric H H E-371 A-14.1 Valeric H H H H E-372 A-14.1 Valeric Valeric H H H E-373 A-14.1 Valeric Valeric Valeric H H E-374 A-14.1 Isovaleric H H H H E-375 A-14.1 Isovaleric Isovaleric H H H E-376 A-14.1 Isovaleric Isovaleric Isovaleric H H E-377 A-14.1 Lipoic H H H H E-378 A-14.1 Lipoic Lipoic H H H E-379 A-14.1 Lipoic Lipoic Lipoic H H E-380 A-14.2 Ac H H H H E-381 A-14.2 Ac Ac H H H E-382 A-14.2 Ac Ac Ac H H E-383 A-14.2 Propionic H H H H E-384 A-14.2 Propionic Propionic H H H E-385 A-14.2 Propionic Propionic Propionic H H E-386 A-14.2 Butyric H H H H E-387 A-14.2 Butyric Butyric H H H E-388 A-14.2 Butyric Butyric Butyric H H E-389 A-14.2 Succinic H H H H E-390 A-14.2 Pyruvic H H H H E-391 A-14.2 Maleic H H H H E-392 A-14.2 Lactic H H H H E-393 A-14.2 Isobutyric H H H H E-394 A-14.2 Isobutyric Isobutyric H H H E-395 A-14.2 Isobutyric Isobutyric Isobutyric H H E-396 A-14.2 Valeric H H H H E-397 A-14.2 Valeric Valeric H H H E-398 A-14.2 Valeric Valeric Valeric H H E-399 A-14.2 Isovaleric H H H H E-400 A-14.2 Isovaleric Isovaleric H H H E-401 A-14.2 Isovaleric Isovaleric Isovaleric H H E-402 A-14.2 Lipoic H H H H E-403 A-14.2 Lipoic Lipoic H H H E-404 A-14.2 Lipoic Lipoic Lipoic H H E-405 A-15 Succinic H H H E-406 A-15 Pyruvic H H H E-407 A-15 Maleic H H H E-408 A-15 Lactic H H H E-409 A-15 Isobutyric H H H E-410 A-15 Isobutyric Isobutyric H H E-411 A-15 Valeric H H H E-412 A-15 Valeric Valeric H H E-413 A-15 Isovaleric H H H E-414 A-15 Isovaleric Isovaleric H H E-415 A-15 Lipoic Lipoic H H E-416 A-16 Ac H H E-417 A-16 Ac Ac H E-418 A-16 Ac Ac Ac E-419 A-16 Propionic H H E-420 A-16 Propionic Propionic H E-421 A-16 Propionic Propionic Propionic E-422 A-16 Butyric H H E-423 A-16 Butyric Butyric H E-424 A-16 Butyric Butyric Butyric E-425 A-16 Isobutyric H H E-426 A-16 Isobutyric Isobutyric H E-427 A-16 Isobutyric Isobutyric Isobutyric E-428 A-16 Valeric H H E-429 A-16 Valeric Valeric H E-430 A-16 Valeric Valeric Valeric E-431 A-16 Isovaleric H H E-432 A-16 Isovaleric Isovaleric H E-433 A-16 Isovaleric Isovaleric Isovaleric E-434 A-16 Lipoic H H E-435 A-16 Lipoic Lipoic H E-436 A-16 Lipoic Lipoic Lipoic E-437 A-16 Hexanoic H H E-438 A-16 Hexanoic Hexanoic H E-439 A-16 Hexanoic Hexanoic Hexanoic E-440 A-16 Heptanoic H H E-441 A-16 Heptanoic Heptanoic H E-442 A-16 Heptanoic Heptanoic Heptanoic E-443 A-16 Octanoic H H E-444 A-16 Octanoic Octanoic H E-445 A-16 Octanoic Octanoic Octanoic E-446 A-16 Decanoic H H E-447 A-16 Decanoic Decanoic H E-448 A-16 Decanoic Decanoic Decanoic E-449 A-16 Dodecanoic H H E-450 A-16 Dodecanoic Dodecanoic H E-451 A-16 Dodecanoic Dodecanoic Dodecanoic E-452 A-17 Ac H H H H E-453 A-17 Ac Ac H H H E-454 A-17 Ac Ac Ac H H E-455 A-17 Propionic H H H H E-456 A-17 Propionic Propionic H H H E-457 A-17 Propionic Propionic Propionic H H E-458 A-17 Butyric H H H H E-459 A-17 Butyric Butyric H H H E-460 A-17 Butyric Butyric Butyric H H E-461 A-17 Isobutyric H H H H E-462 A-17 Isobutyric Isobutyric H H H E-463 A-17 Isobutyric Isobutyric Isobutyric H H E-464 A-17 Valeric H H H H E-465 A-17 Valeric Valeric H H H E-466 A-17 Valeric Valeric Valeric H H E-467 A-17 Isovaleric H H H H E-468 A-17 Isovaleric Isovaleric H H H E-469 A-17 Isovaleric Isovaleric Isovaleric H H E-470 A-17 Lipoic H H H H E-471 A-17 Lipoic Lipoic H H H E-472 A-17 Lipoic Lipoic Lipoic H H E-473 A-17 Hexanoic H H H H E-474 A-17 Hexanoic Hexanoic H H H E-475 A-17 Hexanoic Hexanoic Hexanoic H H E-476 A-17 Heptanoic H H H H E-477 A-17 Heptanoic Heptanoic H H H E-478 A-17 Heptanoic Heptanoic Heptanoic H H E-479 A-17 Octanoic H H H H E-480 A-17 Octanoic Octanoic H H H E-481 A-17 Octanoic Octanoic Octanoic H H E-482 A-17 Decanoic H H H H E-483 A-17 Decanoic Decanoic H H H E-484 A-17 Decanoic Decanoic Decanoic H H E-485 A-17 Dodecanoic H H H H E-486 A-17 Dodecanoic Dodecanoic H H H E-487 A-17 Dodecanoic Dodecanoic Dodecanoic H H E-488 A-18 Ac H H H H E-489 A-18 Ac Ac H H H E-490 A-18 Ac Ac Ac H H E-491 A-18 Propionic H H H H E-492 A-18 Propionic Propionic H H H E-493 A-18 Propionic Propionic Propionic H H E-494 A-18 Butyric H H H H E-495 A-18 Butyric Butyric H H H E-496 A-18 Butyric Butyric Butyric H H E-497 A-18 Isobutyric H H H H E-498 A-18 Isobutyric Isobutyric H H H E-499 A-18 Isobutyric Isobutyric Isobutyric H H E-500 A-18 Valeric H H H H E-501 A-18 Valeric Valeric H H H E-502 A-18 Valeric Valeric Valeric H H E-503 A-18 Isovaleric H H H H E-504 A-18 Isovaleric Isovaleric H H H E-505 A-18 Isovaleric Isovaleric Isovaleric H H E-506 A-18 Lipoic H H H H E-507 A-18 Lipoic Lipoic H H H E-508 A-18 Lipoic Lipoic Lipoic H H E-509 A-18 Hexanoic H H H H E-510 A-18 Hexanoic Hexanoic H H H E-511 A-18 Hexanoic Hexanoic Hexanoic H H E-512 A-18 Heptanoic H H H H E-513 A-18 Heptanoic Heptanoic H H H E-514 A-18 Heptanoic Heptanoic Heptanoic H H E-515 A-18 Octanoic H H H H E-516 A-18 Octanoic Octanoic H H H E-517 A-18 Octanoic Octanoic Octanoic H H E-518 A-18 Decanoic H H H H E-519 A-18 Decanoic Decanoic H H H E-520 A-18 Decanoic Decanoic Decanoic H H E-521 A-18 Dodecanoic H H H H E-522 A-18 Dodecanoic Dodecanoic H H H E-523 A-18 Dodecanoic Dodecanoic Dodecanoic H H E-524 A-19.1 Ac Ac E-525 A-19.1 Propionic Propionic E-526 A-19.1 Butyric Butyric E-527 A-19.1 Isobutyric Isobutyric E-528 A-19.1 Valeric Valeric E-529 A-19.1 Isovaleric Isovaleric E-530 A-19.1 Adamantylcarboxyl Adamantylcarboxyl E-531 A-19.2 Ac Ac Ac Ac E-532 A-19.2 Propionic Propionic Propionic Propionic E-533 A-19.2 Butyric Butyric Butyric Butyric E-534 A-19.2 Isobutyric Isobutyric Isobutyric Isobutyric E-535 A-19.2 Valeric Valeric Valeric Valeric E-536 A-19.2 Isovaleric Isovaleric Isovaleric Isovaleric E-537 A-20.1 Butyric Butyric Butyric E-538 A-20.1 Ac Ac Ac E-539 A-20.1 Propionic Propionic Propionic E-540 A-1 N-Phenyl H H H H CH3 chlorothionoformate E-541 A-1 Imiquimod- H H H H CH3 Succinate E-542 A-1 Resiquimod- H H H H CH3 Succinate E-543 A-1 Succinate- H H H H CH3 ethyl ester E-544 A-1 Indole-3- H H H H CH3 propionic E-545 A-1 Cyclopropanecarboxylic H H H H CH3 E-546 A-1 Cyclobutanecarboxylic H H H H CH3 E-547 A-1 Nicotinic H H H H CH3 E-548 A-1 Chenodeoxycholic H H H H CH3 E-549 A-1 Ferrocenylacetic H H H H CH3 E-550 A-1 Lipoic-S H H H H CH3 derivatives E-551 A-1 Methoxyacetic H H H H CH3 E-552 C2 (see Table 16) Butyric Butyric E-553 A-1 H Butyric Butyric H H CH3 E-554 A-1 H Ac Ac H H CH3 E-555 A-1 H Propionic Propionic H H CH3 E-556 A-1 O-Acetyl H H H CH3 Lactic E-557 A-2 (X = O) Isovaleric H H H H CH3 E-558 A-2 (X = O) Valeric H H H H CH3 E-559 A-1 Methoxyacetic Methoxyacetic Methoxyacetic Methoxyacetic H CH3 E-560 A-1 Cyclobutanecarboxylic Cyclobutanecarboxylic H H H CH3 E-561 A-1 Cyclobutanecarboxylic Cyclobutanecarboxylic Cyclobutanecarboxylic H H CH3 E-562 A-1 Nicotinic Nicotinic H H H CH3 E-563 A-1 Nicotinic Nicotinic Nicotinic H H CH3 E-564 A-2 (X = O) Ac H H H H CH3 E-566 A-10 Isobutyric Isobutyric Isobutyric H CH3 E-567 A-10 Isobutyric Isobutyric H H CH3 E-568 A-10 Isobutyric H H H CH3 E-569 A-10 Valeric Valeric Valeric H CH3 E-570 A-10 Valeric Valeric H H CH3 E-571 A-10 Valeric H H H CH3 E-572 A-10 Isovaleric Isovaleric Isovaleric H CH3 E-573 A-10 Isovaleric Isovaleric H H CH3 E-574 A-10 Isovaleric H H H CH3 E-575 A-11/E-16 Butyric H H H Butyric Butyric E-576 A-19.1 Ac H E-577 A-19.1 Propionic H E-578 A-19.1 Butyric H E-579 A-20.2 Butyric Butyric Butyric E-580 A-20.2 Ac Ac Ac E-581 A-20.2 Propionic Propionic Propionic E-582 A-12 Valeric H H H H E-583 A-12 Isovaleric H H H H E-584 A-19.3 Valeric H H E-585 A-19.3 Valeric H Ethyl E-586 A-19.3 Valeric Valeric H E-587 A-19.3 Valeric Valeric Ethyl E-588 A-19.3 Isovaleric H H E-589 A-19.3 Isovaleric H Ethyl E-590 A-19.3 Isovaleric Isovaleric H E-591 A-19.3 Isovaleric Isovaleric Ethyl E-592 A-19.3 Butyric H H E-593 A-19.3 Butyric H Ethyl E-594 A-19.3 Butyric Butyric H E-595 A-19.3 Butyric Butyric Ethyl E-596 A-17 NO2 H H H H E-597 A-17 NO2 NO2 H H H E-598 A-18 H H NO2 H H E-599 A-18 H NO2 NO2 H H E-600 A-11/E-16 H H no cladinose H H Mannose ring E-601 A-21 NO2 E-602 A-21 NO2 NO2 E-603 A-21 NO2 NO2 H NO2 - Procedures
- Synthesis of E-1: Typical Nitration Procedure
-
Method 1. Acetic acid (40 mL) and Azithromycin (5 g, 6.73 mmol) were charged in a round bottom flask. Initially, the reaction solidified which eventually during stifling, produced a homogenous solution. The resulting solution was cooled in an ice-bath. Acetic anhydride (19.8 mL, 209.5 mmol) was taken up in another reaction flask and cooled in an in ice bath. To this was added dropwise, nitric acid (2.2 mL, 46.43 mmol). After complete addition, the mixture was transferred to a dropping funnel and attached to the first reaction vessel containing the macrolide. The HNO3-Ac2O mixture was slowly added to the reaction (ca. 1 drop per second). After complete addition, the reaction was allowed to warm to room temperature where it was stirred until reaction completion (3 h). The reaction was poured onto a stirred 200 mL ice-water. Stirring was continued until the ice is completely melted. The resulting aqueous solution was neutralized at first with a saturated solution of NaHCO3, followed by pure solid NaHCO3 topH 8 to 9. The aqueous solution was extracted with DCM (5×). The DCM extracts were dried (Na2SO4), evaporated in vacuo. The crude product was purified by column chromatography (3:1 cyclohexane, ethyl acetate, 1% triethylamine) to get compound E-1 as a white foam (30% yield). - These nitration conditions can be applied to other ALCs, and in cases where there is more than one reactive hydroxy species, selective protection is necessary.
-
Method 2. Hydroxyalkyl species (1 mmol) was suspended in acetonitrile in a round bottom flask while stirring (magnetic stir bar, 300 rpm). Silver nitrate (2 eq. per hydroxyl group) was added and the mixture was cooled in an ice bath. Phosgene (solution in toluene, 1 eq. per hydroxyl group) was carefully added dropwise. Immediate precipitation of silver chloride and formation of carbon dioxide indicated formation of nitro donor (caution: too quick CO2 formation may result in strong foaming. Do not seal the flask!). After a couple of minutes a yellow color was obtained and stirring was continued for 15 minutes. When ESI-MS indicated satisfying turn-over rate of starting materials the reaction was quenched by addition of methanol, converting excess nitro donor to volatile methyl nitrate. The system was diluted by addition of DCM and was subject to extraction with saturated sodium bicarbonate solution (3×). Separation of organic phase, drying over sodium sulfate and evaporation of any volatiles in vacuo yielded the product as colorless oil or beige to off-white foam. -
TABLE 3 Nitration Examples Compound Synthesis Degree of Entry Method ALC Substitution Yield MS E-596 2 A-17 Mono nitro n.d.* 822, M + H+ E-597 2 A-17 Di nitro n.d.* 867, M + H +2 A-18 Oxidation n.d.* 954, M + Na+ E-598 2 A-18 Mono nitro n.d.* 999, M + Na+ E-599 2 A-18 Di nitro n.d.* 1045, M + Na+ E-601 2 A-21 Mono nitro n.d.* 793, M + H+ E-602 2 A-21 Di nitro n.d.* 838, M + H+ E-603 2 A-21 Tri nitro n.d.* 883, M + H+ n.d.* not determined - Synthesis of E-2
- Compound E-1 (791 mg, 1.0 mmol) was taken up in 15 mL dichloromethane. Pyridine (89 mL, 1.1 mmol) was added and the resulting solution was cooled in an ice bath for approximately 10 minutes. At this point, a solution of acetic anhydride (113 ml, 1.2 mmol) in dichloromethane (15 mL) was added dropwise. The reaction was stirred continually at this temperature and then progressively warmed to room temperature where it was stirred overnight. The reaction was washed with a saturated solution of ammonium chloride (3×), water (3×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. Co-evaporation with toluene is necessary to remove residual pyridine from the system. This was followed by re-dissolving the residue in DCM and solvent evaporation twice to produce a white foam, which was dried under high-vacuum to produce E-2 (631 mg, 76%).
- Synthesis of E-3
- E-3 was synthesized using standard nitration procedure described above starting from E-20.
- Synthesis of E-4
- A solution of E-3 (1 mmol) and pyridine (1 mmol) in DCM (10 ml) was treated with acetic anhydride (1.5 mmol) at ambient temperature. Stirring was continued until TLC (acetone-cyclohexane 1:3) indicated complete consumption of the starting materials. The system was extracted with an aqueous solution of NH4Cl (2× 10 ml) and water (3× 10 ml). After drying over Na2SO4 all volatile components were evaporated in vacuo, traces of pyridine species were removed by co-evaporation with toluene (2×). The product E-4 was a colorless oil (41%).
- Synthesis of E-5
-
Method 1. A solution of propionic acid (1.2 mmol) in 1.2-dichloroethane was treated with 1-Ethyl-3-(3-dimethyl-aminopropyl)carbodiimid (1.2 mmol) in the presence of a catalytical amount of DMAP for 30 min. at ambient temperature. Temperature was raised to 55°C., E-1 (1 mmol) was added and stirring was continued until TLC (acetone-cyclohexane 1:3) indicated complete consumption of the starting materials. The system was extracted with water (3× 10 ml). After drying over Na2SO4 all volatile components were evaporated in vacuo, traces of pyridine species were removed by co-evaporation with toluene (2×). The crude products were purified by column chromatography (acetone-cyclohexane 1:3), yielding the product E-5 as white amorphous foam (39%). - Alternative Synthesis: Compound E-1 (310 mg, 0.39 mmol) was taken up in dichloromethane (15 mL). At which point, pyridine (32 mL, 0.39 mmol) was added. The solution was stirred for 5 minutes, at which time, propionyl anhydride (51 mL, 0.40 mmol) was added. The reaction was allowed to stir at room temperature for 72 h. An additional propionyl anhydride (0.1 eq) was added and the reaction monitored until complete disappearance of starting material was observed (MS, reaction may take up to 1 week). The reaction was washed successively with a saturated aqueous solution of NH4Cl (3×) and H2O (3×). The organic phase was dried over anhydrous Na2SO4 and evaporated in vacuo. Co-evaporation with toluene is necessary to remove residual pyridine from the system. This was followed by re-dissolving the residue in DCM and solvent evaporation twice to produce E-5 as a white foam (210 mg, 64%).
- Method 3: A-1 (300 mg, 0.40 mmol), was dissolved in DCM (10 mL); to this solution was added TEA (279 μL, 5 eq) and propionylchloride (175 μL, 5 eq) subsequently and the mixture was stirred overnight at room temperature. Additional TEA (112 μL, 2 eq) and propionyl chloride (70 μL, 2 eq) were added and again mixture was stirred overnight at room temperature. Once more additional TEA (112 μL, 2 eq) and propionyl chloride (70 μL, 2 eq) were added and stirring at room temperature was continued overnight. TEA (344 μL, 9 eq) and propionyl chloride (314 μL, 9 eq) were added and the mixture was stirred at room temperature for 5 days. The reaction mixture was washed with aqueous Na2CO3-solution (3×, 10%) and water (3×), dried, concentrated to dryness, and dried at the oil pump. ESI-MS (positive) showed tri- and tetra-propionylation.
-
Method 4 - Propionic acid (4 eq) was taken up in 5 mL dichloromethane (DCM). Compound A-16 (0.5 mmol) and 4-dimethylaminopyridine (DMAP) (4.4 eq) were added and the resulting solution was cooled in an ice bath for approximately 10 minutes. At this point, dicyclohexylcarbodiimide (DCC) (4.4 eq) was added slowly. The reaction was stirred continually at this temperature for 5 minutes and then progressively warmed to room temperature where it was stirred overnight. Dicyclohexylurea (DCC) that was formed during the reaction is filtered off and discarded. The filtrate was collected and then washed with a saturated solution of sodium hydrogencarbonate (3×), water (1×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. This was followed by re-dissolving the residue in a small volume of methanol. The solution was transported dropwise into ice-cold water (2× volume of methanol) and stored in the freezer overnight. The precipitated product was filtered off and dried under high-vacuum to produce
-
TABLE 4 Propionylation Examples Reaction MS Compound Synthesis Substituent Condition Degree of m/z Entry Method ALC equivalent (i.e. Workup) Substitution Yield ([M + H]+) E-5 1 A-1 1.1 as described 1 64% 850.3 above E-18 See A-1 N/ A 1 80% 805.5 example 21 E-419 4 A-16 4 1 50% 791.3 E-420 2 (based on 847.1 E-421 3 tri-ester 903.0 E-52 3 A-1 18 3 Not 917.9 E-51 4 determined 973.8 - Synthesis of E-8
- Erythromycin oxime was nitrated as described in the general procedure, followed by subsequent acetylation of crude nitration product with acetic anhydride in DCM with pyridine as catalyst. Column chromatography (acetone-cyclohexane 1:3) furnished the product E-8 as white amorphous foam (39%, two steps).
- Synthesis of E-10
- A solution of E-9 (1 mmol) in MeOH (20 ml) was vigorously stirred at 50° C. until TLC (acetone-cyclohexane 1:3) indicated complete deacetylation of the starting materials. Volatile components were removed in vacuo, the product E-10 was obtained as white amorphous foam (81%).
- Synthesis of E-11
- Azithromycin was nitrated as described above. After desired mono-nitration MeOH was added to the reaction mixture and stirring was continued for one further hour. Thus in situ generated methyl nitrate acted as methylating agent transferring one methyl group to 11-O-position of the macrolide at ambient temperature. Standard aqueous workup with subsequent purification by column chromatography (acetone-cyclohexane 1:3) delivered methylated macrolide nitrate E-11 as white amorphous solid (63%, two steps).
- Synthesis of E-16
- Azithromycin (20.0 g; 26.7 mmol) was dissolved in 120 ml of MeOH. NaHCO3 (6.0 g; 71.5 mmol) was added, followed by a solution of K2CO3 (12.0 g; in water (80 ml; cooled down to RT), and finally iodine (6.3 g; 24.8 mmol). The mixture was stirred vigorously at ambient temperature until the dark color had disappeared. A second batch of iodine (6.3 g; 24.8 mmol) and K2CO3 carbonate (4.2 g; 30 mmol) were added. The procedure [addition of iodine 6.3 g and K2CO3 (4.2 g; 30 mmol)] was repeated until MS showed (almost) full conversion. Sodium bisulfite was added to remove excess oxidants, and all volatiles were evaporated. The solid residue was finely ground and extensively extracted via Soxhlet extraction with acetonitrile. The extract was concentrated to ca. 75 ml and left standing at ambient temperature at least for 1 day and subsequently for another day in the fridge. All solids were collected and recrystallized from MeOH spiked with ca. 1 to 2 ml of water. Crystallization proceeded for about 3 days in an open vessel to yield 10 g (51%) of 3′-N-demethyl-azithromycin (E-16). A second crop can be obtained from the mother liquors.
- Synthesis of E-20
- A solution of E-16 (5 mmol) in DMSO (20 ml) was treated with decyl bromide (6 mmol) at ambient temperature. Stirring continued for 12 h until TLC (acetone-cyclohexane 1:3, 1% Et3N) indicated consumption of starting materials. The system was diluted with EtOAc. (50 ml) and extracted with water (3× 30 ml). The organic phase was dried over sodium sulfate. Evaporation of the solvent and drying at vacuum yielded E-20 as white amorphous foam (61%).
- Synthesis of E-25
- A solution of azithromycin (13 mmol) and pyridine (13 mmol) in DCM (80 ml) was cooled to 0° C. in an ice bath. A solution of acetic anhydride (14 mmol) in DCM (20 ml) was slowly added to the system. Afterwards the reaction mixture was allowed to warm up to ambient temperature and stirring was continued until TLC (acetone-cyclohexane 1:3, 1% Et3N) indicated complete consumption of the starting materials. The system was extracted with an aqueous solution of NH4Cl (2× 50 ml) and water (3× 50 ml). After drying over Na2SO4 all volatile components were evaporated in vacuo, traces of pyridine were removed by coevaporation with toluene (2×). The product E-25 was a white amorphous solid (67%).
- Synthesis of E-22
- A solution of E-25 (4 mmol) in dry THF (30 ml) was cooled to 0° C. in an ice bath. A solution of propargyl bromide (4.4 mmol, 80% in toluene) was added slowly to the system. Afterwards the reaction mixture was allowed to warm up to ambient temperature and stirring was continued until TLC (acetone-cyclohexane 1:3, 1% Et3N) indicated complete consumption of the starting materials. The system was diluted with EtOAc (50 ml) and extracted with water (3× 50 ml). After drying over Na2SO4 volatile components were evaporated in vacuo. Purification by column chromatography (acetone-cyclohexane 1:3, 1% Et3N) furnished E-22 as white amorphous powder (57%).
- Synthesis of E-12
- A solution of E-22 (0.5 mmol), I-5 (0.5 mmol) and DIPEA (1 mmol) in toluene (5 ml) was treated with triethylphosphito copper(I) iodide complex (0.05 mmol) at ambient temperature. Stirring was continued until TLC (ethyl acetate-cyclohexane 1:1) indicated complete consumption of the starting materials. The mixture was concentrated in vacuo and purified by column chromatography (acetone-cyclohexane 1:1→acetone). The product E-12 was obtained as colorless foam (32%).
- Synthesis of E-23
- A solution of E-25 (5 mmol) and pyridine (5 mmol) in DOA (40 ml) was treated with acetic anhydride (7 mmol) at ambient temperature. Stirring was continued until TLC (acetone cyclohexane 1:3, 1% Et3N) indicated complete consumption of the starting materials. The system was extracted with an aqueous solution of NH4Cl (2× 20 ml) and water (3× 30 ml). After drying over Na2SO4 all volatile components were evaporated in vacuo, traces of pyridine species were removed by co-evaporation with toluene (2×). The product E-23 was a white amorphous powder (54%).
- Synthesis of E-17
- A solution of E-23 (2 mmol) in MeOH (30 ml) was vigorously stirred at 50° C. until TLC (acetone-cyclohexane 1:3, 1% Et3N) indicated complete deacetylation of the starting materials. Volatile components were removed in vacuo, the product E-17 was obtained as white amorphous foam (73%).
- Alternative Synthesis: Compound E-2 (619 mg, 0.74 mmol) was charged in a round bottom flask. To this was added a solution of acetic acid/methanol (2:1, 15 mL). To the stirred solution, was added Zn powder (368 mg, 5.63 mmol, 7.6 eq). The resulting suspension was stirred at room temperature and progressively monitoring the disappearance of the starting material (approx. 3 h). The suspension was filtered and the filtrate evaporated in vacuo. The residue was taken up in dichloromethane (15 mL) producing some white precipitate. The precipitate was filtered off. The dichloromethane filtrate was washed with 10% aqueous Na2CO3 solution (2×), water (1×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo producing E-17 as a white solid (475 mg, 81% yield).
- Synthesis of E-26
- A solution of azithromycin (13 mmol) and pyridine (13 mmol) in DCM (80 ml) was cooled to 0° C. in an ice bath. A solution of benzoyl chloride (14 mmol) in DCM (20 ml) was slowly added to the system. Afterwards the reaction mixture was allowed to warm up to ambient temperature and stirring was continued until TLC (acetone-cyclohexane 1:3, 1% Et3N) indicated complete consumption of the starting materials. The system was extracted with an aqueous solution of NH4Cl (2× 50 ml) and water (3× 50 ml). After drying over Na2SO4 all volatile components were evaporated in vacuo, traces of pyridine species were removed by co-evaporation with toluene (2×). Column chromatography (acetone-cyclohexane 1:3, 1% Et3N) yielded the product E-26 as a white amorphous foam (44%).
- Synthesis of E-13
- A solution of E-5 (1 mmol) and propionic acid (1.2 mmol) in 1,2-dichloroethane (3 ml) was treated portion wise with EDCI (3× 0.8 mmol) and DMAP (1 mmol). The mixture was heated to 55° C. and stirred for 6 days. After TLC (acetone-cyclohexane 1:3) indicated complete consumption of the starting materials the mixture was diluted with EtOAc (30 ml) and extracted with water (3× 20 ml). After drying over Na2SO4 the organic phase was evaporated and the remains were purified by column chromatography (acetone-cyclohexane 1:3). The product E-13 was obtained as colorless amorphous foam (42%).
- Synthesis of E-14
- 3′-N-desmethyl-azithromycin (I-1) (300 mg; 0.41 mmol) and 1-bromo-3-nitrooxy-
propane [17] (90 mg, 0.49 mmol) were dissolved in dry DMSO (1.2 ml). The mixture was shaken at 23° C. for 3 hours. Afterwards additional 1-bromo-3-nitrooxy-propane (90 mg, 0.49 mmol) was added and shaking was continued for another hour. Once again, 1-bromo-3-nitrooxy-propane (90 mg, 0.49 mmol) was added, the reaction mixture was shaken for additional 90 min., and then kept in the freezer (−16° C.) over night. The next morning additional 1-bromo-3-nitrooxy-propane (90 mg, 0.49 mmol) was added and the mixture was shaken for one hour. Water and DCM were added; after extraction, the organic phase was dried (Na2SO4) and concentrated to dryness (without heating). The crude product was purified by column chromatography (eluent: CHCl3:Isopropanol: NH3 (7 M in MeOH 30:1:1). - Synthesis of (I-5)
- Azido-β-D-Glucopyranoside is synthesized from corresponding sugar acetate as is known to literature[16]. After removal of any protective groups sugar azide is nitrated following above procedure. Due to its high explosive risk the substance is always kept as DCM solution and is stashed in the refrigerator.
- Synthesis of E-24
- Compound E-1 (405 mg, 0.51 mmol) was taken up in dichloromethane (15 mL). The resulting solution was cooled to 0° C. After 5 minutes, butyryl chloride (60 mL, 61.8 mg, 0.58 mmol, 1.1 eq.) was added. The reaction was stirred for 10 min. at this temperature, at which point, the reaction was allowed to warm to room temperature, where it was stirred until reaction completion (2 h, or upon continuous monitoring). The reaction was washed with a 10% Na2CO3 aq. solution (3×) followed by H2O (3×), dried over anhydrous Na2SO4 and evaporated in vacuo to give E-24 as a white foam (332 mg, 75% yield).
- Synthesis of E-18
- Compound E-5 (CSY 1076) (126 mg, 0.15 mmol) was charged in a round bottom flask. To this was added a solution of acetic acid/methanol (2:1, 12 mL). To the stirred solution, was added Zn powder (74 mg, 1.12 mmol, 7.6 eq). The resulting suspension was stiffed at room temperature and progressively monitoring the disappearance of the starting material (approx. 3 h). The suspension was filtered and the filtrate evaporated in vacuo. The residue was taken up in dichloromethane (10 mL) producing some white precipitate. The precipitate was filtered off. The dichloromethane filtrate was washed with 10% aqueous Na2CO3 solution (2×), water (1×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo producing E-18 as a white solid (96 mg, 80% yield).
- The reduction conditions for removal of the NO2 group was applied to the syntheses of E-19 from E-24 providing the desired product in 78% yield.
- Synthesis of E-19
- Compound E-24 CSY 4636 (100 mg, 0.12 mmol) was charged in a round bottom flask. To this was added a solution of acetic acid/methanol (2:1, 12 mL). To the stirred solution, was added Zn powder (88 mg, 1.35 mmol, 11.6 eq). The resulting suspension was stirred at room temperature and progressively monitoring the disappearance of the starting material (approx. 3 h). The suspension was filtered and the filtrate evaporated in vacuo. The residue was taken up in dichloromethane (15 mL) producing some white precipitate. The precipitate was filtered off. The dichloromethane filtrate was washed with 10% aqueous Na2CO3 solution (2×), water (1×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo producing E-19 as transparent gel (74 mg, 78% yield).
- Synthesis of E-81
- 250 mg of 2′-(2-Mercaptoethoxy)carbonyl-3-decladinosylazithromycin and 250 mg of ammonium polysulfide are mixed with 10 ml of degassed and argonized glacial acetic acid and stirred with exclusion of oxygen for 12 h. All volatiles are removed in vacuo, and the residue is extracted with oxygen free saturated aqueous sodium
hydrogen carbonate solution 3 times. The residue is washed with water (oxygen free), dried in vacuo and used as such. - Synthesis of E-82
- 250 mg of 2′-(2-Mercaptoethoxy)carbonyl-3-decladinosylazithromycin are dissolved in a mixture of 5 ml of tert. butanol and 5 ml of dichloromethane. 250 μl of tert. butylnitrite are added, and the mixture is stirred for 48 h with exclusion of light. All volatiles are removed i.v. keeping the temperature below 20° C. and light excluded. The red residue is used as such
- Synthesis of E-74
- 380 mg of Azithromycin are dissolved with 20 ml of DMF and cooled in an ice bath. 41 ml of pyridine and then 85 mg (1.1 eq.) of rac-2-acetoxy propionyl chloride, dissolved with 1 ml of dichloromethane, are added and the mixture is allowed to warm up to room temperature with stirring. When mass spectrometry indicates consumption of the macrolide, the mixture is diluted with 50 ml of ethyl acetate, extracted twice with water, 3 times with saturated aqueous sodium hydrogen carbonate solution, once again with water and brine, each, and dried over sodium sulfate. After evaporation and vacuum drying, the diastereomeric mixture (1:1) of target compound E-74 remains as a slightly yellowish foam.
- Yield: 385 mg
- MS: m/z=863.5 ([M+H]−)
- The same procedure can be applied in preparing E-77, E-83, E-84, E-85 and E-86.
-
TABLE 5 Typical Products from the Acylation Procedures Entry Acylating agent Product structure Yield [%] ([M + H]+ E-83 O-Phenyl chlorothionoformate 66 885.7 E-85 2- Bromoethylchloroformate 82 899.6 E-84 Hexanoylchloride 93 847.6 E-77 Lipoyl chloride 72 936.8 E-86 Allylchloroformate 82 833.5 E-540 O-Phenyl chlorothionoformate 23 884 E-26 Benzoyl 44 853 - General Procedure: Synthesis of n-Butyryl-Propanolol, Compound E-133
- Propranolol HCl (200 mg, 0.68 mmol) was taken up in dichloromethane (4 mL). To this was added dropwise butyryl chloride (69 μL, 0.71 mmol) and the reaction was stirred at room temperature for 1 hour. To the reaction was added triethylamine (194 μL, 1.4 mmol). After 30 min, additional butyryl chloride (30 μL, 0.3 mmol) was added. Reaction was monitored by the disappearance of starting material. The reaction was stopped after 20 min by the addition of 10
mL 10% aqueous Na2CO3 solution. The two phases were stirred for 5 min separated. The organic layer was washed successively with 10% aqueous Na2CO3 (1×), H2O (1×) and saturated aq. NaCl (1×), dried with Na2SO4 and evaporated in vacuo to get an oil film. 5 mL HCl in Et2O (2M) and 1 mL MeOH was added and stirred for 5 min, then evaporated in vacuo and dried with the vacuum pump under nitrogen for 1 hour to get a brown oil (yield 91%). - General Procedure: Synthesis of n-Butyryl-Hydroxychloroquine, Compound E-89
- Hydroxychloroquine sulfate (1099 mg, 2.53 mmol) was charged into a round bottom flask. H2O (10 mL) and dichloromethane (10 mL) were added. Pyridine (412 μL, 5.1 mmol) was added and the reaction stirred vigorously for 5 min. Butyric anhydride (420 μL, 2.65 mmol) was added and the reaction stirred at room temperature for 3 h. The phases were separated and the dichloromethane layer was washed successively with a saturated aqueous NH4Cl solution (2×15 mL), H2O (2×10 mL), dried over Na2SO4 and evaporated in vacuo. Co-evaporation with toluene is necessary to remove residual pyridine from the system. This was followed by re-dissolving the residue in DCM and solvent evaporation twice to produce a yellow oil (93 mg, 9% yield).
- This procedure can be applied for the synthesis of the following compounds E-87 to E-88 E-90 to E-97.
- Typical methylation reaction of Hydroxychloroquine or Propranolol was achieved using Eschweiler-Clarke-methylation reaction. Acylation reactions were carried out using typical procedures described above.
- Compounds, prepared by reacting a carrier molecule with acylating agents.
- These carrier molecules are prepared by reacting symmetric or unsymmetric di- or poly-epoxides with secondary amines, thus containing the common structural element of 2 or more alcohols, vicinally neighbored by a tertiary amine.
- Alternatively, carrier molecules can be prepared by reacting epoxides with diethanolamine. The reaction products are containing 2-hydroxy tertiary amines.
-
TABLE 6 Examples for di- or polyepoxides No. of epoxide Entry Name CAS-No. functions A 1,3-Butadiene diepoxide 1464-53-5 2 B 1,4-Butandiole diglycidylether 2425-79-8 2 C N,N-Diglycidylaniline 2095-06-9 2 D Resorcinol diglycidylether 101-90-6 2 E Ethylen glycol diglycidylether 2224-15-9 2 F 1,7-octadienediepoxide 2426-07-5 2 G Diglycidyl ether 2238-07-5 2 H 1,2,4,5,9,10-Triepoxydecane 52338-90-6 3 1 N,N-Diglycidyl-4-glycidyloxyaniline 5026-74-4 3 J Poly(ethylene glycol) diglycidyl ether 72207-80-8 2 (average Mn 500) K Glycerol diglycidylether 72207-80-8 2 L 4,4′-Methylenebis(N,N- 28768-32-3 4 diglycidylaniline) M Bis[4-(glycidyloxy)phenyl]methane 2095-03-6 2 -
TABLE 7 Examples for secondary amines Entry Name CAS-No. 1 Dimethylamine 2 Morpholine 3 4- Methylpiperazine 4 Piperidine 5 1,2,3,4-Tetrahydroisoquinoline 91-21-4 6 Diethylamine 7 Dioctylamine 8 Diethanolamine 9 Sarcosine methyl ester hydrochloride 13515-93-0 10 (R)-pyrrolidine-2-carboxylic acid methyl ester (Prolin methylester) 11 Ethyl 1,4-diazepan-1-ylacetate dihydrochloride - The 2-aminoalcohols of these carriers can be esterified to short chain carboxylic acids or nitric acid. One molecule can contain esters of different of these acids. Examples for short chain carboxylic acids are:
- Acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, 2-methylbutyric acid, 3-methylbutryric acid, lactic acid, pyruvic acid, 3-phenylpropionic acid, succinic acid, maleic acid, fumaric acid, malic acid, lactic acid butyrate (lactic acid butanioate), 2-acetoxy propionic acid, mandelic acid, benzoic acid.
- Structural Examples of such Esters are:
- Alternatively, these carrier molecules are prepared by reacting symmetric or unsymmetric di- or polyamines with epoxides, thus containing the common structural element of 2 or more alcohols, vicinally neighboured by a tertiary amine.
-
TABLE 9 Examples for di- or polyamines No. of reactive Entry Name CAS. No. amines N Spermine 71-44-3 4 O Spermidine 124-20-9 3 P Piperazine 110-85-0 2 Q 1-(2-Aminoethyl)piperazine 140-31-8 2 R L-Lysine 56-87-1 2 S Homopiperazine 505-66-8 2 T 1,3-Diamino-2-propanol 616-29-5 2 U 1,3,5-Triamino-1,3,5-trideoxy-cis-inositol 6988-69-8 3 trihydrochloride V 1,2,3,4-Tetrahydroquinoxaline 3476-89-9 2 W Tetraethylenepentamine 112-57-2 5 -
TABLE 10 Examples for epoxides Entry Name CAS No. 12 Propylene oxide 75-56-9 13 Cyclohexen oxide 286-20-4 14 Ethyl 2,3-epoxypropionate4660-80-4 15 Styrene oxide 96-09-3 16 Glycidol 556-52-5 - The 2-aminoalcohols of these carriers can be esterified to short chain carboxylic acids or nitric acid. One molecule can contain esters of different of these acids. Examples for short chain carboxylic acids are:
- Acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, 2-methylbutyric acid, 3-methylbutryric acid, lactic acid, pyruvic acid, 3-phenylpropionic acid, succinic acid, maleic acid, fumaric acid, malic acid, lactic acid butyrate (lactic acid butanoate), 2-acetoxy propionic acid, mandelic acid, benzoic acid.
- Structural Examples of such Esters are:
- Synthesis of Rac. 2′-Deoxy-2′-S-Thioacetyl ppropranolol[18]
- Diethyl azodicarboxylate (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (25 mL) at 0° C. and treatment is continued for 30 min. Propranolol (5 mmol) and thioacetic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 h at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Synthesis or Rac. 2′-Deoxy-2′-S-Thio Propranolol Sodium Salt
- rac. 2′-Deoxy-2′-S-thioacetyl propranolol (10 mmol) is dissolved in methanol (20 mL) while stirring (magnetic stirrer, 300 rpm) and sodium methoxide (10 mmol) is added at 0° C. The system is allowed to warm up to ambient temperature and treatment is continued until TLC (cyclohexane-ethyl acetate) indicates full conversion of starting materials. Afterwards the reaction mixture is rinsed into ice cold diethyl ether (100 mL). Any precipitates are filtered off and are dried in vacuo to yield a white to slightly yellow product.
- Synthesis of Rac. 2-O-Nitrolactic acid
- Lactic acid (10 mmol) is suspended in acetonitrile (20 mL) in a 3-necked round bottom flask and is cooled to 0° C. in an ice bath while stirring (300 rpm). Diphosgene is added (5 mmol) followed by careful dropwise addition of silver nitrate solution (20 mmol, dissolved in acetonitrile). The mixture is stirred for 30 min at 0° C., subsequently is allowed to warm up to ambient temperature and stirring is continued for further 30 min. Afterwards any precipitates are filtered off and the mixture is carefully concentrated in vacuo, As crude products are likely to be explosive compounds the system was not fully dried but taken up in THF (10 mL) to be immediately used in the following step.
- Synthesis of Rac. 2′-O-(2-O-Nitrolactyl) Propranolol—E-42
- Diethyl azodicarboxylat (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (25 mL) at 0° C. and treatment is continued for 30 min. Propranolol (5 mmol) and rac. 2-O-nitrolactic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 hours at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Rac. Bis-(2′-Deoxy-2′-S-S-Disulfido Propranolol) (Putative)[19]
- A round bottom flask is charged with ethyl acetate (10 mL), graphite (3 g), iodine (0.5 mmol) and cerium(III) chloride heptahydrate (1 mmol). The mixture is stirred for 10 min at ambient temperature, followed by addition of rac. 2′-deoxy-2′-S-thio propranolol sodium salt (10 mmol). Treatment is continued until TLC (cyclohexane-ethyl acetate) indicates full conversion of starting materials. After completion the system is further diluted with additional ethyl acetate (250 mL) and is washed with a saturated solution of aqueous sodium thiosulfate, water, and is dried over sodium sulfate. Upon filtration any volatiles are removed in vacuo and the residue is subject to column chromatography (silica gel, cyclohexane-ethyl acetate).
- Mixed disulfides may also be accessible in this way but require slight alterations.
- Typical Example or Synthesizing ALC Cores A-8 and A-9
- Synthesis of 2-(4-Pyridyl)-3-Amino-4-(3-Methoxyphenyl)Carbonyl Pyrazole
- 10.96 g of 4-(N-phenyl)amino-3-(3-methoxyphenyl)carbonylacrylonitrile and 6.27 g of 4-pyridylhydrazine hydrochloride are combined with 6.2 ml of triethylamine in 140 ml of ethanol, flushed with argon and heated to reflux for 5 h. The mixture is concentrated to 50 ml and diluted with 200 ml of cyclohexane. The precipitate is filtered off and washed with diethyl ether, until no further colour is extracted any more. The remaining solid is dissolved with a mixture of dichloromethane and water (300 ml each). The organic phase is dried with brine and sodium sulfate and concentrated to dryness.
- Yield: 7.07 g (61%); MS: m/z=295 ([M+H]+)
- Synthesis of 2-(4-Pyridyl)-3-Amino-4-(3-Hydroxyphenyl)Carbonyl Pyrazole
- 2.6 g of 2-(4-Pyridyl)-3-amino-4-(3-methoxyphenyl)carbonylpyrazole are suspended in 10 ml of a solution of 33% hydrobromic acid in acetic acid. The mixture is heated to 70° C. for 16 h. After cooling, the reaction mix is poured into 150 ml of water. The precipitate is filtered off, washed with saturated aqueous sodium hydrogen carbonate solution (twice) and water, and dissolved in 10 ml of a solution of ammonia in methanol (7M). After 30 min, all volatiles are removed by evaporation, and the residue is dissolved in 50 ml of boiling methanol. The product is precipitated by pouring into 250 ml of water. Filtration and drying yield 2.35 g of an off white powder.
- Synthesis of 2-(4-Pyridyl)-3-Amino-4-(3-[2,3-Dihydroxypropyloxy]Phenyl)-Carbonyl Pyrazole
- 2.09 g of 2-(4-Pyridyl)-3-amino-4-(3-hydroxyphenyl)carbonyl pyrazole are dissolved with 25 ml of dimethylformamide. 3.5 g of potassium carbonate and 580 mg of glycidol are added. The mixture is kept stirring at 60° C. for 18 h. The reaction mixture is partitioned between water and ethyl acetate. The organic phase is washed with water, dried with brine and sodium sulfate, and concentrated i.v. The residue is subjected to preparative HPLC to yield 1.4 g of the product.
- Synthesis of 2-(4-Pyridyl)-3-Amino-4-(3-[2,3-Di{Butyroyloxy}Propyloxy]Phenyl)Carbonyl Pyrazole E-199
- 500 mg of 2-(4-pyridyl)-3-amino-4-(3-[2,3-dihydroxypropyloxy]phenyl)carbonylpyrazole are dissolved with 5 ml of pyridine. 500 μl of butyric acid anhydride are added, and the mixture is stirred at 50° C. over night. 1 ml of methanol is added, and the mixture is stirred for further 30 min. The reaction is allowed to reach room temperature and partitioned between water and ethyl acetate. The organic phase is extracted with
water 5 times, then with brine and dried over sodium sulfate. After evaporation of all volatiles, the product is purified by chromatography over silica gel. - Yield: 290 mg
- The same conditions can be applied to synthesis of 2-(4-fluorophenyl)-3-amino-4-(3-[2,3-di{butyroyloxy}propyloxy]phenyl)carbonylpyrazole E-210
- Synthesis of Chenodeoxycholic Acid Azithromycin-2′-Ester
- 1 g of Chenodeoxy cholic acid is dissolved with 50 ml of dry dichloromethane and cooled in an ice bath. 500 mg of carbonyl diimidazole are added, and the mixture is stirred for 2 h, while reaching room temperature. 2 g of Azithromycin are added, and the mixture is stirred for 72 h. The mixture is extracted with water (3×) and then with 5% citric acid. The citric acid phase is washed with dichloromethane (2×). It is then vigorously stirred with ethyl acetate, while portions of sodium hydrogencarbonate are added, so that gas evolution is under control. When no gas is developed any more, the organic phase is isolated, washed with brine and dried over sodium sulfate. Concentration and chromatography with a gradient starting at 10% of acetone in cyclohexane (always containing 0.2% of triethylamine) yields 350 mg of the desired product.
- Synthesis of 2′-(Succinyl-1-Hydroxymethylferrocene)-11-Nitro-Azithromycin
- Compound E-10 (200 mg, 0.25 mmol) was dissolved in dry dichloromethane (5 mL). To this was added subsequently, 4-dimethylaminopyridine (4-DMAP, 3 mg, 0.25 mmol. 0.1 eq.) and succinic anhydride (28 mg, 0.28 mmol). The reaction was stirred overnight at room temperature. The solvent was removed in vacuo and the resulting white amorphous foam was used directly for the next step.
- Fresh dry dichloromethane (5 mL) was added to the resulting foam, followed by 1-Hydroxy-methylferrocene (60 mg, 0.28 mmol, 1.1 eq.). The reaction was cooled to 0° C. and to this was added EDCI (96 mg, 0.5 mmol, 2 eq.). The reaction was allowed to progressively warm to room temperature where it was stirred overnight. Additional dichloromethane (20 mL) was added and washed several times with saturated aqueous ammonium chloride, brine (2×), dried under anhydrous Na2SO4 and the solvent removed in vacuo. The resulting crude product was purified by chromatography with a gradient starting at 10% of acetone in cyclohexane (0.2% Et3N) yields 150 mg of the desired product (53%).
- Similarly, the following compound may be obtained using the procedure above starting from compound E-19
- Activity of substances in the inhibition of growth of bacteria. Bacteria including the species Escherichia coli, Bacillus pumilus, Salmonella sp., Micrococcus luteus and Staphylococcus carnosus are cultured in appropriate media (Luria broth for all except S. canosus). Overnight cultures are mixed with fresh medium to reach an optical density at 600 nM of ca. 0.1 AU. These cultures are mixed with solutions of substances to be tested at concentrations ranging from 100 μM to 0.05 μM in a microtitre plate. The growth of the culture is monitored by measuring the optical density at various times after the addition of the inhibitor. Reduction in the rate of increase in optical density corresponds to an inhibition of bacterial growth. In the following tables, the activity of various of the test substances may be observed by reductions in optical density relative to untreated control cultures. The data are summarized in Table 3 and Table 4.
-
TABLE 12 Inhibition of growth of Staphylococcus carnosus by compounds after 9-20 h: Conc. Absorbance of culture medium at 600 nm (μM): 100 50 25 13 6 3 2 0.8 E-2 0.395 0.425 0.456 0.542 0.626 0815 0.766 0.760 E-5 0.302 0.347 0.403 0.452 0.525 0.805 0.726 0.819 E-13 0.421 0.437 0.282 0.488 0.530 0.668 0.755 0.765 E-1 0.157 0.096 0.078 0.068 0.625 0.864 0.856 0.902 E-12 0.494 0.523 0.574 0.548 0.591 0.577 0.688 0.783 E-9 0.545 0.522 0.426 0.677 0.752 0.830 0.737 0.765 E-10 0.576 0.433 0.595 0.702 0.699 0.768 0.826 0.862 E-11 0.641 0.574 0.819 0.822 0.887 0.890 0.918 0.941 No 0.887 compound -
TABLE 13 Inhibition of growth of Salmonella typhimurium by compounds after 9-20 h: Conc. Absorbance of culture medium at 600 nm (μM): 100 50 25 13 6 3 2 0.8 E-2 0.251 0.168 0.314 0.621 0.382 0.410 0.441 0.452 E-5 0.390 0.395 0.396 0.437 0.478 0.511 0.568 0.574 E-13 0.398 0.407 0.427 0.459 0.505 0.543 0.605 0.634 E-1 0.557 0.484 0.736 0.722 0.741 0.711 0.761 0.722 E-12 0.332 0.270 0.326 0.343 0.400 0.354 0.457 0.455 E-9 0.221 0.319 0.395 0.382 0.348 0.327 0.272 0.300 E-10 0.280 0.315 0.390 0.399 0.382 0.402 0.361 0.334 E-11 0.562 0.650 0.697 0.633 0.627 0.623 0.587 0.555 No 0.943 compound - Substances may act directly on bacteria, or they may act to promote the killing of the bacteria by phagocytes. To measure this effect, cultures murine macrophages are incubated with a test bacteria and the number of bacteria surviving are counted in terms of the viable colony forming units (CFU). The method for determining the rate of phagocytosis is as follows:
- Intracellular killing of S. Typhimurium by mouse macrophage cellline J 774 A.1
- seed a monolayer of cells in 200 μl Media into the wells of a 96 well plates
- incubate O/N 37° C.
- remove medium and add fresh medium
- add Bacteria (Salmonella typhimurium) e.g. 5 μl of 1:100 diluted O/N culture (MOI=10) (=108 cfu/ml)
-
centrifuge 10 min 800 g (˜2000 rpm) - incubate 20-30 minutes at 37° C. (phagocytosis)
- remove media
- wash 1-2× with PBS
- add medium with 100 μg/ml Gentamicin, stock: 10 mg/ml (=1:100)
- incubate 45′ at 37° C.
- wash 2× with PBS
- add fresh medium (200 μl/well)
- add compounds to test
- incubate 2-3 hours at 37° C.
- remove medium
- lyse cells with water: add 200 μl H2O incubate 10′, push a few times through 27 gauge needle using a 1 ml syringe
-
plate 100 μlf 1:10 dilution onto LB-agar plates (=1:100 dil) - Monolayer of J 774 A.1 in 96 well plate=˜1-5×104 cells
- Overnight culture of Salmonella thyph.=˜1×1010 cfu/ml
- Overnight culture of Staph. carnosus=˜5×109 cfu/ml MOI=50 (=5 μl of 1:10 dil. O/N culture)
- MOI=Multiplicity of Infection
- Medium: DMEM/RPMI 7.5 FCS
- The potential efficacy of a Compound for Inflammatory bowel disease may be modeled as follows. C57 BLK6 or BALBc mice are provided with drinking water containing 2.5% or 2.8% dextran sulfate. Animals are weighed and observed for signs of intestinal disturbance daily. Signs include diarrhea or occult blood. Compound is formulated by mixing with a solution of 0.1 up to 1% citric acid depending on concentration. Compound is provided by oral gavage daily. Example data for the efficacy of compounds cited here is provided in
FIG. 3, 7, 8 or 10-19 . - The potential efficacy of a Compound for rheumatoid arthritis may be modeled as follows. DBA1 mice are induced by a subcutaneous injection of bovine collagen in 0.05M acetic acid, emulsified in Freund's adjuvant. 21 days later, a second injection of this material is made without inclusion of mycobacterial material in the adjuvant. Animals are weighed and observed for signs of inflammation daily. Signs include weight loss, swelling of paws, redness and reduced mobility. Compound is formulated by mixing with a solution of 1% citric acid. Compound is provided by oral gavage daily. Data for the efficacy of compounds cited here is provided in
FIG. 2 . - The potential efficacy of a Compound in modulating immune reactions may be determined as follows. Swiss or C57 Blk6 mice are induced to produce cytokines by a subcutaneous injection of lipopolysaccharide, Typically, compound is provided at
time 0. Compound is formulated by mixing with a solution of 1% citric acid for oral treatment or, dissolved inPEG 300 and diluted in water for intra-peritoneal treatment. Compound is provided by oral gavage. 30 minutes after providing compound, animals are treated with an intra-peritoneal injection of a solution of lipopolysaccharide in the concentration range that will provide 0.01 mg/kg lipopolysaccharide. Data for the efficacy of compounds cited here is provided inFIG. 1 . - The potential efficacy of a Compound in treating a malignant disease may be determined as follows. Tumours are known to be deficient in nitric oxide and this is considered to be a cause of local tolerance. Providing a nitric oxide donor that is accumulated in macrophages in the tumour environment provides a means to artificially modify the local NO status. C57 Blk6 mice are injected subcutaneously with an murine ovarian cancer cell line expressing ovalbumin. Mice bearing tumours are selected after 14 days. Typically, compound is provided at this time. Compound is formulated by mixing with a solution of 1% citric acid for oral treatment. Compound is provided by oral gavage. Animals are monitored daily for tumour size, body weight and activity score. The activity of the compound may be determined in combination with other therapies including anti-bodies or vaccines based on a tumour antigen. In this case ovalbumin, can serve as a model antigen.
- Synthesis of 2′-O-(2-Ferrocenyl) Acetyl-11-O-Nitro-Azithromycin
- 11-O-Nitro-azithromycin (0.25 mmol) was dissolved in dry dichloromethane (5 mL). To this was added EDCI (2 eq., 0.5 mmol) and 2-ferrocenyl acetic acid (1.1 eq., 0.28 mmol). The reaction was stirred overnight at room temperature. The solvent was removed in vacuo and the resulting white amorphous foam. The resulting crude product was purified by column chromatography with a gradient starting at 10% of acetone in cyclohexane (0.2% Et3N).
- Similarly, the following compound may be obtained using the procedure above starting from 2′-O-Nitro-azithromycin:
- 2′-O-Nitro-11-O-(2-Ferrocenyl) Acetyl-Azithromycin
- Rac. 2′-O-Propionyl Propranolol
- Diethyl azodicarboxylat (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (2.5 mL) at 0° C. and treatment is continued for 30 min. Propranolol (5 mmol) and propionic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 hours at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Rac. 2′-O-Acetoxypropionyl Propranolol
- Diethyl azodicarboxylate (DEAD, 10 mmol) is added to a stirred (magnetic stirrer, 300 rpm) solution of triphenylphosphin (10 mmol) in dry THF (25 mL) at 0° C. and treatment is continued for 30 min. Propranolol (5 mmol) and 2-acetoxypropionic acid (10 mmol) both dissolved in THF (10 mL) are added dropwise and stirring is continued for 1 h at 0° C. and further 2 hours at ambient temperature. Any precipitates are filtered off, the remaining solution is concentrated in vacuo and desired product is isolated by column chromatography (silica gel, cyclohexane-ethyl acetate).
- Synthesis of
Azithromycin - 380 mg of azithromycin-2′-lipoate (E-77) are dissolved in 25 ml of dichloromethane and cooled in an ice bath. 125 mg of lipoyl are adde, then 50 μl of pyridine. The mixture is allowed to reach room temperature and stirred for 16 h. The reaction mixture is extracted with
water 3 times, then once with 5% aqueous citric acid. The citric acid phase is extracted with dichloromethane, then combined with ethyl acetate and carefully made basic with sodium hydrogen carbonate and vigorous stirring. When gas evolution ceases, the organic phase is separated, washed with water and brine, and dried with sodium sulfate. After evaporation of all volatiles, the residue is chromatographed with a gradient starting at cyclohexane-acetone 5-1, containing 0.5% of triethylamine. Yield: 140 mg - Synthesis of Azithromycin 11-Lipoate
- 350 mg of
Azithromycin - Formation of Acetic Esters of ALCs
- Method 1: ALC (1.0 mmol) was taken up in 15 mL dichloromethane. Pyridine (1.2 eq.) was added and the resulting solution was cooled in an ice bath for approximately 10 minutes. At this point, a solution of acetic anhydride (1.2 eq) was added dropwise. The reaction was stirred continually at this temperature and then progressively warmed to room temperature where it was stirred overnight. Reaction progress was monitored either by TLC and/or MS. The reaction was washed with a saturated solution of ammonium chloride (3×), water (3×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. Co-evaporation with toluene is necessary to remove residual pyridine from the system. This was followed by re-dissolving the residue in DCM and solvent evaporation twice to produce a white foam, which was dried under high-vacuum to produce acetylated product.
- This acetylation conditions can be extended for other ALCs. In the case where the acetylation proceeds sluggish, alternative reaction conditions were undertaken as described below:
-
Method 2. Compound A-12 (0.85 mmol) was taken up in DCM (10 mL). To this was added triethylamine (3.5 eq) and acetyl chloride (3.5 eq). Reaction was monitored by TLC and MS until disappearance of starting ALC. Reaction was filtered. The filtrate was either evaporated in vacuo and directly purified by column chromatography or the filtrate was washed with 10% aq. Na2CO3 solution, brine, dried over Na2SO4 and evaporated in vacuo to get the crude product. -
Method 3. Acetic acid (4 eq) was taken up in 5 mL dichloromethane (DCM). Compound A-16 (0.5 mmol) and 4-dimethylaminopyridine (DMAP) (4.4 eq) were added and the resulting solution was cooled in an ice bath for approximately 10 minutes. At this point, dicyclohexylcarbodiimide (DCC) (4.4 eq) was added slowly. The reaction was stirred continually at this temperature for 5 minutes and then progressively warmed to room temperature where it was stirred overnight. Dicyclohexylurea (DCU) that was formed during the reaction is filtered off and discarded. The filtrate was collected and then washed with a saturated solution of sodium hydrogencarbonate (3×), water (1×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. This was followed by re-dissolving the residue in a small volume of methanol. The solution was transported dropwise into ice-cold water (2× volume of methanol) and stored in the freezer overnight. The precipitated product was filtered off and dried under high-vacuum to produce a product. -
TABLE 14 Acetylation Examples Reaction MS Compound Synthesis Substituent Condition Degree of m/z Entry Method ALC equivalent (i.e. Workup) Substitution Yield ([M + H]+) E-2 1 A-1 1.2 as described above 1 76% 837 E-4 1 A-1 1.5 as described above 1 41 % E-8 1 A-1 1.2 39 % E-23 1 A-1 2.0 as described above 2 54% E-25 1 A-1 1.1 as described above 1 67 % E-418 3 A-16 4 as described above 3 20% CHMA02063 E-228 1 A-10 4 as described above 2 56% 673 E-453 A-17 Overall 1 and 2 49% 819.7 A-17 12 equiv. (referring to 861.5 Ac2O the di-ester) E-266/ 2 A-12 3 as described above, 2 > 4 77% 675, 759 E-268 filtered through a silica gel plug using CHCl3:iPrOH:7M NH3 in MeOH (30:1:1) as mobile phase E-23/ E-50 A-1 2 and 3 16% 833, 875 E-564 1 A-2 (X = O) 1 89% 776 E-29 1 E-19 1.2 direct chromatography 1× 85% 861 for purification - Formation of Butyric and Isobutyric Esters of ALCs
- Method 1: Compound A-1 was taken up in dichloromethane and stirred for 10 min. At this point, a solution of carboxylic anhydride and triethylamine in dichloromethane was added dropwise. The reaction was stirred continually at room temperature. The reaction solution was washed with 5% citric acid three times to extract the product. Acidic solution was then washed with ethyl acetate (2×) and afterwards neutralized with Na2CO3. Product was extracted with ethyl acetate (3×). The solution was washed with a saturated solution of sodium chloride (2×), water (2×) and dried over anhydrous Na2SO4. The to solvent was evaporated in vacuo to produce a white foam containing product.
- Method 2: Compound A-1 was taken up in dichloromethane and was cooled in an ice bath for approximately 10 minutes. At this point, a solution of carboxylic chloride in dichloromethane was added dropwise. The reaction was stirred continually at this temperature for 15 min and then progressively warmed to room temperature where it was stirred for 2.5 h.
- The reaction was washed with a 10% solution of Na2CO3 (3×), water (3×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. Co-evaporation with toluene is necessary three times. This was followed by re-dissolving the residue in dichloromethane to produce a white foam, which was dried under high-vacuum to produce product.
- Method 3: Starting material was taken up in dichloromethane and stirred for 10 min. At this point, a solution of carboxylic chloride and triethylamine in dichloromethane was added dropwise. The reaction was stirred continually at room temperature for two days. The reaction solution was washed with 5% citric acid three times to extract the product. Acidic solution was then washed with ethyl acetate (2×) and afterwards neutralized with Na2CO3. Product was extracted with ethyl acetate (3×). The solution was washed with a saturated solution of sodium chloride (2×), water (2×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to produce a white foam containing product.
- Method 4: Compound E-48 or E-39 was solved in methanol to hydrolyze butyric esters. The reaction was stirred continually at room temperature for two days. The reaction solution was washed with ethyl acetate three times to extract the product. The ethyl acetate phase was washed with 5% citric acid (3×). Acidic solution was then washed with ethyl acetate (2×) and afterwards neutralized with Na2CO3. Product was extracted with ethyl acetate (3×). The solution was washed with a saturated solution of sodium chloride (2×), water (2×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to produce a white foam containing product.
- Method 5: Carboxylic acid (180 mg, 2.04 mmol) was solved in 3 mL dichloromethane. Under stirring conditions 4-Dimethylaminopyridine (274 mg, 2.24 mmol) and A-16 were added. The reaction solution was cooled to 0° C. and N,N′-Dicyclohexylcarbodiimide (463 mg, 2.24 mmol) was added. The reaction was stirred continually at this temperature for 5 min and then progressively warmed to room temperature where it was stirred for 12 h. Precipitation was removed via filtration. The reaction was washed with a saturated solution of NaHCO3 (3×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. Product was solved in methanol and water was added. Solution was cooled to −20° C., a precipitation occurred which was extracted and dried in vacuo.
- Workup 1: Column chromatography over silica gel was carried out to separate different products. As eluent a mixture of chloroform, 2-propanol and ammonia in methanol (60:1:1) was used. The solvent was evaporated in vacuo.
- Workup 2: Preparative chromatography over RP-C18-silica gel was carried out to separate different products. As eluent a mixture of water (with trifluoroacetic acid 0.05%) and methanol (with trifluoroacetic acid 0.05%) was used. The solvent was evaporated in vacuo.
- Workup 3: Column chromatography over silica gel was carried out to separate different products. As eluent a mixture of cyclohexane, acetone (7:1) with 0.5% triethylamine was used. The solvent was evaporated in vacuo.
-
TABLE 15 Butyrylation/Isobutyrylation Examples Compound Synthesis Reaction Condition Degree of Entry Method ALC Substituent (i.e. Workup) Substitution Yield MS E-35 1 A-1 Butyric Workup 1 1x 76% 819 E-39 3 A-1 Butyric Workup 2 2x 10% 889 E-48 3 A-1 Butyric Workup 2 3x 12% 959 E-47 3 A-1 Butyric Workup 2 4x 10% 1029 E-424 5 A-16 Butyric none 3x 97% 944 E-458 2 A-17 Butyric none 1x 89% 847 E-19 4 E-39 Butyric Workup 2 1x 85% 819 E-82 4 E-48 Butyric Workup 3 1x 35% 819 E-553 4 E-48 Butyric Workup 3 2x 30% 889 E-44 1 A-1 Isobutyric Workup 1 1x 67% 819 E-458, 3 A-17 Butyric Workup 1 1x, 2x, 3x 86% 847, E-459, 917, E-460 987 E-238 1 A-10 Butyric none 1x 96% 659 E-241, 3 A-10 Butyric Workup 1 2x, 3x, 4x 85% 730, E-249, 800, 870 E-250 E-111 3 E-1 Butyric Workup 2 1x 38% 864 E-255* 1 A-11 Butyric Workup 1 2x 3% 892 E-256* 1 A-11 Butyric Workup 1 3x 5.6% 964 E-85* 1 A-11 Butyric Workup 1 3x 964 E-257* 1 A-11 Butyric Workup 1 4x 3% 1036 E-24 3 E-1 Butyric Workup 1 1x 75 864 E-89 1 A-3 Butyric n/a 1x 9% 406 *isolated from one reaction - Formation of Valeric Esters of ALCs
-
Method 1. The ALC was taken up in DCM. To this were added pyridine and valeric acid anhydride (1 equiv. pyridine/1 equiv. valeric acid anhydride). The mixture was stirred at room overnight or over the weekend and was then poured on an aqueous citric acid solution (5% or 10%; at RT and was stirred for 15 min. The aqueous phase was extracted with EtOAc (2×) and was afterwards brought to pH=8 with solid Na2CO3. The alkaline aqueous layer was extracted with EtOAc (2×) and the combined organic phases were washed with water (1×) and saturated aqueous NaCl-solution (1×), dried (Na2SO4), concentrated to dryness and dried at the oil pump. Products were obtained as colorless solids or foams. -
Method 2. Analogue to 2A but after stirring at RT for 2 h additional pyridine (2 equiv.) and valeric acid anhydride (2 equiv.) were added and stirring was continued overnight. Products were obtained as colorless foams or solids. -
Method 3. The ALC was taken up in DCM. To this were added pyridine (4 equiv.) and valeric acid anhydride (4 equiv.). The mixture was stirred at room overnight or over the weekend. Additional pyridine (2 equiv.) and valeric acid anhydride (2 equiv.) were added and the mixture was stirred overnight. Reaction mixture was filled into a separation funnel and washed with saturated aqueous NH4Cl-solution (3×) and water (3×). The organic phase was dried (Na2SO4) and concentrated to dryness. The residue was co-evaporated with toluene (3×) and with DCM (3×). Afterwards the crude product was purified by column chromatography on silica gel. Eluent: Chloroform/Isopropanol/NH3 (7 M in Methanol) 30/1/1 - The product was dried at the oil pump. Products were obtained as colorless solids or foams.
-
TABLE 16 Valeric Ester Examples Overall MS Compound Synthesis equiv. of acid Degree of m/z Entry Method ALC or anhydride Re Substitution Yield ([M + H]+) E-72 3 A-1 6 Amount DCM: 5 mL 2 65% 917.5 E-558 1 A 25 Anhydro erythromycin 1 7% 800.5 (Anhydro) products are formed Amount DCM: 25 mL E-569 3 A-10 6 Amount DCM: 5 mL 2 45% 757.5 E-582 2 A-12 6 Amount DCM: 10 mL 1 89% 675.5 Citric acid: 10% E-411 1 A-15 4 Amount DCM; 25 mL 1 and 2 81% 878.3 E-412 Citric acid: 5% 962.3 E-428 1 A-16 3 Amount DCM: 25 mL 1 and 2 83% 819.0 E-429 Citric acid: 5% 902.8 E-464 1 A17 5 Amount DCM: 25 mL 1 94% 861.7 Citric acid: 5% - Formation of Isovaleric Esters of ALCs
- Method 1: Isovaleric acid (4.4 equiv./equiv. ALC) and
HOBt 85% (4.4 equiv./equiv. ALC) were dissolved in DMF (12.5 mml/mmol ALC). The solution Was cooled down to 0-5° C. in an ice-bath. At this temperature a solution of Dicyclohexylcarbodiimide (4.5 equiv./equiv. ALC) in DCM (5 ml/mmol ALC) was added dropwise within 30 min. the solution was kept at this temperature for another 10 min. Then Azithromycin (1 equiv.) was added in one portion. While stirring, the solution was allowed to come to room temperature within 2 h. Stirring was continued for another 2 h at 50° C. The reaction mixture was allowed to stand at RT for 12 h. A white precipitate was removed by suction. The solvent was evaporated completely at 12 mbar and 50° C. The residue was dissolved in DCM (12.5 mL/mmol ALC) and washed with water (7.5/mmol ALC). A small amount of a white precipitate was removed. Then the solution was treated with citric acid (25 mL/mmol ALC, 5%). The aqueous phase was washed with DCM (5 ml/mmol ALC).NaOH 10% was added until the aqueous phase was basic (pH 12) and was washed with DCM (2×10 ml/mmol ALC). After phase separation the organic phase was evaporated to dryness, products were obtained as white solids. - Method 2A. The ALC was taken up in DCM. To this were added pyridine and isovaleric acid anhydride (1 equiv. pyridine/1 equiv. isovaleric acid anhydride). The mixture was stirred at room overnight or over the weekend and was then poured on an aqueous citric acid solution (5% or 10%) at RT and was stirred for 15 min. The aqueous phase was extracted with EtOAc (2×) and was afterwards brought to pH=8 with solid Na2CO3. The alkaline aqueous layer was extracted with EtOAc (2×) and the combined organic phases were washed with water (1×) and saturated aqueous NaCl-solution (1×), dried (Na2SO4), concentrated to dryness and dried at the oil pump. Products were obtained as colorless solids or foams.
- Method 2B. Analogue to 2A but after stirring at room temperature for 2 h additional pyridine (2 equiv.) and isovaleric acid anhydride (2 equiv.) were added and stirring was continued overnight.
- Products were obtained as colorless foams or solids.
- Method 2C. The ALC was taken up in DCM. To this were added pyridine (4 equiv.) and isovaleric acid anhydride (4 equiv.). The mixture was stirred at room for approximately 2 h, then a catalytic amount of DMAP was added, followed by another catalytic amount approximately another 2 h later. The mixture was stirred at room temperature for approximately 2 h before additional pyridine (2 equiv.) and isovaleric acid anhydride (2 equiv.) were added. The mixture was stirred at room overnight and then poured on an aqueous citric acid solution (5%,) and stirred at room temperature for 30 min. The aqueous phase was extracted with EtOAc and afterwards brought to pH=8 with solid Na2CO3. The alkaline aqueous layer was extracted with EtOAc (2×) and the combined organic phases were washed with water (1×) and saturated aqueous NaCl-solution (1×), dried (Na2SO4), concentrated to dryness and dried at the oil pump. Products were obtained as colorless solids or foams.
-
TABLE 17 Isovaleric Ester Examples Overall MS Compound Synthesis equiv. of acid Degree of m/z Entry Method ALC or anhydride Annotations Substitution Yield ([M + H]+) E-45 1 A-1 1 91% 833.5 E-557 2A A 2 5 Anhydro erythromycin 1 17% 800.5 (Anhydro) products are formed Amount DCM: 25 mL Citric acid: 5% E-573 2C A-10 6 Amount DCM: 7.5 mL 2 19% 757.5 Citric acid: 5% E-583 28 A12 6 Amount DCM: 10 mL 1 83% 675.5 Citric acid: 10% E-413 2A A-15 4 Amount DCM: 25 mL 1 95% 878.3 Citric acid: 5% E-431 2A A-16 3 Amount DCM: 25 mL 2 87% 818.8 E-432 Citric acid: 5% 902.7 E-467 2A A-17 5 Amount DCM: 25 mL 1 90% 861.6 Citric acid: 5% - Long Chain (>C5) Fatty Acid Substation of Tildipirosin
- Hexanoic acid (290 mg, 2.5 mmol) was taken up in 5 mL dichloromethane (DCM). Compound A-16 (367 mg, 0.5 mmol) and 4-Dimethylaminopyridine (DMAP) (336 mg, 2.75 mmol) were added and the resulting solution was cooled in an ice bath for approximately 10 minutes. At this point, dicyclohexylcarbodiimide (DCC) (567 mg, 2.75 mmol) was added slowly. The reaction was stirred continually at this temperature for 5 minutes and then progressively warmed to room temperature where it was stirred overnight. Dicyclohexylurea (DCU) that was formed during the reaction is filtered off and discarded. The filtrate was collected and then washed with a saturated solution of ammonium chloride (3×), sodium hydrogencarbonate (3×), water (1×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo. This was followed by re-dissolving the residue in a small volume of methanol. The solution was transported dropwise into ice-cold water (2× volume of methanol) and stored in the freezer overnight. The precipitated product was filtered off and dried under high-vacuum to produce a mixture of E-437, E-438 and E-439 (56%).
- This esterification conditions can be extended for other acids.
-
TABLE 18 Long chain fatty acid substitution of ALC Degree of Compound Substituent Substitu- Entry Acid equivalent tion Yield MS E-437, Hexanoic acid 5 2 and 3 56% 931.7 E-438, 1028.8 E-439 E-440, Heptanoic acid 5 1, 2 and 3 46% 846.9 E-441, 959.3 E-442 1071.9 E-445 Octanoic acid 5 3 17% 1113.5 E-447, Decanoic acid 5 2 and 3 41% 1043.3 E-448 1197.5 E-450, Dodecanoic 5 2 and 3 60% 1099.5 E-451 acid 1281.4 - General Procedure for Preparing Cores A-13 and A-14
- Macrolide (1 mmol) is dissolved in DMF (500 μl). Epichlorohydrin (1 mL) is added and the mixture is heated to 80° C. for 12 h. When MS analysis indicates complete conversion, all volatiles are removed in vacuo and the residue is dissolved in ethanol (1 ml). The solution is poured into 25 ml of water. The precipitate is isolated and can be used directly for the next step or is chromatographed to obtain the pure epoxide.
- The following macrolides were used to form epoxides as precursor to the desired cores.
-
TABLE 19 Epoxide Formation MW Entry Macrolide epoxide Yield 1 Azithromycin 703 25% 2 Gamithromycin 731 12% 3 3-decladinosyl-3-oxoazithromycin 543 5% 4 Tildipirosin 689 5% - Epoxide (1 mmol) is dissolved in 2-propanol (500 μl), and an excess of 5 equivalent of an amine is added. The mixture is heated from 12 h to 100 h at 80° C. When MS indicates complete conversion, all volatiles are evaporated and the residue subjected to chromatography to separate the 2 regioisomeric amines.
-
TABLE 20 Epoxide opening by amines Epoxide Entry opening (Table 9) Amine position R1 R2 [M + H]+ Yield [%] Comment 1 dimethylamine 3′ Me Me 749 66 NMR identical to azithromycin 2′ 22 regioisomer of Azithromycin 1 morpholine 3′ R1 = R2 = morpholine ring 791 30 unpolar product (A-13.1) 2′ 61 polar product (A-13.2) 1 diethanolamine 3′ C2H4OH C2H4OH 809 22 unpolar product (A-14.1) 2′ 47 polar product (A-14.2) 1 ammonia H H 721 n.d.* 1 N-methyl Me OH 751 n.d.* hydroxylamine 1 Iminodiacetic —CH2C(O)OEt —CH2C(O)OEt 893 n.d.* some cyclized acid product with diethylester [M + H]+ = 865 is formed, too 2 morpholine R1 = R2 = morpholine ring n.d.* *n.d. not determined - Further Acylation Reactions of ALC
- Method 1: Compound A-1 (2000 mg, 2.67 mmol) was taken up in 10 mL dichloromethane and stirred. Separately 4.4 eq of a carboxylic acid and 4.4 eq of 1,1′-Carbonyldiimidazole were solved in dichloromethane (10 mL) and stirred over 20 min. Both solutions were unified and stirred continually at room temperature. The dichloromethane phase was washed with saturated NaHCO3 solution (2×) and dried with Na2SO4 (anhydrous). The solvent was evaporated in vacuo to produce a white foam containing products of reaction.
- Method 2: Compound E-1 (265 mg, 0.33 mmol) was taken up in 10 mL dichloromethane and stirred. Separately 1.6 eq of methoxyacetic acid and 1.6 eq of 1,1′-Carbonyldiimidazole were solved in dichloromethane (5 mL) and stirred over 20 min. Both solutions were unified and stirred continually at room temperature. The reaction solution was washed with 5% citric acid three times to extract the product. Acidic solution was then washed with ethyl acetate (2×) and afterwards neutralized with Na2CO3. Product was extracted with ethyl acetate (3×). The solution was washed with a saturated solution of sodium chloride (2×), water (2×) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to produce a white foam containing E12 (238 mg, 90%).
- Workup 1: Column chromatography over silica gel was carried out to separate different products. As eluent a mixture of chloroform, 2-propanol and ammonia in methanol (60:1:1) was used. The solvent was evaporated in vacuo.
- Workup 2: Column chromatography over silica gel was carried out to separate different products. As eluent a mixture of cyclohexane, acetone (3:1) with 0.5% triethylamine was used. The solvent was evaporated in vacuo.
-
TABLE 21 Typical Products from the Acylation Procedures (2) Reaction Cpd Synthesis Condition Degree of Entry Method Carboxylic acid ALC (i.e. Workup) Substitution Yield MS E-545 1 Cyclopropanecarboxylic acid A-1 Workup 1 1× 30% 817 E-546 1 Cyclobutanecarboxylic acid A-1 Workup 1 1× 10% 830 E-546, 1 Cyclobutanecarboxylic acid A-1 Workup 1 1×, 2×, 3× 22.5% 830, E-560, 913, E-561 995 E-547 1 Nicotinic acid A-1 Workup 2 1× 10.3% 854 E-547, 1 Nicotinic acid A-1 Workup 2 1×, 2× 11.8% 854, E-562 959 E-551 1 Methoxyacetic acid A-1 Workup 1 1× 4.4 820 E-14, 1 Methoxyacetic acid A-1 2×, 3×, 4× Reaction 893, E-22, solution 965, E-559 1037 E-12 2 Methoxyacetic acid E-1 none 1× 90% 866 E-81 1 3-Phenylpropionic acid A-1 Workup 1 1× 30% 881 E-544 1* Indole-3-propionic acid A-1 Workup 1 1× 45% 920 *instead of 1,1′-carbonyl diimidazole, HATU was used as coupling agent. - Synthesis of E-541 and E-542
- E-27 (1.2 mmol) and Quinoline-amine (1 eq) was taken up in DCM (5 mL). To this was added HATU (1.2 eq) neat. The reaction was stirred overnight at room temperature. Reaction was very sluggish an additional 0.5 eq of HATU was added. Reaction was stirred for 2 days or disappearance of starting material was observed (TLC or MS). Reaction solution was removed in vacuo and the crude material directly purified by chromatography to get the desired product.
-
TABLE 22 Decoration of ALC (E-27) with potential TLR-agents Cpd Degree of Entry Quinoline Substitution Yield MS E-541 Imiquimod 1 35% 1071 E-542 Resiquimod 1 25% 1145 - Examples of Polyamines as ALC
- These ALCs can be prepared by reacting symmetrical or unsymmetrical di- or poly-epoxides with secondary amines. This will provide ALCs that contains common structural element of 2 or more alcohols, vicinally neighbored by a tertiary amine. Some polyamines are also commercially available.
- Alternatively, ALCs can be prepared by reacting epoxides with diethanolamine. The reaction products are containing 2-hydroxy tertiary amines.
- General Procedure for Preparation of some polyamine ALC Bearing hydroxy Functionalities:
- Polyamine (1 mmol) containing at least 2 NH-functions and the epoxide are mixed and heated without solvent to 80° C. Excess epoxide can be removed by column chromatography selectively. Products are sufficient, when at least 2 tertiary ß-hydroxyamines are present.
-
TABLE 23 Examples of Polyamine ALCs Eq. of Reaction [M + H]+ Entry Amine Epoxide Epoxide time Product Yield Remark 1 hexamethylene diamine 1,2- 4.2 40 h 966 n.d. product contains epoxytetradecane a small amount of triple alkylation 2 bis- cyclohexene 12 240 h 608 n.d. main product is (hexamethylene)triamine oxide tetraalkylated - Reactions of Polyepoxides with Amines:
- Corresponding polyepoxide (1 mmol) is mixed with 1.05 mmol secondary amine per epoxide function and heated to 80° C. without solvent for 12 h.
-
TABLE 24 Further Examples Polyamine ALCs [M + H]+ Entry Epoxide Amine Product Yield 1 1,2,7,8-diepoxyoctane morpholine 317 100% 2 Diglycidyl ethylenglycol morpholine 377 90% - Synthesis of E-552
- 1.45 g of 1,10-dimorpholino-2,9-dihydoxy-4,7-dioxadecane are combined with 1.5 ml of butyric anhydride in 5 ml of chloroform. After stirring for 1 h, MS indicates complete conversion ([M+H]+=517). The mixture is extracted with 2 N KOH, saturated aqueous sodium bicarbonate solution and brine, dried and chromatographed over silica gel to obtain 1.57 g of the target compound (72%).
- Substitution of Polyamine ALC (see Table 1, Entry A-19)
- Substitution ALC A-19.1/A-20.1/A-20.2
- Method 1: N-Hydroxyalkyl compound (5 mmol) was suspended in excess carboxyl acid anhydride (>100 mmol, >20 eq.) in a round bottom flask while stirring (magnetic stir bar, 500 rpm). The mixture was cooled in an ice bath and sulfuric acid (>96%, 3 drops) was carefully added as catalyst. Stirring was continued until a clear solution was obtained. When ESI-MS indicated full conversion of starting materials the reaction mixture was poured on ice. The system was stirred for 2 or more hours in order to hydrolyze any anhydride. The mixture was neutralized by addition of sodium bicarbonate and extracted with dichloromethane (3×). Separation of organic phase, drying over sodium sulfate and evaporation of any volatiles in vacuo yielded the product as colorless oil.
-
Method 2. Carboxylic acid (1.5 eq per hydroxyl group) was placed into a round bottom flask along with a stir bar and carbonyl diimidazole (CDI, 1.6 eq per hydroxyl group). Dichloromethane (DCM, 10 mL per gram carboxylic acid) was added carefully while stirring (500 rpm) at ambient temperature. Immediate formation of carbon dioxide indicated conversion of corresponding acid to the acyl donor (caution: too quick CO2 formation may result in strong foaming. Do not seal the flask!). After a couple of minutes, a clear solution was obtained and stirring was continued for 15 minutes. N-Hydroxyalkyl compound (5 mmol) was added at ambient temperature and the reaction mixture was stirred overnight. When ESI-MS indicated full conversion of starting materials the reaction was quenched by addition of methanol, converting excess acyl donor to methyl ester. The system was diluted by addition of further DCM and was subject to extraction with saturated sodium bicarbonate solution (3×). Separation of organic phase, drying over sodium sulfate and evaporation of any volatiles in vacuo yielded the product as colorless oil. -
TABLE 25 Substitution of ALC A-19.1/A-20.1/A-20.2 Compound Synthesis Degree of MS Entry Method ALC Substitution Yield [M + H+ E-524 1 A-19.1 Di acyl 85% 259, M + H+ E-576 1 A-19.1 Mono acyl 23% 217, M + H+ E-525 1 A-19.1 Di acyl 94% 287, M + H+ E-577 1 A-19.1 Mono acyl 12% 231, M + H+ E-526 2 A-19.1 Di acyl 87% 315, M + H+ E-578 2 A-19.1 Mono acyl 45% 245, M + H+ E-527 1 A-19.1 Di acyl 56% 315, M + H+ E-529 1 A-19.1 Di acyl 8% 343, M + H+ E-530 2 A-19.1 Di acyl 76% 499, M + H+ E-538 1 A-20.1 Tri acyl 85% 299, M + Na+ E-537 1 A-20.1 Tri acyl 76% 383, M + Na+ E-580 1 A-20.2 Tri acyl 61% 391, M + Na+; 368, M− - Substitution ALC A-19.2
- 1,1′-Carbonyldiimidazole was dissolved in dichloromethane (dry, 25 mL) and to this was added the carboxylic acid slowly at room temperature. The solution was stirred at room temperature before a suspension of N;N,N′,N′-tetrakis (2-hydroxyethyl)-ethylendiamine (A-19.2) in dichloromethane (dry, 5 mL) was added in one portion at room temperature and the mixture was stirred at RT. The reaction mixture was filled into a separation funnel and washed. The organic phase was dried (Na2SO4) and concentrated to dryness in vacuo. The crude product was purified by column chromatography.
- Eluent: CHCl3: Isopropanol: NH3 (7 M in MeOH)=60:1:1.
-
TABLE 26 Substitution of ALC A-19.12 Amount Time for Carboxylic stirring Cpd Amount acid Amount carboxylic Reaction Washing Entry ALC (A-19.2) (mg) CDI acid and CDI Time steps Yield E-531 A-19.2 521 mg Glacial acetic 2.49 g 35 min 22h 30 min NaHCO3 297 mg (73.4%) acid 15.35 (2 × 20 (45%) 1.64 800 μL mmol mL) mmol 13.99 mmol E-532 A-19.2 498 mg Propionic acid 2.46 g 20 min 1.5 h with Water 144 mg (73.4%) 943 μL 15.17 with argon argon stream (1 × 20 (20%) 1.55 12.6 mmol mmol stream 69 h 45 minmL) mmol under argon sat. atmosphere NaHCO3 (2 × 20 mL) E-533 A-19.2 495 mg Butyric acid 2.51 g 35 min 46 h 45min NaHCO 3 20 mg (73.4%) 1.2 mL 15.45 (2 × 20 (pure) 1.54 13.55 mmol mmol mL) 224 mg mmol (with impuri- Ties Overall yield: (19%) - Analytical Data:
- E-531:
- ESI-MS (positive): m/z=405.2 [M+H]+, 427.1 [M+Na]+
- Purity according to HPLC (ELSD): >99.9%
- 1H-NMR (300 MHz, CDCl3): 1.98 (s, 12 H, 4-H, 4′-H, 4″-H, 4″′-H), 2.57 (s, 4 H, 1-H, 1′H), 2.72 (t, J2,3 and J2′,3′, J2″,3″, J2″′,3″′=6.04, 8 H, 2-H, 2′-H, 2″-H, 2″′-H), 2.72 (t, J3,2 and J3′,2′, J3″,2″, J3″′,2″′=4.04, 8 H, 2-H, 2′-H, 2″-H, 2″′-H).
- 13C-NMR (75 MHz, CDCl3): 20.77 (q, C-4, C-4′, C-4″, C-4″′), 53.15 (t, C-2, C-2′, C-2″, C-2″′), 53.44 (t, C-1, C-1′), 62.43 (t, C-3, C-3′, C-3″, C-3″′), 170.74 (s, 4×C=O).
- E-532:
- ESI-MS (positive): m/z=461.2 [M+H]+, 483.3 [M+Na]+
- Purity according to HPLC (ELSD): >99.9%
- 1H-NMR (300 MHz, CDCl3): 1.08 (t, J5,4, J5′,4′, J5″,4″, J5″′,4″′=7.6 Hz, 12 H, 5-H, 5′-H, 5″-H, 5″40 -H), 2.27 (q, J4,5, J4′,5′, J4″,5″, J4″′,5″′=7.6 Hz), 2.57, 4-H, 4′-H, 4″-H, 4 ″′ 2.60 (s, 4 H, 1-H, 1′H), 2.74 (t, J2,3 and J2′,3′, J2″,3″, J2″′,3″′=6.04, 8 H, 2-H, 2′-H, 241 -H, 2″′-H), 4.07 (t, J3,2 and J3′,2′, J3″,2″, J3″′=6.04, 8 H, 2-H, 2′-H, 2″-H, 2″′-H).
- 13C-NMR (75 MHz, CDCl3): 8.96 (q, C-5, C-5′, C-5″, C-5″′), 27.44 (t, C-4, C-4′, C-4″, C-4″′), 53.22 (t, C-2, C-2′, C-2″, C-2″′), 53.54 (t, C-1, C-1′), 62.36 (t, C-3, C-3′, C-3″, C-3″′), 172.20 (s, 4×C=O).
- E-533:
- ESI-MS (positive): m/z=617.3 [M+H]+, 539.3 [M+Na]+
- Purity according to HPLC (ELSD): >99.9%
- 13C-NMR (75 MHz, CDCl3): 13.53 (q, C-6, C-6′, C-6″, C-6″′) 18.26 (t, C-5, C-5′, C-5″, C-5″′), 36.00 (t, C-4, C-4′, C-4″, C-4″′), 53.21 (t, C-2, C-2′, C-2″, C-2″′), 53.45 (t, C-1, C-1′), 62.24 (t, C-3, C-3′, C-3″, C-3″′), 173.36 (s, 4×C=O):
- Substitution ALC A-19.3
- H-L-orn(Boc)2CT Resin (0.68 mmol/g, 100-200 mesh, 2.99 g, 2.07 mmol) was filled into a 20 mL syringe with frit. Dichloromethane (dry, 10 mL), MeOH (2 mL) and diisopropylethylamine (2 mL) are added to the resin for endcapping. The mixture was shaken at room temperature for 30 min, then the liquid was sucked off and the resin was washed (3×
dimethylformamide 15 mL, 1×diethylether 15 mL). - The resin was filled into a 100 mL round bottom flask. DMF (25 mL) was added and the resin was swollen for 5 min. Then diisopropylethylamine (3.8 mL, 22.3 mmol) and 2-bromoethanol (1.434 mL, 20.3 mmol) were added subsequently at room temperature. The reaction mixture was stirred at 60° C. (bath temperature) for 24 h.
- The resin was filled into a 20 mL syringe with frit and was washed:
- 4× dimethylformamide (20 mL), 3× methanol (20 mL), 3× dichloromethane (20 mL), 3× diethyl ether (20 mL).
- Half of the resin (1.035 mmol) was filled into a 20 mL syringe with frit.
- Valeric acid (568 μL, 5.69 mmol) was added to a mixture of dimethylformamide/dichloro-methane 1:1 (10 mL). HOBt*H2O (870 mg, 5.69 mmol) was added and mixture was stirred at room temperature for 5 min before diisipropylcarbodiimide (881 μL, 5.69 mmol) was added. Stirring at room temperature was continued for 10 min, then the whole mixture was added to the resin and the resin was shaken at room temperature for 5 h.
- The liquid was sucked off and the resin was washed:
- 4× dimethylformamide (10 mL), 3× methanol (10 mL), 3× dichloromethane (10 mL), 3× diethyl ether (10 mL).
- A test cleavage showed the product by mass spectrometry
- ESI-MS (positive): m/z=261.1 [M+H]+
- Synthesis of 2′-O-(2-Ferrocenyl) Acetyl-Azithromycin E-549
- ALC A-1 (0.25 mmol) was dissolved in dry dichloromethane (5 mL). To this was added EDCI (2 eq., 0.5 mmol) and 2-ferrocenyl acetic acid (1.1 eq., 0.28 mmol). The reaction was stirred overnight at room temperature. The solvent was removed in vacuo and the resulting white amorphous foam. The resulting crude product was purified by column chromatography with a gradient starting at 10% of acetone in cyclohexane (0.2% Et3N).
- Synthesis of E-258
- Compound A-11/E-16 was dissolved in dry dichloromethane (DCM) in a round bottom flask equipped with magnetic stir bar. Penta-O-acetyl-α-D-mannopyranoside (1.2 eq) was added and the system was cooled in an ice bath while stirring (300 rpm). Catalytic amount of boron trifluoride diethyl ether complex was carefully added dropwise and the system was allowed to warm up while stirring overnight. Upon dilution with further DCM the mixture was subject to extraction with saturated sodium bicarbonate solution (3×). Separation of organic phase, drying over sodium sulfate and evaporation of any volatiles in vacuo yielded the product as colorless oil or beige to off-white foam. [M+H]+ m/z 907
- The reaction conditions also produced the des-cladinosyl product E-600.
- Synthesis of E-550
- 350 mg of
compound E 77 are dissolved with 15 ml of carbon disulfide. 250 mg of sulfur are added and the mixture is stirred for 7 days. The mixture is extracted with 5% aqueous citric acid solution. The aqueous extract is combined with 10 ml of ethyl acetate and made alkaline by addition of sodium carbonate with intense stirring. The organic phase is separated, washed with brine, dried over sodium sulfate and concentrated in vacuo to yield 280 mg of a product, that contains various higher sulfides along with some starting material, as indicated by mass spectrometry ([M+H]+=969, 1001, 1033, 1065). - Pharmacokinetics
- The distribution of compounds to target organs is of specific importance to the efficacy of anti-infective compounds. To determine distribution the compounds are formulated and administered to a suitable animal model. Compounds were administered p.o. 10 mg/kg in 2% citric acid in BALBc and organs were recovered at 6 h. Organs were extracted in Acetonitrile (6× volume of the sample), centrifuged at 14000 g for 5 minutes. Samples were analysed by LCMSMS (SCIEX 4500). Data are the mean of 3 animals.
- Selection of ALC via Concentration into Immune Cells
- The distribution of compounds to target cells is of specific importance to the efficacy of anti-infective compounds. To determine uptake the compounds are dissolved in DMSO or citric acid and mixed with whole blood, plasma or cell medium. To these solutions are added cultured macrophages, cultured immune cells, bone marrow derived macrophages, peritoneal macrophages or buffy coat cells. The mixture is incubated at 37° C. for 1, 2, or 3 hours. After incubation, the immune cells are separated from the medium and the concentration of the compounds is determined by extraction in Acetonitrile (6× volume of the sample), followed by centrifugation at 14000 g for 5 minutes. The resulting extracts are analyzed by LCMSMS (SCIEX 4500 in positive mode). Data are the mean of 3 animals.
- Other Embodiments
- All of the features disclosed in this specification may be combined in any combination. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
- It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
- Abbreviations
- The following abbreviations were used as noted:
-
- MeOH: methanol
- NaHCO3: sodium bicarbonate
- K2CO3: potassium carbonate
- MS: mass spectrometry
- DMSO: dimethyl sulfoxide
- TLC: thinlayer chromatography
- Et3N: triethylamine
- EtOAc: ethyl acetate
- DCM: dichloromethane
- NH4Cl: ammonium chloride
- THF: tetrahydrofuran
- Na2CO3: sodium carbonate
- EDCI: N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride
- DMAP: 4-dimethylamino pyridine
- HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-hexafluorphosphat
- DIPEA N,N-Diisopropylethylamine
- US2007238882A1
- US2003105066A1
- US2008221158A1
- US2008027012A1
- US6455576B1
- US5677287A
- EP1748994B1
- WO2007025632A2
- WO9530641A1
- WO0002567A1
- [1] L. J. Ignarro, Nitric Oxide Biology and Pathobiology, Academic Press, 2000, p. xvii.
- [2] H. Al-Sa'doni, A. Ferro, 2000, Clinical Science, 98, pp 507-520.
- [3] P. G. Wang et. al., Chem. Rev., 2002, 102 (4), pp 1091-1134.
- [4] E. Oberdisse, E. Hackenthal, K. Kuschinsky, Pharmakologie und Toxikologie, Kapitel 16.2.6, Springer-Verlag, Berlin Heidelberg New York, 2001, pp 292-293.
- [5] G. H. Hakimelahi, H. Sharghi, H. Zarrinmayeh, A. Khalafi-Nezhad, Helv. Chim. Acta.
- 1984, 67, 906-915, and literature cited therein.
- [6] G. A. Olah et al., J. Org. Chem. 1990, 55 (17), 5179-5180.
- [7] H. Burton, P. F. G. Praill, J. Chem. Soc. 1955, 729-731.
- [8] E. Santaniello, M. Ravasi, P. Ferraboschi, J. Org. Chem. 1983, 48, 739-740.
- [9] J. A. R. Rodrigues, A. P. O. Filho, P. J. S. Moran, Synth. Comm. 1999, 29 (12), 2169-2174.
- [10] F. Francis et al.,
Berichte 1906, 39, 3798-3804. - [11] M. E. Kurz, E. P. Zahora, D. Layman, J. Org. Chem. 1973, 38 (13), 2277-2281.
- [12] M. E. Kurz, E. Woodby, J. Org. Chem. 1976, 41 (14).
- [13] Ronchetti D, Borghi V, Gaitan G, Herrero J F, Impagnatiello F. Br J. Pharmacol. 2009 September; 158(2):569-79
- [14] Lemaire S, Van Barnbeke F, Tulkens P M. Antimicrob Agents Chemother. 2009 September; 53(9):3734-43
- [15] Martinez L R, Han G, Chacko M, Mihu M R, Jacobson M, Gialanella P, Friedman A J, Nosanchuk J D, Friedman J M. J Invest Dermatol. 2009 October; 129(10):2463-9
- [16] N. Pietrzik, C. Schips, T. Ziegler, Synthesis 2008, 519-526, and literature cited therein.
- [17] R. Shan, C. Velaquez, E. E. Knaus, J. Med Chem. 2004, 47, 244-261.
- [18] Volante, R. P., Tethed. Lett. 1981, 22, 3119-3122
- [19] Silveira et al., Tethed. Lett. 2007, 48, 7469-7471
Claims (21)
1. A compound, or salt thereof, comprising an amphiphilic lysosomally trapped compound (alc) conjugated via an ester, thioester, amide, or nitroester to one or more products of anaerobic metabolism (pams) of the same or different types.
2. The compound as in claim 1 in which the PAM is selected from one or more of Short Chain Fatty Acid (SCFA), NO, H2S, mercaptans, polyamines, decarboxylated amino acids, TLR ligands, or polyphenol metabolites like phenylpropionic acid.
3. The compound as in claim 1 in which the ALC is selected from a macrolide, polyamine, propranolol analog, chloroquine analog, amodiaquine, dextromethorphan, dextrorphan, paroxetine, fluoxetine, astemizole or imipramine analog.
4. A method of stimulating immune or epithelial cells to form an anti-infective barrier or anti-infective response comprising contacting the cells with a compound of Formula 1, or salt thereof, wherein the contacting results in the intracellular release of a PAM comprising one or more of a molecule type selected from TLR ligands, SCFA, NO, H2S, sulfides, polyamines, decarboxylated amino acids or polyphenol metabolites like phenylpropionic acid from the compound of Formula 1, or salt thereof.
5. The method as in claim 4 comprising the intracellular release of one or more types of a short chain fatty acid moiety from the compound of Formula 1.
6. The method as in claim 5 comprising the intracellular release of a short chain fatty acid moiety containing 2 or more carbons from an appropriate carrier molecule.
7. (canceled)
8. The compound of claim 1 , wherein the compound is one of the following:
(Formula 2)
Wherein,
X=—N(CH3)—CH2—;
—CH2—N[(CH2)n—CH3]— wherein n is 0-4;
—C(═O)—;
—C(═NOR8)—;
—C(═NR12)—;
R1 is:
-(C1-C10)alkyl;
-(C1-C10)alkyliden-OH;
-(C1-C10)alkyliden-ONO2;
R2 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
R3 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
If Z=O, R4 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
R5 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
or Z=O or NR9 and the R4 and R5 bearing atoms are connected via —C(═O)— (If Z=O: carbonate linkage, if Z=NR9: carbamate linkage);
or the R4 and R5 bearing atoms are connected via W;
W is:
—(—)CH-(C1-C12)alkyl;
—(—)CH-(C3-C12)alkenyl;
—(—)CH-(C3-C12)alkynyl;
—(—)CH-(C1-C8)[(C1-C4)alkoxy]alkyl;
—(—)CH-(C1-C8)[(C1-C4)alkoxy]alkenyl;
wherein alkyl, alkenyl, alkynyl are optionally substituted by one to five substituents selected independently from halogen, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxy, nitro, cyano, azido, mercapto, —NR14R15, R14C(═O)—, R14C(═O)O—R14OC(═O)O—, R14NHC(═O)—, R14C(═O)NH—, R14R15NC(═O)—, R14OC(═O)—, and —xNO2 with x=O;S;N;
R6 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)OR7, —C(═S)OR7, —C(═O)R7, —C(═S)R7, —C(═O)(NH)R7, —C(═S)(NH)R7;
each R7 is independently:
—H;
-ferrocene;
-C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from:
ferrocene, halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), —NR14R15, R14C(═O)—, R14C(═O)O—, R14OC(═O)O—, R14NHC(═O)—, R14C(═O)NH—, R14R15NC(═O)—, R14OC(═O)—, and —XNO(y) with X=O; S; N and y=1 or 2;
R8 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)—R7;
-(C1-C12)alkyl;
-(C1-C12)alkenyl;
-(C1-C12)alkynyl;
-(C1-C8)[(C1-C4)alkoxy]alkyl;
-(C1-C8)[(C1-C4)alkoxy]alkenyl;
-(C6-C10)aryl-(C1-C5)alkyl;
-(C2-C9)heteroaryl-(C1-C5)alkyl;
R9 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)—R7;
-(C1-C12)alkyl;
-(C1-C12)alkenyl;
-(C1-C12)alkynyl;
-(C1-C8)[(C1-C4)alkoxy]alkyl;
-(C1-C8)[(C1-C4)alkoxy]alkenyl;
-(C6-C10)aryl-(C1-C5)alkyl;
-(C2-C9)heteroaryl-(C1-C5)alkyl;
R12 is:
—H;
—NO(y) with y=1 or 2;
—C(═O)—R7;
-(C1-C12)alkyl;
-(C1-C12)alkenyl;
-(C1-C12)alkynyl;
-(C1-C8)[(C1-C4)alkoxy]alkyl;
-(C1-C8)[(C1-C4)alkoxy]alkenyl;
-(C6-C10)aryl-(C1-C5)alkyl;
-(C2-C9)heteroaryl-(C1-C5)alkyl;
R14, R15 are each independently:
—H;
-(C1-C12)alkyl;
-(C1-C12)alkenyl;
-(C1-C12)alkynyl;
-(C1-C8)[(C1-C4)alkoxy]alkyl;
-(C1-C8)[(C1-C4)alkoxy]alkenyl;
-(C6-C10)aryl-(C1-C5)alkyl;
-(C2-C9)heteroaryl-(C1-C5)alkyl;
wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are optionally substituted by one to five substituents selected independently from halogen (as can be F, Cl, Br, I), (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C6)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), and —XNOy with X=O; S; N and y=1 or 2;
or N(R14R15) is an aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane, 1-substituted piperazine, or morpholine moiety.
9. The compound of claim 1 , wherein the compound is one of the following:
1. Formula 3:
Wherein R1,R2,R4,R5,R6, X and Z are defined as in formula 2;
R3a, R3b=both —H;
or if R3a is —H, then R3b is:
—OH;
—OR14;
NR14R15;
—C(═O)—R7;
or R3a=R3b=(═O);
=a cyclic or non-cyclic acetal;
(=NR12);
=a cyclic or non-cyclic aminal;
—OC(═O)R7;
OR14;
and R7, R14, and R15 are defined as in formula 2 in claim 8 ;
or salt thereof.
10. A compound as in:
Where X is O or S;
When X=O, R1 is —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
R2=R3=H;
Y=a 5-membered saturated ring containing a disulfide bond; or
When X=O, R1 is —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
R2=CH3; R3=H; or
When X=O, R1=NO2; R2 consists of linker —CH2CH2OR4, where R4 is —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, or —(C═O)CH2CH2CH2CH2Y; R3=H;
Y =a 5-membered saturated ring containing a disulfide bond; or
When X=O, R1 is —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
Y=a 5-membered saturated ring containing a disulfide bond;
R2 consists of linker —CH2CH2OR4, where R4=NO2; R3=H; or
When X=O, R1 is NO2, R2=H or CH3, R3=OR5, where R5 is —(C═O)CH3, —(C═O)CH2CH3, —(C═O)CH2CH2CH3, —(C═O)CH2CH2COOH, —(C═O)(C═O)CH3, —(C═O)CHCHCOOH, —(C═O)CH(OH)CH3, —(C═O)C(CH3)2, —(C═O)CH2CH2CH2CH3, —(C═O)CH2C(CH3)2, —(C═O)CH2CH2CH2CH2Y, or —(C═O)CH(ONO2)CH3;
Y=a 5-membered saturated ring containing a disulfide bond; or
When X=S, R1 is —(C═O)CH3, a metal salt, or forms a disulfide bridge with itself, R2=R3=H.
12. The compound of claim 3 , wherein the ALC is selected from a compound of Formula 6:
Wherein
Mac=a macrolide ring or macrolide ring system, for example, but not limited to azithromycin or gamithromycin, each without the desosamin residue
R′=independently of each other
—H;
—NO(y) with y=1 or 2;
—C(═O)OR3, —C(═S)OR3, —C(═O)R3, —C(═S)R3, —C(═O)(NH)R3, —C(═S)(NH)R3;
R1, R2=independently of each other H, OH, OR4, -C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl;
wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: fluorine, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C9)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), (C1-C4)alkthio, —NR4R5, R4C(═O)—, R4C(═O)O—, R4OC(═O)O—, R4NHC(═O)—, R4C(═O)NH—, R4R5NC(═O)—, R4OC(═O)—, and —XNO(y) with X=O; S; N and y=1 or 2;
or N(R1R2) is an aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane, 1-substituted piperazine, or morpholine moiety;
R3=-C1-C10 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl groups are optionally substituted by one to five substituents selected independently from: halogen, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C9)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), (C1-C4)alkthio, —NR6R7, R6C(═O)—, R6C(═O)O—, R6OC(═O)O—, R6NHC(═O)—, R6C(═O)NH—, R6R7NC(═O)—, R6OC(═O)—, and —XNO(y) with X=O; S; N and y=1 or 2;
R4, R5, R6 and R7 are each independently:
—H;
-(C1-C12)alkyl;
-(C1-C12)alkenyl;
-(C1-C12)akynyl;
-(C1-C8)[(C1-C4)alkoxy]alkyl;
-(C1-C8)[(C1-C4)alkoxy]alkenyl;
-(C6-C10)aryl-(C1-C5)alkyl;
-(C2-C9)heteroaryl-(C1-C5)alkyl;
wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are optionally substituted by one to five substituents selected independently from ferrocene, halogen, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, (C3-C7)cycloalkyl, (C1-C9)heterocycloalkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C4)alkoxy, hydroxyl (—OH), (C1-C6)acyloxy, nitro (—NO2), cyano (—CN), azido (—N3), mercapto (—SH), and —XNOy with X=O; S; N and y=1 or 2.
13. The compound of claim 8 , wherein the number of PAMs is 0.
14. The compound of claim 9 , wherein the number of PAMs is 0.
15. A non-nitrate salt of a compound as in claim 1 .
16. A pharmaceutical composition comprising a compound of claim 1 , or salt, solvate, or hydrate thereof, and a pharmaceutically acceptable carrier.
17. The composition of claim 16 , further comprising an additional therapeutic agent.
18. A method of treating a disease, disorder, or symptom thereof in a subject comprising administering to the subject a compound of claim 1 , or salt, solvate, or hydrate thereof.
19. The method of claim 18 , wherein the disease or disorder is an infectious disease, an inflammatory disease, or a malignant disease.
20. The method of claim 18 , further comprising administering an antibacterial compound.
21. The method of claim 18 , further comprising administering a macrolide compound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/873,451 US20230159581A1 (en) | 2017-03-03 | 2022-07-26 | Novel anti-infective and anti-inflammatory compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762466827P | 2017-03-03 | 2017-03-03 | |
PCT/US2018/020769 WO2018161039A1 (en) | 2017-03-03 | 2018-03-02 | Novel anti-infective and anti-inflammatory compounds |
US201916490459A | 2019-08-30 | 2019-08-30 | |
US17/873,451 US20230159581A1 (en) | 2017-03-03 | 2022-07-26 | Novel anti-infective and anti-inflammatory compounds |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/020769 Division WO2018161039A1 (en) | 2017-03-03 | 2018-03-02 | Novel anti-infective and anti-inflammatory compounds |
US16/490,459 Division US11420995B2 (en) | 2017-03-03 | 2018-03-02 | Anti-infective and anti-inflammatory compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230159581A1 true US20230159581A1 (en) | 2023-05-25 |
Family
ID=63371127
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,459 Active US11420995B2 (en) | 2017-03-03 | 2018-03-02 | Anti-infective and anti-inflammatory compounds |
US17/873,451 Pending US20230159581A1 (en) | 2017-03-03 | 2022-07-26 | Novel anti-infective and anti-inflammatory compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,459 Active US11420995B2 (en) | 2017-03-03 | 2018-03-02 | Anti-infective and anti-inflammatory compounds |
Country Status (3)
Country | Link |
---|---|
US (2) | US11420995B2 (en) |
EP (1) | EP3589327A4 (en) |
WO (1) | WO2018161039A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020259997A1 (en) * | 2019-04-18 | 2021-11-25 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
CN114025759A (en) | 2019-04-18 | 2022-02-08 | 阿祖拉眼科有限公司 | Compounds and methods for treating ocular diseases |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
US20230131943A1 (en) * | 2020-03-24 | 2023-04-27 | Burnet Micheal W | Anti-infective and anti-viral compounds and compositions |
CN113801143A (en) * | 2020-06-16 | 2021-12-17 | 中国石油大学(华东) | Long-chain zinc tetraphenylporphyrin (II) dimer and preparation method thereof |
US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
WO2023028364A1 (en) | 2021-08-27 | 2023-03-02 | Sepelo Therapeutics, Llc | Targeted compositions and uses therof |
CN115010681A (en) * | 2021-09-07 | 2022-09-06 | 安徽荣灿生物科技有限公司 | Cationic liposome molecule and preparation and application thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL300886A (en) * | 1962-11-23 | |||
US4201866A (en) * | 1977-01-17 | 1980-05-06 | American Home Products Corporation | O-Hemi-succinate of propranolol |
JPS55151598A (en) * | 1979-05-11 | 1980-11-26 | Taisho Pharmaceut Co Ltd | Erythromycin a derivative and its preparation |
JP2678652B2 (en) * | 1989-02-28 | 1997-11-17 | 雪印乳業株式会社 | Novel propranolol derivative and its hydrochloride |
US5393743A (en) * | 1993-07-06 | 1995-02-28 | Abbott Laboratories | Erythromycin derivatives |
BR9708929A (en) * | 1996-05-07 | 1999-08-03 | Abbott Lab | Compound pharmaceutical composition and processes for controlling bacterial infection in a mammal and for preparing macrolide compounds |
KR100576988B1 (en) * | 1996-09-04 | 2006-05-10 | 아보트 러보러터리즈 | 6-0-substituted ketolides having antibacterial activity |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
IT1314184B1 (en) * | 1999-08-12 | 2002-12-06 | Nicox Sa | PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF STRESS-OXIDATIVE CONDITIONS |
CN1886132A (en) * | 2003-12-02 | 2006-12-27 | 尼科克斯公司 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive drugs |
US7265094B2 (en) * | 2004-01-09 | 2007-09-04 | Enanta Pharmaceuticals, Inc. | 9N-substituted 6-11 bicyclic erythromycin derivatives |
JP2012516305A (en) * | 2009-01-30 | 2012-07-19 | グラクソ グループ リミテッド | 9-deoxo-9A-methyl-9A-aza-9A-homoerythromycin A derivatives for the treatment of neutrophil predominant inflammatory diseases |
DE102009037555A1 (en) * | 2009-08-13 | 2011-03-03 | Synovo Gmbh | A novel, gentle process for the direct nitration of hydroxyl, thiol and amino groups in organic molecules by means of in situ generated carbonic acid dinitrate |
WO2013008928A1 (en) * | 2011-07-14 | 2013-01-17 | 大正製薬株式会社 | Macrolide derivative |
EP2768824B1 (en) * | 2011-10-21 | 2016-12-07 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and their use in treating cancer |
WO2013148874A1 (en) * | 2012-03-27 | 2013-10-03 | Burnet Michael W | Anti-inflammatory macrolides |
WO2014053592A1 (en) * | 2012-10-03 | 2014-04-10 | Proponent Biotech Gmbh | Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
CN103588833B (en) * | 2013-10-30 | 2016-08-17 | 北京科技大学 | The preparation method of animal antibiotic tulathromycin |
-
2018
- 2018-03-02 WO PCT/US2018/020769 patent/WO2018161039A1/en unknown
- 2018-03-02 EP EP18761736.0A patent/EP3589327A4/en not_active Withdrawn
- 2018-03-02 US US16/490,459 patent/US11420995B2/en active Active
-
2022
- 2022-07-26 US US17/873,451 patent/US20230159581A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11420995B2 (en) | 2022-08-23 |
EP3589327A4 (en) | 2022-04-06 |
US20200262857A1 (en) | 2020-08-20 |
EP3589327A1 (en) | 2020-01-08 |
WO2018161039A1 (en) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230159581A1 (en) | Novel anti-infective and anti-inflammatory compounds | |
US20230131943A1 (en) | Anti-infective and anti-viral compounds and compositions | |
TW200901962A (en) | Lipoic acid derivatives | |
US11077198B2 (en) | Pegylated carfilzomib compounds | |
US20140248263A1 (en) | Bisphenol compounds and methods for their use | |
NZ188174A (en) | Amine and amidine derivatives of glycerol and propane diols | |
US10117904B2 (en) | Use of anti-bacterial agents for the treatment of epithelial-related conditions | |
EP0033255A1 (en) | Oximes derived from erythromycin A, their preparation, their application in pharmaceuticals and pharmaceutical compositions containing them | |
JPS5923300B2 (en) | D-(threo)-1-aryl-2-acylamido-3-fluoro-1-propanol compound, method for producing the same, and antibacterial pharmaceutical composition containing the compound | |
JP2002505292A (en) | Steroid-derived antibiotics | |
EA021826B1 (en) | Improved method for synthesizing pirfenidone | |
CN108135909A (en) | Cationic steroidal Antimicrobe compound and the method for preparing such compound | |
US10683318B2 (en) | Scalable synthesis of reduced toxicity derivative of amphotericin B | |
EP1562975A2 (en) | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments | |
US20230048560A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
CN102249968B (en) | Synthetic method for sulforaphane | |
EA019579B1 (en) | Mutilin derivatives and their use as pharmaceuticals | |
PT92539B (en) | PROCESS FOR THE PREPARATION OF ANFOTERICIN B DERIVATIVES | |
EP3489225A1 (en) | Vortioxetine analogue and use and preparation thereof | |
EP1185526A1 (en) | Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use | |
JP2019089847A (en) | Intermediates and methods for synthesizing calicheamicin derivatives | |
JPH0380792B2 (en) | ||
WO1992007833A1 (en) | Novel dihydroquinoline derivatives, pharmaceutical compositions and methods of use of dihidroquinoline derivatives as modulators of the arachidonic acid cascade | |
US20050143346A1 (en) | Composition for treating cancer containing n,n-dimethylphytosphingosine | |
EP4091672A1 (en) | Stable bioisostere of resolvin e2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SYNOVO GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PIETRZIK, NIKOLAS;BAEUERLEIN, CHRISTIANE;EGGERS, MARY;AND OTHERS;SIGNING DATES FROM 20190703 TO 20190704;REEL/FRAME:061644/0469 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |